<SEC-DOCUMENT>0001193125-18-107644.txt : 20180404
<SEC-HEADER>0001193125-18-107644.hdr.sgml : 20180404
<ACCEPTANCE-DATETIME>20180404171533
ACCESSION NUMBER:		0001193125-18-107644
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180524
FILED AS OF DATE:		20180404
DATE AS OF CHANGE:		20180404
EFFECTIVENESS DATE:		20180404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		18738129

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d474270ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167;240.14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Neurocrine
Biosciences, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San&nbsp;Diego, CA 92130 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice of
Annual Meeting of Stockholders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held on May&nbsp;24, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE STOCKHOLDERS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN
that the 2018 Annual Meeting of Stockholders of Neurocrine Biosciences, Inc., a Delaware corporation (the &#147;Company&#148;), will be held on May&nbsp;24, 2018, at 10:30&nbsp;a.m., local time, at the Company&#146;s corporate headquarters located
at 12780 El Camino Real, San&nbsp;Diego, California 92130, for the following purposes as more fully described in the Proxy Statement accompanying this Notice: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The election of the two nominees for Class&nbsp;I Director named herein to the Board of Directors to serve for a term of three years; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">An advisory vote on the compensation paid to the Company&#146;s named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">To approve an amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">To approve the Company&#146;s 2018 Employee Stock Purchase Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The ratification of the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">To transact such other business as may properly come before the Annual Meeting of Stockholders or any continuation, adjournment or postponement thereof. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on March&nbsp;29, 2018 are entitled to receive notice of and to vote at the Annual
Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stockholders are cordially invited to attend the Annual Meeting of Stockholders in person. Your vote is
important. Whether or not you plan to attend the Annual Meeting, we hope you will vote as soon as possible. You may vote over the Internet, as well as by telephone, or, if you requested to receive printed proxy materials, by mailing a proxy or
voting instruction form. Please review the instructions on each of your voting options described in this proxy statement, as well as in the Notice you received in the mail. Stockholders attending the Annual Meeting may vote in person even if they
have returned a proxy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By&nbsp;Order&nbsp;of&nbsp;the&nbsp;Board&nbsp;of&nbsp;Directors,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g474270g59p42.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Darin Lippoldt</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief&nbsp;Legal&nbsp;Officer&nbsp;and&nbsp;Corporate&nbsp;Secretary</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San&nbsp;Diego, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;3, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Meeting to be Held on May&nbsp;24, 2018 at 10:30 a.m. Local Time at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real, San Diego, California 92130. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The proxy statement and annual report to stockholders are available at </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>www.proxyvote.com</U>. Please have the control number on your Notice available. </B></P></div>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12780 El Camino Real </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San&nbsp;Diego, California 92130 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy is solicited on behalf of Neurocrine Biosciences, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;Neurocrine&#148;),
for use at its 2018 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on May&nbsp;24, 2018 beginning at 10:30&nbsp;a.m., local time, or at any continuations, postponements or adjournments thereof for the purposes set forth
in this proxy statement and the accompanying Notice of Annual Meeting of Stockholders. The Annual Meeting will be held at the Company&#146;s corporate headquarters, located at 12780 El Camino Real, San&nbsp;Diego, California 92130. The
Company&#146;s phone number is <FONT STYLE="white-space:nowrap">(858)&nbsp;617-7600.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THE ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Why did I receive a notice regarding the availability of proxy materials on the internet? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to rules adopted by the Securities and Exchange Commission (the &#147;SEC&#148;), the Company has elected to provide access to the
Company&#146;s proxy materials over the internet. Accordingly, the Company has sent you a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) because the Board of Directors of the Company is soliciting your proxy to vote at
the Annual Meeting, including at any adjournments or postponements of the Annual Meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy
materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to mail the Notice on or about April&nbsp;3, 2018 to all shareholders of record entitled to vote at the annual meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with rules adopted by the SEC, we may furnish proxy materials, including this proxy statement and our Annual Report, to our
stockholders by providing access to such documents on the Internet instead of mailing printed copies. Most stockholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice, which was mailed to our
stockholders, will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice also instructs you as to how you may submit your proxy on the Internet. If you would like to receive a paper or email copy of
our proxy materials, you should follow the instructions for requesting such materials in the Notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the purpose of the Annual Meeting?
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, stockholders will act upon the matters outlined in the Notice of Annual Meeting of Stockholders on the
cover page of this proxy statement, including the election of the two nominees for Class&nbsp;I Director named herein, an advisory vote on the compensation paid to the Company&#146;s named executive officers, approval of an amendment increasing the
number of shares of common stock reserved for issuance under the Company&#146;s 2011 Equity Incentive Plan from 17,000,000 to 19,000,000, approval of the Company&#146;s 2018 Employee Stock Purchase Plan and ratification of the appointment of
Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018. In addition, following the Annual Meeting, management will report on the performance of the Company and
respond to questions from stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who can attend the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All stockholders of record at the close of business on March&nbsp;29, 2018 (the &#147;Record Date&#148;), or their duly appointed proxies, may
attend the Annual Meeting. If you attend, please note that you may be asked to present valid picture identification, such as a driver&#146;s license or passport. Cameras, recording devices and other electronic devices will not be permitted at the
Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please also note that if you hold your&nbsp;shares in &#147;street name&#148; (that is, through a broker or other
nominee), you will need to bring a copy of a brokerage statement reflecting your stock ownership as of the record date and check in at the registration desk at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who is entitled to vote at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of record at the close of business on the Record Date are entitled to receive notice of and to participate in the Annual Meeting.
At the close of business on the Record Date, 89,882,062 shares of the Company&#146;s common stock, $0.001&nbsp;par value per&nbsp;share, were issued and outstanding. If you were a stockholder of record on that date, you will be entitled to vote all
of the&nbsp;shares that you held on that date at the Annual Meeting, or any continuations, postponements or adjournments of the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding&nbsp;share of the Company&#146;s common stock will be entitled to one vote on each proposal considered at the Annual Meeting.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What constitutes a quorum? What are broker <FONT STYLE="white-space:nowrap">non-votes?</FONT> What are advisory votes? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of the aggregate voting power of the common stock
outstanding on the Record Date will constitute a quorum, permitting the Company to conduct its business at the Annual Meeting. As of the Record Date, 89,882,062 shares of common stock, representing the same number of votes, were outstanding. Thus,
the presence of the holders of common stock representing at least 44,941,032 shares will be required to establish a quorum. The presence of a quorum will be determined by the Inspector of Elections (the &#147;Inspector&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proxies received but marked as abstentions, as well as &#147;broker <FONT STYLE="white-space:nowrap">non-votes,&#148;</FONT> will be included
in the calculation of the number of&nbsp;shares considered to be present at the Annual Meeting. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur when a holder of&nbsp;shares in &#147;street name&#148; does not give instructions to the
broker or nominee holding the&nbsp;shares as to how to vote on <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Under the rules and interpretations of the New York Stock Exchange (the &#147;NYSE&#148;), <FONT
STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantively affect the rights or privileges of stockholders, such as mergers, stockholder proposals and elections of directors, even if not contested. In
addition, as required by Section&nbsp;957 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, advisory votes on executive compensation are <FONT STYLE="white-space:nowrap">non-routine</FONT> matters for which brokers do not
have discretionary authority to vote&nbsp;shares held by account holders. Only ratification of our independent registered public accounting firm under Proposal Five is considered a routine matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote on Proposal Two is advisory. The approval or the disapproval of Proposal Two will not be binding on the Company or the Board of
Directors and will not create or imply any change to the fiduciary duties of the Board of Directors. However, the Company and the Board of Directors will consider the results of the advisory vote on Proposal Two in making future decisions about
compensation of the Company&#146;s named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How do I vote my shares in person at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may vote your shares held in your name as the stockholder of record in person at the Annual Meeting. You may vote your shares held
beneficially in street name in person at the Annual Meeting only if you obtain a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legal proxy from the broker, bank, trustee, or nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting, we recommend that you also
submit your proxy or voting instructions as described below so that your vote will be counted if you later decide not to attend the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can I vote my shares without attending the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct how your shares are voted without
attending the Annual Meeting. If you are a stockholder of record, you may vote by proxy. You can vote by proxy over the Internet by following the instructions provided in the Notice, or, if you requested to receive printed proxy materials, you can
also vote by mail or telephone pursuant to instructions provided on the proxy card. If you hold shares beneficially in street name, you may also vote by proxy over the Internet by following the instructions provided in the Notice, or, if you
requested to receive printed proxy materials, you can also vote by telephone or mail by following the voting instruction form provided to you by your broker, bank, trustee, or nominee. The deadline for voting by telephone or electronically is
11:59&nbsp;p.m., Eastern Time, on May&nbsp;23, 2018.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who will bear the cost of soliciting votes for the Annual Meeting?
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent such costs are incurred, the cost of solicitation of proxies will be borne by the Company. The Company will
reimburse expenses incurred by brokerage firms and other persons representing beneficial owners of&nbsp;shares in forwarding solicitation material to beneficial owners. To assist in soliciting proxies (votes), the Company may retain a professional
proxy solicitation firm, at an approximate cost of $10,000. Proxies also may be solicited by certain of the Company&#146;s directors, officers and regular employees, without additional compensation, personally, by telephone or by other appropriate
means. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Can I change my vote after I return my proxy? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yes. Even after you have submitted your proxy, you may change your vote at any time before the proxy is exercised by filing with the Corporate
Secretary of the Company either a notice of revocation or a duly executed proxy bearing a later date. Your proxy will also be revoked if you attend the Annual Meeting and vote in person. Attendance at the Annual Meeting will not by itself revoke a
previously granted proxy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What does it mean if I receive more than one Notice? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you receive more than one Notice, your common stock is registered in more than one name or are registered in different accounts. Please
complete a proxy for each separate Notice that you receive to ensure that all of your&nbsp;shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What are the Board of Directors&#146;
recommendations? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless you give other instructions on your proxy, the persons named as proxy holders on the proxy will vote in
accordance with the recommendations of the Board of Directors. The Board of Directors&#146; recommendation is set forth together with the description of each item in this proxy statement. In summary, the Board of Directors recommends a vote: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>for</I> election of the two nominees for Class&nbsp;I Director named herein (see Proposal&nbsp;One); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>for</I> an advisory vote on the compensation paid to the Company&#146;s named executive officers (see Proposal Two); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>for</I> approval of the amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000 (see Proposal Three);
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>for</I> approval of the Company&#146;s 2018 Employee Stock Purchase Plan (see Proposal Four); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>for</I> ratification of the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018 (see Proposal&nbsp;Five).
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to any other matter that properly comes before the meeting, the proxy holders will vote as recommended by the
Board of Directors or, if no recommendation is given, in their own discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What vote is required to approve each item? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Election of Directors.</B> The affirmative vote of a plurality of the votes cast at the Annual Meeting is required for the election of
directors. A properly executed proxy marked &#147;WITHHOLD AUTHORITY&#148; with respect to the election of one or more directors will not be voted with respect to the director or directors indicated, although it will be counted for purposes of
determining whether there is a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Other Items.</B> For each other item, the affirmative vote of the holders of a majority of
the&nbsp;shares represented in person or by proxy and entitled to vote on the item will be required for approval. A properly executed proxy marked &#147;ABSTAIN&#148; with respect to any such matter will not be voted, although it will be counted for
purposes of determining the number of&nbsp;shares represented in person or by proxy at the Annual Meeting. Accordingly, an abstention will have the effect of a negative vote for each item. If you hold your&nbsp;shares in &#147;street name&#148;
through a broker or other nominee, your broker or nominee will not be permitted to exercise voting discretion with respect to each of the matters to be acted upon, other than Proposal Five. Thus, if you do not give your broker or nominee specific
instructions, your&nbsp;shares will not be voted on and will not be counted for any other matter to be acted upon, other than Proposal Five. Shares represented by such &#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;</FONT> will,
however, be counted in determining whether there is a quorum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who counts the votes? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes cast by proxy or in person at the Annual Meeting will be tabulated by the Inspector. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How can I find out the results of the voting at the Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> within
four business days after the meeting, we intend to file a Form <FONT STYLE="white-space:nowrap">8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an amended Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to publish the final results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OWNERSHIP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who are the principal stockholders, and how much stock does management own? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of the Company&#146;s common stock as of February 28, 2018 by (i)&nbsp;each of the
executive officers named in the table under the heading &#147;Summary Compensation Table,&#148; (ii)&nbsp;each current director, (iii)&nbsp;all current directors and executive officers as a group and (iv)&nbsp;all persons known to the Company to be
the beneficial owners of more than 5% of the Company&#146;s common stock. The table is based upon information supplied by our executive officers, directors and principal stockholders and a review of Schedules&nbsp;13D and 13G, if any, filed with the
Securities and Exchange Commission (the &#147;SEC&#148;). A total of 89,708,872 shares of the Company&#146;s common stock were issued and outstanding as of February&nbsp;28, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:146.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common&nbsp;Stock<BR>Owned&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;of<BR>Common<BR>Stock<BR>Acquirable<BR>Within<BR>60&nbsp;Days&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Number<BR>of&nbsp;Shares&nbsp;of<BR>Common<BR>Stock<BR>Beneficially<BR>Owned&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FMR LLC (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,273,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,273,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">245 Summer Street, Boston, MA 02210</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,125,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,125,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 Vanguard Blvd., Malvern, PA&nbsp;19355</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">T. Rowe Price Associates, Inc. (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,231,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,231,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">100 East Pratt Street, Baltimore, MD&nbsp;21202</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Janus Henderson Group plc (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">201 Bishopsgate EC2M 3AE, United Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Advisors LLC (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,151,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,151,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 Astor Place, 10th Floor, New York, NY 10003</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,775,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,775,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">55 East 52<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, New York, NY
10055</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,329,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr., M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin,&nbsp;M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (16&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,074,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,894,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of the Company&#146;s common stock as of February 28, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The address of each beneficial owner named is c/o Neurocrine Biosciences, Inc., 12780 El Camino Real, San Diego, CA 92130, unless otherwise indicated. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents shares of common stock owned, excluding shares of common stock subject to stock options that are listed under the heading &#147;Number of Shares of Common Stock Acquirable Within 60 Days,&#148; by the named
parties as of February&nbsp;28, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Shares of common stock subject to stock options currently exercisable or exercisable within 60 days of February&nbsp;28, 2018. regardless of exercise price, are deemed to be outstanding for computing the percentage
ownership of the person holding such options and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Except as indicated by footnote, and subject to community property
laws where applicable, the Company believes that the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on Amendment No.&nbsp;8 to Schedule 13G filed by FMR LLC (&#147;FMR&#148;) on February&nbsp;13, 2018, reporting ownership as of December&nbsp;31, 2017. According to such filing, FMR beneficially owns 13,273,956
shares of common stock and has sole voting power as to 1,879,529 shares of common stock. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock held by FMR.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on Amendment No.&nbsp;2 to Schedule 13G filed by The Vanguard Group, Inc. (&#147;Vanguard Group&#148;) on February&nbsp;9, 2018, reporting ownership as of December&nbsp;31, 2017. According to such filing, Vanguard
Group beneficially owns 7,125,393 shares of common stock and sole voting power as to 48,890 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on Amendment No.&nbsp;6 to Schedule 13G filed by T. Rowe Price Associates, Inc. (&#147;Price Associates&#148;) filed on February&nbsp;14, 2018, reporting ownership as of December&nbsp;31, 2017. According to such
filing, Price Associates beneficially owns 6,231,030 shares of common stock and has sole voting power as to 1,023,752 shares of common stock. These securities are owned by various individual and institutional investors which Price Associates serves
as an investment adviser with power to direct investments and/or sole power to vote the securities. For the purposes of the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), Price Associates is
deemed to be a beneficial owner of such securities; however, Price Associates expressly disclaims that it is, in fact, the beneficial owner of such securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on a Schedule 13G filed by Janus Henderson Group plc (&#147;Janus&#148;) on February&nbsp;12, 2018, reporting ownership as of December&nbsp;31, 2017. According to such filing, Janus beneficially owns 5,772,111
shares of common stock and sole voting power as to 0 shares of common stock. These securities are owned by various institutional investors for which Janus has a controlling ownership interest. As a result of its role as an investment adviser or <FONT
STYLE="white-space:nowrap">sub-adviser</FONT> to such institutional investors, for the purposes of the reporting requirements of the Exchange Act, Janus is deemed to be a beneficial owner of such securities; however, Janus expressly disclaims that
it is, in fact, the beneficial owner of such securities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on Amendment No.&nbsp;1 to Schedule 13G filed by Perceptive Advisors LLC (&#147;Perceptive&#148;) on February&nbsp;14, 2018, reporting ownership as of December&nbsp;31, 2017. According to such filing, Perceptive
beneficially owns 5,151,589 shares of common stock and sole voting power as to 0 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Based on Amendment No.&nbsp;5 to Schedule 13G filed by BlackRock, Inc. (&#147;BlackRock&#148;) on February&nbsp;8, 2018, reporting ownership as of December&nbsp;31, 2017. According to such filing, BlackRock beneficially
owns 4,775,746 shares of common stock and sole voting power as to 4,473,636 shares of common stock. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of shares of the common
stock held by BlackRock. No one person&#146;s interest in the common stock held by BlackRock is more than five percent of the Company&#146;s total outstanding common stock. </TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s officers and directors, and persons who beneficially own 10% or greater of a
registered class of the Company&#146;s equity securities, to file reports of ownership on Form&nbsp;3 and reports of changes in ownership on Form&nbsp;4 or Form&nbsp;5 with the SEC. Such officers, directors and 10% or greater stockholders are also
required by SEC rules to furnish the Company with copies of all Section&nbsp;16(a) forms they file. Based solely on its review of the copies of such forms received by it, and written representations from certain reporting persons, the Company
believes that its officers, directors and 10% or greater stockholders complied with all Section&nbsp;16(a) filing requirements applicable to them during the fiscal year ended December&nbsp;31, 2017, except that one report, covering one transaction
was inadvertently filed late by the Company on behalf of Stephen A. Sherwin, M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOARD OF DIRECTORS AND COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s bylaws, as
amended, provide that the Board of Directors will be comprised of eight directors. The Company&#146;s Certificate of Incorporation provides that the Board of Directors is divided into three classes. There are currently two directors in Class&nbsp;I
(William H. Rastetter, Ph.D. and George J. Morrow), three directors in Class&nbsp;II (Corinne H. Nevinny, Richard F. Pops and Stephen A. Sherwin,&nbsp;M.D.), and three directors in Class&nbsp;III (Kevin C. Gorman,&nbsp;Ph.D., Gary A. Lyons and
Alfred W. Sandrock, Jr., M.D., Ph.D.). With the exception of Kevin C. Gorman,&nbsp;Ph.D., who is the Chief Executive Officer of the Company, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under
the Nasdaq Stock Market qualification standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors in Class&nbsp;III hold office until the 2020 Annual Meeting of
Stockholders, the directors in Class&nbsp;II hold office until the 2019 Annual Meeting of Stockholders, and the directors in Class&nbsp;I hold office until the 2018 Annual Meeting of Stockholders (or, in each case, until their earlier resignation,
removal from office, or death). After each such election, the directors in each such case will then serve in succeeding terms of three years and until a successor is duly elected and qualified. Officers of the Company serve at the discretion of the
Board of Directors. There are no family relationships among the Company&#146;s directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for
directors William J. Rastetter, Ph.D. and George J. Morrow will expire at the 2018 Annual Meeting of Stockholders. At the 2018 Annual Meeting of Stockholders, the stockholders will elect two Class&nbsp;II directors for a term of three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Biographies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kevin C.
Gorman,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B>&nbsp;has been employed with the Company since 1993. He was appointed President and Chief Executive Officer in January 2008 after having served as Executive Vice President and Chief Operating
Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He currently serves as Chief Executive Officer and has served on the Board of Directors since
January 2008. From 1990 until 1993, Dr.&nbsp;Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc.,
Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr.&nbsp;Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los&nbsp;Angeles and did further post-doctoral training at
The Rockefeller University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>William H. Rastetter, Ph.D.</I></B> has served on the Board of Directors since February 2010 and as
Chairman of the Board of Directors since May 2011. Currently, he serves as the Chairman of the Board of Directors for each of Fate Therapeutics, a publicly traded company focused on cellular therapies, and Grail, Inc., a private company developing
deep sequencing approaches to disease diagnosis, with an initial focus on the early diagnosis of cancer. Dr.&nbsp;Rastetter also serves on the Board of Directors for each of Regulus Therapeutics, a publicly traded company focused on RNA based
therapeutics, and Dar&eacute; Bioscience, Inc. (previously known as Cerulean Pharma Inc.), a publicly traded company focused on women&#146;s health care. Dr.&nbsp;Rastetter was a partner in the venture capital firm, Venrock, from 2006 through early
2013 and was Executive Chairman of Biogen Idec, Inc. from 2003 to 2005. Earlier, he served as Chairman and Chief Executive Officer of IDEC Pharmaceuticals Corporation until its merger with Biogen in 2003; he joined IDEC Corporation as its Chief
Executive Officer at the company&#146;s founding in 1986. From 1984 to 1986, Dr.&nbsp;Rastetter was Director of Corporate Ventures at Genentech, where from 1982 to 1984 he held scientific positions. He held a series of faculty positions including
Associate Professor at the Massachusetts Institute of Technology (&#147;MIT&#148;) from 1975 to 1982. Dr.&nbsp;Rastetter has a Bachelor of Science degree in chemistry from MIT, and received Master of Art and doctorate degrees in chemistry from
Harvard University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gary A. Lyons</I></B> has served on the Board of Directors since joining Neurocrine in
February 1993. Mr.&nbsp;Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr.&nbsp;Lyons held a number of senior management positions at Genentech, Inc.,
including Vice President of Business Development and Vice President of Sales. Mr.&nbsp;Lyons is currently the Chairman of the Board of Directors for each of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the
treatment of inflammatory/autoimmune and metabolic diseases, and Retrophin, an ultra-orphan disease commercial stage company. Mr.&nbsp;Lyons is a member of the Board of Directors of Vical Incorporated, a biotechnology company focused on the
prevention and treatment of serious or life-threatening diseases, Cytori Therapeutics, a company focused on stem cell therapies, and Novus Therapeutics, Inc., a biotechnology company focused on ear, nose and throat therapies. Mr.&nbsp;Lyons was
previously a director of Poniard Pharmaceuticals, Inc., Neurogesx, and Facet Biotech Corporation. Mr.&nbsp;Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University&#146;s J.L. Kellogg
Graduate School of Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>George J. Morrow </I></B>has served on the Board of Directors since October 2015. Mr.&nbsp;Morrow
served as Executive Vice President, Global Commercial Operations at Amgen Inc., a global biotechnology company, from 2003 until his retirement in 2011. He joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing. His
responsibilities included oversight of all commercial functions for Amgen&#146;s broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr.&nbsp;Morrow
held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer
of Glaxo Wellcome, Inc. (U.S.). Mr.&nbsp;Morrow currently serves on the board of directors of Otonomy, Inc., a biotechnology company, Vical, Inc., a biotechnology company and Align Technology, Inc., a global medical device company. He has previously
served on the boards of Glaxo Wellcome, Inc., Human Genome Sciences, Inc., Safeway, Inc., National Commerce Bank, the John Hopkins School of Public Health, and the Duke University Fuqua School of Business. Mr.&nbsp;Morrow holds a B.S. in chemistry
from Southampton College, Long Island University, an M.S. in biochemistry from Bryn Mawr College and an M.B.A. from Duke University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Corinne H. Nevinny</I></B> has served on the Board of Directors since June 2004. Ms.&nbsp;Nevinny is currently a General Partner of
LMNVC LLC, a privately held venture firm. From 2003 to 2010, Ms.&nbsp;Nevinny held various positions at Edwards Lifesciences, Inc., the global leader in the science of heart valves and hemodynamic monitoring. She served as Corporate Vice President
and the General Manager of the Cardiac Surgery Systems and Vascular business units, was responsible for Edwards&#146; global operations and served as Chief Financial Officer and Treasurer. Before joining Edwards in 2003, Ms.&nbsp;Nevinny was Vice
President, Chief Financial Officer of Tularik, Inc., a company involved in the discovery and development of drugs based on gene regulation, which was sold to Amgen, Inc. in 2004. Prior to joining Tularik, she was Executive Director-Health Care Group
at Warburg Dillon Read LLC, an investment bank. Ms.&nbsp;Nevinny was previously on the Board of Directors of Onyx Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cancer that was sold to Amgen during 2013, and was on
the Board of Directors at Avanir Pharmaceuticals, Inc., a biopharmaceutical company focused on central nervous system disorders that was sold in 2015 to Otsuka Pharmaceuticals. Ms.&nbsp;Nevinny received her undergraduate degree in industrial
engineering from Stanford University and her Master&#146;s degree in business administration from Harvard Business School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Richard
F. Pops</I></B> has served on the Board of Directors since April 1998. Mr.&nbsp;Pops is the Chairman and Chief Executive Officer of Alkermes, Inc. He joined Alkermes as Chief Executive Officer in February 1991. Under his leadership, Alkermes has
grown from a privately held research based company with 25 employees to an international, publicly traded pharmaceutical company with more than 1,200 employees. In addition to Alkermes, he currently serves on the Board of Directors of: Acceleron
Pharma, Inc., a biotechnology company focused on musculoskeletal and metabolic therapeutics; Epizyme Corporation, a biotechnology company focused on epigenetics; the Biotechnology Industry Organization; and the Pharmaceutical Research and
Manufacturers of America (PhRMA). He holds a B.A. in economics from Stanford University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alfred W. Sandrock, Jr., M.D., Ph.D.</I></B> has served on our Board of Directors
since September 2015. Dr.&nbsp;Sandrock is currently Executive Vice President of the Neurology Discovery&nbsp;&amp; Development Center, Neurodegeneration Therapeutic Area and also serves as Chief Medical Officer of Biogen Inc., a publicly traded
global biotechnology company. From May 2013 to December 2015 he served as Group SVP, Development Sciences / Chief Medical Officer. From February 2012 to April 2013 he served as Senior Vice President/ Chief Medical Officer of Biogen, and since
joining Biogen in 1998, has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development, and Vice President of Clinical Development, Neurology. During
his tenure at Biogen, Dr.&nbsp;Sandrock has been responsible for the clinical development and approval of Tysabri<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Plegridy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
Tecfidera<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Alprolix<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Eloctate<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Dr.&nbsp;Sandrock received his B.A. in
human biology from Stanford University, an M.D. from Harvard Medical School and a Ph.D. in neurobiology from Harvard University. Dr.&nbsp;Sandrock completed an internship in medicine, a residency and chief residency in neurology, and a clinical
fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) at Massachusetts General Hospital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stephen A.
Sherwin, M.D.</I></B> has served on the Board of Directors since April 1999. Dr.&nbsp;Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a
Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr.&nbsp;Sherwin currently serves on the Board of Directors
of Aduro Biotech and Biogen. He is a Venture Partner with Third Rock Ventures and a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. Previously Dr.&nbsp;Sherwin was chairman and chief executive officer of
Cell Genesys, a cancer immunotherapy company, from 1990 until the company&#146;s merger in 2009with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also a <FONT STYLE="white-space:nowrap">co-founder</FONT> and chairman of Abgenix, an
antibody company which was acquired by Amgen in 2006, and <FONT STYLE="white-space:nowrap">co-founder</FONT> and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr.&nbsp;Sherwin held
various positions in clinical research at Genentech, most recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr.&nbsp;Sherwin previously served on the board of directors of the
Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011, and was a member of the President&#146;s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013.
Dr.&nbsp;Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School, is board-certified in internal medicine and medical oncology, and is a fellow of the American College of Physicians. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CORPORATE GOVERNANCE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>We have long believed that good corporate governance is important to ensure that Neurocrine is managed for the long-term benefit of
its&nbsp;stockholders. We periodically review our corporate governance policies and practices. The Board of Directors has adopted Corporate Governance Guidelines which describe our corporate governance practices and address corporate governance
issues such as Board composition, responsibilities and director qualifications. These guidelines are available at <U>www.neurocrine.com. </U> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the Board&#146;s leadership structure? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the Company&#146;s policy to separate the roles of Chief Executive Officer and Chairman of the Board. This separation recognizes the
independent roles of the Board of Directors, Chairman of the Board and Chief Executive Officer. The Board of Directors sets Company strategy and provides oversight and accountability for the Chief Executive Officer and Company management. The
Chairman of the Board presides over the Board of Directors and provides guidance to the Chief Executive Officer. The Chief Executive Officer and the balance of the Board of Directors set Company goals with the Chief Executive Officer providing
leadership and day to day oversight in furtherance of those goals. The Company believes that separation of the Board of Directors and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company leadership reinforces the independence of the Board of Directors in its oversight of the business and affairs of the Company, and creates an environment that is more conducive to
objective evaluation and oversight of management&#146;s performance, increasing management accountability and improving the ability of the Board of Directors to monitor whether management&#146;s actions are in the best interests of the Company and
its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Are the members of the Board independent? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors annually reviews the independence of each of the directors. With the exception of Kevin C. Gorman,&nbsp;Ph.D., who is
the Chief Executive Officer of Neurocrine, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under the Nasdaq Stock Market qualification standards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How often did the Board meet during fiscal 2017? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors held a total of six meetings during 2017. For 2017, the Board of Directors had an Audit Committee, a Compensation
Committee, a Nominating/Corporate Governance Committee, and a Science and Medical Technology Committee. Charters for each of these committees have been established and approved by the Board of Directors and current copies of the charters for each of
the committees have been posted on the Company&#146;s website at<I></I><I>&nbsp;www.neurocrine.com.</I>&nbsp;During 2017, no director attended fewer than 75% of the aggregate of the total meetings of the Board of Directors and no director attended
fewer than 75% of the total number of meetings held by all committees of the Board of Directors on which such director served. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What are the various
committees of the Board and which directors are on those committees? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Audit Committee is comprised entirely of
directors who meet the independence requirements set forth in Nasdaq Stock Market Rule&nbsp;5605(c)(2)(A). Information regarding the functions performed by the committee, its membership, and the number of meetings held during the fiscal year is set
forth in the &#147;Report of the Audit Committee,&#148; included in this proxy statement. The members of the Audit Committee are Corinne H. Nevinny, Richard F. Pops and Stephen A. Sherwin, M.D. The Board of Directors has determined that Corinne H.
Nevinny, Richard F. Pops and Stephen A. Sherwin, M.D. are &#147;audit committee financial experts&#148; within the meaning of item&nbsp;407(d)(5) of SEC <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> This committee met four times
during 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Compensation Committee consists of directors Richard F. Pops, George J. Morrow and Corinne H. Nevinny.
This committee met six times during 2017. The Compensation Committee reviews and recommends to the Board of Directors the compensation of executive officers and other employees of the Company. Under its charter, the Compensation Committee may form,
and delegate authority to, subcommittees as appropriate. Each of the current members of the Compensation Committee is an &#147;independent director&#148; as defined by Nasdaq Stock Market Rule&nbsp;5605(a)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Alfred W.
Sandrock, Jr. M.D., Ph.D., all of whom are &#147;independent directors&#148; as defined by Nasdaq Stock Market Rule&nbsp;5605(a)(2). The Nominating/Corporate Governance Committee is responsible for developing and implementing policies and practices
relating to corporate governance, including administration of the Company&#146;s Code of Business Conduct and Ethics, which applies to all of the Company&#146;s officers, directors and employees, and is available on the Company&#146;s website
at<I></I><I>&nbsp;www.neurocrine.com.</I> The functions of this committee also include consideration of the composition of the Board of Directors and recommendation of individuals for election as directors of the Company. The Nominating/Corporate
Governance Committee will consider nominees recommended by stockholders, provided such nominations are made pursuant to the Company&#146;s bylaws and applicable law. This committee met two times during 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Science and Medical Technology Committee consists of directors Gary&nbsp;A. Lyons, William&nbsp;H. Rastetter, Ph.D. and
Alfred W. Sandrock, Jr. M.D., Ph.D.&nbsp;The purpose of the Science and Medical Technology Committee is to assist the Board of Directors in its oversight of management&#146;s exercise of its responsibility to make significant scientific judgments
relating to the Company&#146;s research and development activities and portfolio. This committee met one time during 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee interlocks and insider participation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, the Compensation Committee consisted of Joseph A. Mollica, George J. Morrow, Richard F. Pops, and Corinne H. Nevinny.
Mr.&nbsp;Mollica served on the Compensation Committee until he resigned from the Board of Directors on October&nbsp;17, 2017. Ms.&nbsp;Nevinny joined the Compensation Committee in October 2017. No interlocking relationship existed between any member
of the Compensation Committee and any member of any other company&#146;s Board of Directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our director
nomination process? </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In selecting <FONT STYLE="white-space:nowrap">non-incumbent</FONT> candidates and reviewing the qualifications
of incumbent candidates for the Board of Directors, the Nominating/Corporate Governance Committee considers the Company&#146;s corporate governance principles, which include the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors should possess the highest ethics, integrity and values, and be committed to representing the long-term interest of
the stockholders. They also must have experience they can draw upon to help direct the business strategies of the Company together with sound judgment. They must be actively engaged in the pursuit of information relevant to the Company&#146;s
business and must constructively engage their fellow Board members and management in dialogue and the decision-making process. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors must be willing to devote sufficient time to carrying out their duties and responsibilities effectively, and should
be committed to serve on the Board of Directors for an extended period of time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors should notify the Chairman of
the Board and Chairman of the Nominating/Corporate Governance Committee in the event of any significant change in their employment responsibilities or affiliations. Director nominees should meet the Director Qualification requirements set forth in
the Company&#146;s Corporate Governance Guidelines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating director nominees, the Nominating/Corporate Governance
Committee considers the following factors: personal and professional integrity, ethics and values including any potential conflicts of interest; experience in corporate management and the biopharmaceutical industry, such as serving as an officer or
former officer of a publicly held company; experience as a board member of another publicly held company; and additionally, for nominees seeking <FONT STYLE="white-space:nowrap">re-election,</FONT> meeting attendance and participation and compliance
with Company policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the Company&#146;s policy to have a diversity of skills, professional experience, education, associations,
achievements, training, points of view and individual qualities and attributes represented on the Board of Directors. The Nominating/Corporate Governance Committee considers the diversity of the Board of Directors when evaluating candidates for
election or <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating/Corporate Governance
Committee&#146;s goal is to assemble a Board of Directors that brings to the Company a variety of perspectives and skills derived from high quality business and professional experience. In doing so, the Nominating/Corporate Governance Committee also
considers candidates with appropriate <FONT STYLE="white-space:nowrap">non-business</FONT> backgrounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, the
Nominating/Corporate Governance Committee Charter and Corporate Governance Guidelines set forth minimum criteria for director nominees. The Nominating/Corporate Governance Committee may also consider such other facts as it may deem are in the best
interests of the Company and its stockholders. The Nominating/Corporate Governance Committee does, however, believe that at least one, and preferably several members of the Board of Directors, meet the criteria for an &#147;audit committee financial
expert&#148; as defined by SEC rules. The following paragraphs provide information as of the date of this proxy statement about the specific experience, qualifications, attributes and skills of each nominee and current member of the Board of
Directors that led the Board to conclude that such person should serve as a director. In addition to the information below regarding each Board member, we also believe that all of our directors have a reputation for honesty, integrity and highest
ethical standards. They each have demonstrated business acumen, an ability to exercise sound judgment and a commitment to serve the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;I Directors Nominated for <FONT STYLE="white-space:nowrap">Re-election</FONT> at the 2018
Annual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination of <B><I>George</I></B><B><I></I></B><B><I>&nbsp;J.</I></B><B><I></I></B><B><I>&nbsp;Morrow</I></B> for
election to the Company&#146;s Board of Directors is based on his extensive commercialization experience at Amgen, his broad executive experience at GlaxoSmithKline Inc., and his years of experience in corporate governance as a board member of
several publicly traded companies.&nbsp;Mr.&nbsp;Morrow&#146;s board, leadership experience and commercialization expertise prove valuable strategic insights to the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nomination of<B><I> William H. Rastetter, Ph.D.</I></B> for election to the Company&#146;s Board of Directors is based on
Dr.&nbsp;Rastetter&#146;s scientific and technical expertise combined with his business experience in leading rapidly growing companies in the life science industry. The Company&#146;s continued growth is dependent on scientific and technical
advances, and the Board of Directors believes that Dr.&nbsp;Rastetter offers both strategic and technical insight into the risks and opportunities associated with our business. In addition, Dr.&nbsp;Rastetter&#146;s board and executive leadership
experience at other life science companies provides valuable strategic and governance insight to the Board of Directors as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;II
Directors Continuing Until 2019 Annual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<B><I> Corinne H. Nevinny</I></B> on the Company&#146;s Board
of Directors is based on her global expertise as a prior President for Global Operations of Edward Lifesciences, Inc., her financial background as a prior Chief Financial Officer for Edwards Lifesciences and Tularik, Inc., her experience as board
and audit committee members at other publicly traded biotechnology companies, and her capital markets experience as Executive Director-Health Care Group at Warburg Dillon Read LLC. Her combination of financial, global and capital markets experience
has in the past, and will in the future, help guide the Company&#146;s financial and capital strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<B><I>
Richard F. Pops</I></B> on the Company&#146;s Board of Directors is based on his leadership experience and track record for growing companies, his strength in business strategy and his financial acumen and capital markets experience. In addition,
Mr.&nbsp;Pops is recognized for his service to the biopharmaceutical industry as a member of the Boards of the Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America. His breadth and range of industry
experience from operations and strategy is a significant contribution to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<B><I> Stephen
A. Sherwin, M.D.</I></B> on the Company&#146;s Board of Directors is based on his experience and credentials in the biotechnology industry as the former Chief Executive Officer of Cell Genesys, Inc., the former chairman and co-founder of Abgenix,
Inc., the chairman and <FONT STYLE="white-space:nowrap">co-founder</FONT> of Ceregene, Inc., and his positions at Genentech, Inc. and the National Cancer Institute. Dr.&nbsp;Sherwin is also currently Chairman Emeritus of the Biotechnology Industry
Organization. In addition to his biotechnology credentials, Dr.&nbsp;Sherwin&#146;s medical expertise in internal medicine and medical oncology provides a unique contribution to the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;III Directors Continuing Until 2020 Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<B><I> Kevin C. Gorman, Ph.D.</I></B> on the Company&#146;s Board of Directors is based on the fact that as Chief
Executive Officer of the Company, Dr.&nbsp;Gorman has extensive knowledge of our product candidates, our employees and the industry in which we operate. Dr.&nbsp;Gorman has also demonstrated exceptional leadership skills, sound business judgment and
a strong commitment to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of<B><I> Gary A. Lyons</I></B> on the Company&#146;s Board of Directors is
based on Mr.&nbsp;Lyons&#146; extensive business development and corporate governance experience and, as the Company&#146;s former Chief Executive Officer, his <FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of the Company&#146;s
product candidates, management and culture. With this history with the Company and management, Mr.&nbsp;Lyons brings a unique perspective and point of view to the Company&#146;s Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continued service of
<B><I>Alfred</I></B><B><I></I></B><B><I>&nbsp;W.</I></B><B><I></I></B><B><I>&nbsp;Sandrock, Jr., M.D., Ph.D.</I></B> on the Company&#146;s Board of Directors is based on his extensive experience and credentials in the biotechnology industry as an
Executive Vice President of Biogen and his extensive experience in successfully leading development teams. In addition, Dr.&nbsp;Sandrock&#146;s medical expertise in neurology and his scientific background provide a unique contribution to the Board
of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Identification and Evaluation of Nominees for Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating/Corporate Governance Committee identifies nominees for director by first evaluating the current members of the Board of
Directors willing to continue in service. Current members with qualifications and skills that are consistent with the Nominating/Corporate Governance Committee&#146;s criteria for service and who are willing to continue are considered for <FONT
STYLE="white-space:nowrap">re-nomination,</FONT> balancing the value of continuity of service by existing members of the Board of Directors with that of obtaining members who would offer a new perspective. If any member of the Board of Directors
does not wish to continue in service, or if the Board of Directors decides not to <FONT STYLE="white-space:nowrap">re-nominate</FONT> a member for <FONT STYLE="white-space:nowrap">re-election,</FONT> the Nominating/Corporate Governance Committee
identifies the desired skills and experience of a new nominee in light of the criteria above. The Nominating/Corporate Governance Committee generally polls the Board of Directors and members of management for their recommendations and may also seek
input from third-party search firms. The Nominating/Corporate Governance Committee may also seek input from industry experts or analysts. The Nominating/Corporate Governance Committee reviews the qualifications, experience and background of the
candidates. Final candidates are then interviewed by the Company&#146;s independent directors and executive management. In making its determinations, the Nominating/Corporate Governance Committee evaluates each individual in the context of the
Company&#146;s Board of Directors as a whole, with the objective of assembling a group that can best perpetuate the success of the Company and represent stockholder interests through the exercise of sound judgment. After review and deliberation of
all feedback and data, the Nominating/Corporate Governance Committee makes its recommendation to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
received director candidate recommendations from the Company&#146;s stockholders and do not have a formal policy regarding consideration of such recommendations. However, any recommendations received from stockholders will be evaluated in the same
manner that potential nominees suggested by members of our Board of Directors, management or other parties are evaluated. Accordingly, our Board of Directors believes a formal policy regarding consideration of such recommendations is unnecessary.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our process for stockholder communications with the Board of Directors? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders of the Company wishing to communicate with the Company&#146;s Board of Directors or an individual director may send a written
communication to the Board of Directors or such director c/o&nbsp;Neurocrine Biosciences, Inc., 12780 El Camino Real, San&nbsp;Diego, CA 92130, Attn: Corporate Secretary. Each communication must set forth: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name and address of the Company stockholder on whose behalf the communication is sent;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of Company&nbsp;shares that are beneficially owned by such stockholder as of the date of the communication. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each stockholder communication will be reviewed by the Company&#146;s Corporate Secretary to determine whether it is appropriate for
presentation to the Board or such director. Examples of inappropriate communications include advertisements, solicitations or hostile communications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Communications determined by the Corporate Secretary to be appropriate for presentation to the Board or such director will be submitted to the
Board or such director on a periodic basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is the Board&#146;s role in risk oversight? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Board of Directors has ultimate oversight responsibility for the risk management process, it has delegated portions of this
responsibility to various committees. The Board of Directors and its committees oversee risk throughout the business with focus on financial risk, legal/compliance risk and strategic risk. The Audit Committee focuses on financial risk and internal
controls and receives an annual financial risk assessment from the Company&#146;s independent registered public accounting firm. The Nominating/Corporate Governance Committee and Audit Committee each focus on legal/compliance risk with the
Nominating/Corporate Governance Committee taking the lead on the governance and management process and the Audit Committee taking the lead on SEC reporting and compliance. The Compensation Committee addresses compensation policies and practices as
they relate to risk management practices and risk-taking incentives. The participation of the full Board of Directors in setting the Company&#146;s business strategy incorporates assessment of strategic risk for the Company overall. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>How do the Company&#146;s compensation policies and practices relate to risk management practices and risk-taking incentives? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2017, the Compensation Committee, in conjunction with the Board of Directors, conducted an assessment of how the Company&#146;s
compensation policies and practices relate to risk management practices and risk-taking incentives. As part of the process, the Compensation Committee engaged the services of an external, independent compensation consulting firm to conduct an
independent risk assessment. Based on this assessment, the Compensation Committee concluded that the Company&#146;s compensation policies and practices do not create risks that are reasonably likely to have a material adverse effect on the Company.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>What is our policy regarding Board member attendance at the Company&#146;s Annual Meeting? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not have a formal policy regarding attendance by members of the Board of Directors at the Annual Meeting. Directors
Dr.&nbsp;Rastetter and Dr.&nbsp;Gorman attended the 2017 Annual Meeting of Stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following Report of the Audit Committee does not constitute soliciting material and should not be deemed filed or incorporated by
reference into any other Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates this Report by reference therein. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee is currently comprised of directors Corinne H. Nevinny, Richard F. Pops, and Stephen A. Sherwin, M.D. All current
committee members satisfy the definition of &#147;independent director&#148; as established in the Nasdaq Stock Market qualification requirements. The Audit Committee met four times during the year ended December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the Company&#146;s financial reporting process on behalf of the Board of Directors. Management has the primary
responsibility for the Company&#146;s financial statements and the reporting process, including the Company&#146;s systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee has reviewed and discussed with
management the Company&#146;s audited financial statements as of and for the year ended December&nbsp;31, 2017, including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant
judgments and the clarity of disclosures in the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee also has reviewed and discussed the
Company&#146;s audited financial statements as of and for the year ended December&nbsp;31, 2017 with the Company&#146;s independent registered public accounting firm, who are responsible for expressing an opinion on the conformity of those audited
financial statements with accounting principles generally accepted in the United States, as well as their judgments as to the quality, not just the acceptability, of the Company&#146;s accounting principles and such other matters as are required to
be discussed with the Audit Committee under Auditing Standard No.&nbsp;16,<I></I><I>&nbsp;Communications with Audit Committees</I> , as adopted by the Public Company Accounting Oversight Board (United States) (the &#147;PCAOB&#148;). The independent
registered public accounting firm also is responsible for performing an independent audit of the Company&#146;s internal control over financial reporting in accordance with the auditing standards of the PCAOB. In addition, the Audit Committee has
discussed the independent registered public accounting firm&#146;s independence from management and the Company, including the matters in the written disclosures and the letter from the independent registered public accounting firm required by
applicable requirements of the PCAOB and considered the compatibility of <FONT STYLE="white-space:nowrap">non-audit</FONT> services with the auditors&#146; independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee discussed with the Company&#146;s independent registered public accounting firm the overall scope and plans for their
audits. The Audit Committee meets with the independent registered public accounting firm, with and without management present, to discuss the results of their examinations, their evaluations of the Company&#146;s internal controls, and the overall
quality of the Company&#146;s financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reliance on the reviews and discussions referred to above, the Audit Committee
recommended to the Board of Directors that the audited financial statements be included in the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2017, for filing with the
Securities and Exchange Commission. The Audit Committee and the Board of Directors are also seeking stockholder ratification of the selection of the Company&#146;s independent registered public accounting firm for the year ending December&nbsp;31,
2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Respectfully submitted by:</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">AUDIT COMMITTEE</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin, M.D.</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> fees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fees billed to the Company by Ernst&nbsp;&amp; Young LLP, the Company&#146;s independent registered public accounting firm, for
the indicated services for each of the last two fiscal years were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,123,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">479,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit related fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,213,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">518,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit fees consist of fees for professional services performed by Ernst&nbsp;&amp; Young LLP for the integrated audit of the Company&#146;s annual financial statements and internal control over financial reporting and
review of financial statements included in the Company&#146;s <FONT STYLE="white-space:nowrap">10-Q</FONT> filings, review of registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and Form
<FONT STYLE="white-space:nowrap">S-8,</FONT> and services that are normally provided in connection with statutory and regulatory filings or engagements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Audit related fees consist of fees for assurance and related services performed by Ernst&nbsp;&amp; Young LLP that are reasonably related to the performance of the audit or review of the Company&#146;s financial
statements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Tax fees consist of fees for professional services performed by Ernst&nbsp;&amp; Young LLP with respect to tax compliance, tax advice and tax planning. For 2017, these fees included $74,970 for tax preparation services
and $15,000 for services related to Section&nbsp;382 studies for net operating loss utilization. For 2016, these fees were related to tax preparation services. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">All other fees consist of fees for other permissible work performed by Ernst&nbsp;&amp; Young LLP that does not meet with the above category descriptions </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has considered whether the provision of <FONT STYLE="white-space:nowrap">non-audit</FONT> services is compatible with
maintaining the independence of Ernst&nbsp;&amp; Young LLP, and has concluded that the provision of such services is compatible with maintaining the independence of that firm. All of the services rendered by Ernst&nbsp;&amp; Young LLP were <FONT
STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee in accordance with the Audit Committee <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee policy regarding <FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services of our independent registered public accounting firm </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s
Audit Committee has established a policy that all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by the Company&#146;s independent registered public accounting firm will be
<FONT STYLE="white-space:nowrap">pre-approved</FONT> by the Audit Committee. These services may include audit services, audit related services, tax services and other services. The Audit Committee considers whether the provision of each <FONT
STYLE="white-space:nowrap">non-audit</FONT> service is compatible with maintaining the independence of the Company&#146;s registered public accounting firm. <FONT STYLE="white-space:nowrap">Pre-approval</FONT> is detailed as to the particular
service or category of services and is generally subject to a specific budget. The Company&#146;s independent registered public accounting firm and management are required to periodically (at least quarterly) report to the Audit Committee regarding
the extent of services provided by the independent registered public accounting firm in accordance with this <FONT STYLE="white-space:nowrap">pre-approval,</FONT> and the fees for the services performed to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following Report of the Committee does not constitute soliciting material and should not be deemed filed or incorporated by reference
into any other Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent the Company specifically incorporates this Report by reference therein. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Company has reviewed and discussed the Compensation Discussion and Analysis required by Item&nbsp;402(b) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> with management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy
statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Respectfully submitted by:</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">COMPENSATION COMMITTEE</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL&nbsp;ONE: ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s bylaws, as amended, provide that the Board of Directors will be comprised of eight directors. The Company&#146;s
Certificate of Incorporation provides that the Board of Directors is divided into three classes. There are currently two directors in Class&nbsp;I (George J. Morrow and William&nbsp;H. Rastetter, Ph.D.), three directors in Class&nbsp;II (Corinne H.
Nevinny, Richard F. Pops and Stephen&nbsp;A. Sherwin,&nbsp;M.D.), and three directors in Class&nbsp;III (Kevin C. Gorman,&nbsp;Ph.D., Gary A. Lyons and Alfred&nbsp;W. Sandrock, M.D., Ph.D.). With the exception of Kevin C. Gorman,&nbsp;Ph.D., who is
the Chief Executive Officer of Neurocrine, all current members of the Board of Directors meet the definition of &#147;independent director&#148; under the Nasdaq Stock Market qualification standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The directors in Class&nbsp;I hold office until the 2018 Annual Meeting of Stockholders, the directors in Class&nbsp;II hold office until the
2019 Annual Meeting of Stockholders and the directors in Class&nbsp;III hold office until the 2020 Annual Meeting of Stockholders (or, in each case, until their earlier resignation, removal from office, or death). After each such election, the
elected directors will then serve in succeeding terms of three years and until a successor is duly elected and qualified. Officers of the Company serve at the discretion of the Board of Directors. There are no family relationships among the
Company&#146;s directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of office for directors George J. Morrow and William H. Rastetter, Ph.D. will
expire at the 2018 Annual Meeting of Stockholders. At the 2018 Annual Meeting of Stockholders, the stockholders will elect two Class&nbsp;I directors for a term of three years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election at the Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the nominees (George J. Morrow and William H. Rastetter, Ph.D.) are currently Class&nbsp;I directors of the Company. All of the nominees
were previously elected to the Board of Directors by the Company&#146;s stockholders. Information about the nominees is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Position&nbsp;in&nbsp;the&nbsp;Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow (2) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Chairman&nbsp;of&nbsp;the&nbsp;Board</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Who are the remaining Directors that are not up for election this year? </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;II and&nbsp;III directors will remain in office after the 2018 Annual Meeting of Stockholders. The names and certain other
current information about the directors whose terms of office continue after the Annual Meeting are set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Position&nbsp;in&nbsp;the&nbsp;Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Chief&nbsp;Executive&nbsp;Officer<BR>and Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2008</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny (1) (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops (1) (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr. M.D., Ph.D. (3) (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin,&nbsp;M.D. (1) (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Audit Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Compensation Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Nominating/Corporate Governance Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the Science and Medical Technology Committee. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominees receiving the highest number of affirmative votes of the&nbsp;shares present in person or represented by proxy at the 2018 Annual
Meeting of Stockholders and entitled to vote on the election of directors will be elected to the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Votes withheld from
any director are counted for purposes of determining the presence or absence of a quorum, but have no other legal effect under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise instructed, the proxy holders will vote the proxies received by them for the Company&#146;s Class&nbsp;I nominees named
above. If any of the Company&#146;s nominees is unable or declines to serve as a director at the time of the Annual Meeting, the proxies will be voted for any nominee who is designated by the present Board of Directors to fill the vacancy. It is not
expected that any of the Company&#146;s nominees will be unable or will decline to serve as a director.<B> The Board of Directors unanimously recommends that stockholders vote &#147;FOR&#148; the Class</B><B></B><B>&nbsp;I nominees named above. </B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL TWO: ADVISORY VOTE ON </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION PAID TO THE COMPANY&#146;S NAMED EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the 2017 Annual Meeting of
Stockholders, the Board of Directors, as a matter of good corporate governance, recommended that the stockholders approve an advisory vote on Named Executive Officer compensation
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;say-on-pay&#148;)</FONT></FONT> on an annual basis. Approximately 94% of the&nbsp;stockholder votes cast at the 2017 Annual Meeting of Stockholders were for the Company&#146;s
recommendation, and in response the Company holds an annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote. This annual vote is not intended to address any specific compensation item, but rather the
overall compensation of the Company&#146;s Named Executive Officers and the philosophy, policies and practices described in this proxy statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Company&#146;s Executive Compensation Philosophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Board of Directors (the &#147;Committee&#148;) bases its executive compensation decisions on a number of
objectives which include aligning management incentives with interests of stockholders, providing competitive compensation, appropriately balancing compensation risk in the context of the Company&#146;s business strategy and meeting evolving
compensation governance standards. The philosophy of the Committee in establishing the Company&#146;s compensation policy for executive officers as well as all other employees is to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">align compensation plans with both short-term and long-term goals and objectives of the Company and stockholder interests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain highly skilled individuals by offering compensation that compares favorably to other employers who are competing for available employees; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incentivize employees through a mix of base salary, bonus amounts based on achievement of defined corporate and personal goals and long-term equity awards to generate returns for stockholders; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay for performance by ensuring that an ever-increasing percentage of an individual&#146;s compensation is performance-based as they progress to higher levels within the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed below in the Compensation Discussion and Analysis, we believe we have adopted a compensation philosophy that provides strong
alignment between executive pay and performance based on strategic goals designed to provide both near-term and long-term growth in stockholder value. The historical approval rates, on an advisory basis, for the Company&#146;s executive compensation
program have been approximately 99% for each of the 2015, 2016 and 2017 Annual Meetings of Stockholders. The Committee and our Board of Directors believe that this level of approval of our executive compensation program is indicative of our
stockholders&#146; strong support of our compensation philosophy and goals as well as the overall administration of executive compensation by the Committee and the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are being asked to approve on an advisory basis, the compensation paid to the Company&#146;s Named Executive Officers as set forth in the
Compensation Discussion and Analysis, Summary Compensation Table and related notes and narrative set forth herein. This vote is not intended to address any specific compensation item, but rather the overall compensation of the Company&#146;s Named
Executive Officers and the philosophy, policies and practices described in this proxy statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#145;say-on-pay&#146;</FONT></FONT> vote is advisory and therefore not
binding on the Company, the Committee or the Board of Directors. However, we value the opinions of our stockholders and will review and will continue to consider the outcome of this advisory vote when making future compensation decisions for our
Named Executive Officers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and will evaluate whether any actions are necessary to address the stockholders&#146; concerns. Approval of this advisory vote requires the affirmative vote of the majority of&nbsp;shares
represented in person or by proxy and entitled to vote on the item.<B> The Board of Directors unanimously recommends voting &#147;FOR&#148; approval of the Company&#146;s Named Executive Officers compensation. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL THREE: APPROVAL OF AN AMENDMENT TO THE 2011 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Neurocrine Biosciences, Inc.
2011 Equity Incentive Plan was originally approved by the Board of Directors and the stockholders of the Company in 2011, and was subsequently amended by the Board of Directors and our stockholders most recently in 2017 (the &#147;2011 Plan&#148;).
Subject to stockholder approval, our Board of Directors approved an amendment of the 2011 Plan on February&nbsp;6, 2018 (the 2011 Plan, as amended, the &#147;Amended 2011 Plan&#148;). The Board of Directors is requesting stockholder approval of the
Amended 2011 Plan, which includes the following material changes to the 2011 Plan, as described in more detail under &#147;Summary of the Amended 2011 Plan&#148; below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to increase in the maximum number of shares of common stock that may be issued under the 2011 Plan pursuant to the exercise of incentive stock options from 17,000,000 to 19,000,000 shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors believes that the proposed increase in the number of shares of common stock reserved for issuance under the Amended
2011 Plan will allow the Company to attract and retain valuable employees and continue to provide its employees, consultants and directors with a proprietary interest in the Company. In particular, the Company anticipates a material increase in its
number of employees in 2018 in connection with: (i)&nbsp;the commercialization of the Company&#146;s first approved product, INGREZZA<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (valbenazine) capsules, which occurred in April 2017; and
(ii)&nbsp;development activities related to the Company&#146;s other development programs. Within the Company, equity awards foster an ownership culture and are a critical tool for driving stockholder value and for recruiting, retaining and
motivating employees. The Company grants annual equity awards to employees as an incentive to retain its work force and remain competitive. The terms of the Company&#146;s annual equity awards and the Company&#146;s employee policies are designed to
align employee and stockholder interests. The Company grants equity awards to a broad group of employees and such awards constitute a significant component of the Company&#146;s employees&#146; total compensation. The Company&#146;s equity awards
contain long-term vesting, performance-based vesting, and provisions designed to encourage employees to focus on the Company&#146;s long-term goals and success. If our stockholders do not approve the Amended 2011 Plan, the Company strongly believes
that it will be unable to successfully use equity as part of its compensation program, as most of its competitors in the industry do, putting the Company at a significant disadvantage and compromising its ability to enhance stockholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2011 Plan authorizes the grant to our employees of options that qualify as incentive stock options under Section&nbsp;422 of the
Code. The 2011 Plan also authorizes the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance stock awards and other stock awards (collectively &#147;stock awards&#148;) to our
employees, directors and consultants. The 2011 Plan also provides that certain nonstatutory stock options will be automatically granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and the Chairman of the Board of Directors of
the Company, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;1, 2018, under the 2011 Plan there were options outstanding to purchase 6,295,430
shares of common stock, and 4,990,996 shares were available for future stock awards; 1,483,801 shares were subject to outstanding restricted stock units; and 2,382,100 shares previously issued upon exercise of options granted and 1,847,673 shares
previously issued upon vesting of restricted stock units under the 2011 Plan are now outstanding shares of common stock. As of March&nbsp;28, 2018, there were approximately 440 employees and directors eligible to receive grants under the 2011 Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, whether granted under the 2011 Plan or otherwise, an aggregate of <U></U>6,417,530 shares are issuable upon
exercise of outstanding options with a weighted average exercise price of $<U></U>36.29 and a weighted average remaining contractual term of <U></U>7.1 years; and <U></U>1,533,501 shares are subject to unvested restricted stock units. The closing
price of the Company&#146;s common stock on March&nbsp;29, 2018 was $<U></U>82.93 with <U></U>89,882,062 shares outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, the stockholders are being asked to approve the Amended 2011 Plan. The affirmative vote of the holders of a majority of
the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the item will be required to approve the Amended 2011 Plan. <B>The Board of Directors recommends voting &#147;FOR&#148; the approval of the Amended 2011
Plan.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Amended 2011 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The essential features of the Amended 2011 Plan are summarized below. This summary does not purport to be complete and is subject to, and
qualified by reference to, all provisions of the Amended 2011 Plan. The Amended 2011 Plan, which reflects all of the changes proposed to be made to the 2011 Plan, is attached as Appendix A&nbsp;to this proxy statement and is incorporated herein by
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Purpose</I></B>. The purpose of the Amended 2011 Plan is to enable the Company to attract and retain the best available
personnel, to provide additional incentives to the employees, directors and consultants of the Company and to promote the success of the Company&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Administration</I></B>. Our Board of Directors has the authority to administer the Amended 2011 Plan. Our Board of Directors also has
the authority to delegate some or all of the administration of the Amended 2011 Plan (except the <FONT STYLE="white-space:nowrap">Non-Discretionary</FONT> Grant Program summarized below) to a committee or committees composed of one or more members
of the Board of Directors or Company officers (the Board of Directors or any such committee, the &#147;Administrator&#148;). The Amended 2011 Plan may be administered by different committees with respect to different groups of employees and
consultants. The Administrator may make any determinations deemed necessary or advisable for the Amended 2011 Plan. The Administrator, in its discretion, selects the employees, directors and consultants to whom stock awards may be granted, the time
or times at which such awards shall be granted, the number of shares subject to each such grant, and other terms of the stock awards. All decisions, determinations and interpretations of the Administrator shall be final and binding on all holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility</I></B>. Incentive stock options may be granted only to our employees. Nonstatutory stock options, stock appreciation
rights, restricted stock awards, restricted stock unit awards, performance stock awards and other stock awards may be granted under the Amended 2011 Plan to our employees, directors and consultants. Participation in the <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> grant program is limited to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors (see <FONT STYLE="white-space:nowrap">&#147;Non-Discretionary</FONT> Grant Program&#148; below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Subject to the Amended 2011 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to stockholder approval of this Proposal Three and adjustments for changes in our capitalization, an aggregate of 19,000,000 shares of
common stock will be reserved for issuance under the Amended 2011 Plan. Shares may be issued in connection with a merger or acquisition as permitted by the rules of the applicable national securities exchange, and such issuance shall not reduce the
number of shares available for issuance under the Amended 2011 Plan. If a stock award granted under the Amended 2011 Plan expires or otherwise terminates without all of the shares having been issued, or if any shares of common stock issued pursuant
to a stock award are forfeited to us because of the failure to meet a contingency or condition required for the vesting of such shares, then the shares of common stock not issued under such stock award, or forfeited to us, shall revert to and again
become available for issuance under the Amended 2011 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any shares subject to a stock award are not delivered to a participant
because such shares are withheld for the payment of taxes or the stock award is exercised through a reduction of shares subject to the stock award (i.e. &#147;net exercised&#148;), or an appreciation distribution in respect of a stock appreciation
right is paid in shares of common stock, the number of shares that are not delivered will not again become available for issuance under the Amended 2011 Plan. If the exercise price of any stock award is satisfied by tendering shares of common stock
held by the participant, then the number of shares so tendered will not become available for issuance under the Amended 2011 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maximum number of shares of common stock that may be issued under the Amended
2011 Plan pursuant to the exercise of incentive stock options, subject to stockholder approval of this Proposal Three, is 19,000,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Per-Person</FONT> Award Limitations</I></B>. The Amended 2011 Plan provides that no employee may be
granted, in any fiscal year of the Company, stock options, stock appreciation rights (and any other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least the fair market value on the date of
grant) (all such options, stock appreciation rights and other stock awards &#147;appreciation awards&#148;) covering more than 500,000 shares of common stock. Notwithstanding this limit, however, in connection with an employee&#146;s initial
employment, he or she may be granted appreciation awards covering up to an additional 500,000 shares of common stock. Additional <FONT STYLE="white-space:nowrap">per-person</FONT> limitations apply to performance stock awards, as described below in
the section entitled &#147;Terms of Performance Awards&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Full Value Stock Award Limitations</I></B>. In addition, subject to
adjustments upon changes in our capitalization or in connection with a merger or other similar event, the maximum number of shares of common stock that may be issued pursuant to the grant of &#147;full value stock awards&#148; (i.e., restricted
stock, restricted stock units, performance stock and other stock awards, but not including stock options or stock appreciation rights) is 50% of the total number of shares of common stock issuable under the Amended 2011 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Minimum Vesting</I></B>. Generally, no full value stock award that vests on the basis of the participant&#146;s continuous service with
the Company shall vest at a rate that is any more rapid than ratably over a three-year period, and no full value stock award that vests based on the satisfaction of performance goals shall have a performance period of less than twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limited Exception to Minimum Vesting Restrictions</I></B><I>. </I>Up to five percent (5%)&nbsp;of the total number of shares of common
stock available for issuance under the Amended 2011 Plan may in the aggregate be issued as full value stock awards that are not subject to the minimum vesting requirements set forth in the Amended 2011 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Limit on <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</I></B><I>. </I>The aggregate value of all
compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any period commencing on the date of the Company&#146;s annual meeting of stockholders for
a particular year and ending on the date of the Company&#146;s annual meeting of stockholders for the next subsequent year, including stock awards granted under the Amended 2011 Plan and cash fees paid to such
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $1,250,000 in total value. In addition, the aggregate value of the initial option grant or other similar stock award(s) granted under the Plan or otherwise to any
individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon or in connection with his or her initial election or appointment to the Board of Directors will not exceed $2,000,000 in total value. For purposes of
these limitations, the value of stock awards is calculated based on the grant date fair value of such stock awards for financial reporting purposes.&nbsp;The Board of Directors has the authority to make exceptions to these limits in extraordinary
circumstances, in its discretion, provided that any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Section</I></B><B><I></I></B><B><I>&nbsp;162(m) Transition Relief for Performance-Based Compensation</I></B>. Certain provisions in
the Amended 2011 Plan refer to the &#147;performance-based compensation&#148; exception under Section&nbsp;162(m) of the Code. Pursuant to the Tax Cuts and Jobs Act, this exception was recently repealed with respect to taxable years beginning after
December&nbsp;31, 2017. However, an award may still be eligible for this exception if, among other requirements, it is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the
Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act for remuneration provided pursuant to a written binding contract which was in effect on November&nbsp;2, 2017 and which was not modified in any material respect on or after
such date. For purposes of this Proposal Three, the term &#147;Section&nbsp;162(m) Transition Relief&#148; refers to such transition relief. As of the date the Board of Directors approved the Amended 2011 Plan, the U.S. Department of the Treasury
and the Internal Revenue Service had not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued any applicable guidance, rulings or regulations regarding the Section&nbsp;162(m) Transition Relief. Accordingly, the provisions in the Amended 2011 Plan which refer to the
&#147;performance-based compensation&#148; exception under Section&nbsp;162(m) of the Code were not removed so as not to jeopardize the ability of certain awards to qualify for the Section&nbsp;162(m) Transition Relief before any such guidance,
rulings or regulations are issued. However, such provisions will only apply to any award that is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the
Section&nbsp;162(m) Transition Relief and, therefore, are not applicable to any other awards granted under the Amended 2011 Plan. Because of certain ambiguities and uncertainties as to the application and interpretation of Section&nbsp;162(m) of the
Code and the regulations issued thereunder, including the uncertain scope of the Section&nbsp;162(m) Transition Relief, we do not know the extent to which any award granted under the Amended 2011 Plan will be eligible for the Section&nbsp;162(m)
Transition Relief, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms and Conditions of Options and Stock Appreciation Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options and stock appreciation rights may be granted under the Amended 2011 Plan pursuant to stock option agreements and stock appreciation
right agreements. The following is a description of the permissible terms of options and stock appreciation rights under the Amended 2011 Plan. Individual grants may be more restrictive as to any or all of the permissible terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise Price</I></B>. The Administrator determines the exercise price of options and strike price of stock appreciation rights at the
time the options or stock appreciation rights are granted as set forth in the applicable stock award agreement. The exercise price of a stock option and strike price of a stock appreciation right may not be less than 100% of the fair market value of
the common stock on the date such award is granted. In the case of an incentive stock option granted to an optionee who owns more than 10% of all classes of stock of the Company or any parent or subsidiary of the Company, the exercise price may not
be less than 110% of the fair market value of the common stock on the date such option is granted. The fair market value of the common stock is generally determined with reference to the closing sale price for the common stock on the date the option
or stock appreciation right is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights</I></B>. Each stock appreciation right is denominated in shares
of common stock equivalents. Upon exercise of a stock appreciation right, we will pay the participant an amount equal to the excess of (i)&nbsp;the aggregate fair market value of our common stock on the date of exercise over (ii)&nbsp;the strike
price determined by the Administrator on the date of grant. The appreciation distribution upon exercise of a stock appreciation right will be paid in shares of our common stock, in cash, any combination of the two or any other form of consideration
determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Repricing; Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock
Awards</I></B>. Under the Amended 2011 Plan, the Administrator does not have the authority to reprice any outstanding stock awards by reducing the exercise price of the stock award or to cancel any outstanding stock awards in exchange for cash or
other stock awards without obtaining the approval of our stockholders within 12 months prior to the repricing or cancellation and <FONT STYLE="white-space:nowrap">re-grant</FONT> event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise; Form of Consideration</I></B>. The Administrator determines when options and stock appreciation rights become exercisable as
set forth in the applicable stock award agreement. The means of payment for shares issued upon exercise of an option is specified in each option agreement. The Amended 2011 Plan permits payment to be made to the extent permitted under applicable
laws by cash, check, other shares of common stock of the Company (with some restrictions), net exercise, cashless exercise, any other form of consideration permitted by applicable law, or any combination thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term</I></B>. The Administrator determines the term of options and stock appreciation rights granted under the Amended 2011 Plan as set
forth in the applicable stock award agreement. The term of options and stock appreciation rights granted under the Amended 2011 Plan may be no more than 10 years from the date of grant. In the case of an incentive stock option granted to an optionee
who owns more than 10% of all classes of stock of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company or any parent or subsidiary of the Company, the term of the option may be no more than five years from the date of grant. No option or stock appreciation right may be exercised after
the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Continuous Service</I></B>. Options and stock appreciation rights granted under the
Amended 2011 Plan generally terminate three months after termination of the participant&#146;s service unless (i)&nbsp;such termination is due to the participant&#146;s disability, in which case the stock award may, but need not, provide that it may
be exercised (to the extent the stock award was exercisable at the time of the termination of service) at any time within 12 months of such termination; (ii)&nbsp;the participant dies before the participant&#146;s service has terminated, or within
the period specified in the stock award agreement after termination of such service, in which case the stock award may, but need not, provide that it may be exercised (to the extent the stock award was exercisable at the time of the
participant&#146;s death) within 18 months of the participant&#146;s death by the person or persons to whom the rights to exercise such stock award pass by will or by the laws of descent and distribution; (iii)&nbsp;the stock award by its terms
specifically provides otherwise, or (iv)&nbsp;the termination is for cause. Except as provided otherwise in a participant&#146;s stock award agreement, or otherwise set forth in an employment agreement, upon termination of a participant&#146;s
service for cause, the stock award shall immediately terminate and may not thereafter be exercised. A participant may designate a beneficiary who may exercise the stock award following the participant&#146;s death. Individual grants by their terms
may provide for exercise within a longer or shorter period of time following termination of service. In no event, however, may an option or stock appreciation right be exercised beyond the expiration of its maximum term. The option or stock
appreciation right term generally is extended in the event that exercise of the stock award within the foregoing periods is prohibited. A participant&#146;s stock award agreement may provide that if the exercise of the stock award following the
termination of the participant&#146;s service would be prohibited because the issuance of stock would violate the registration requirements under the Securities Act of 1933, as amended, then the stock award will terminate on the earlier of
(i)&nbsp;the expiration of the term of the stock award or (ii)&nbsp;three months after the termination of the participant&#146;s service during which the exercise of the stock award would not be in violation of such registration requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Provisions</I></B>. The stock option agreement may contain other terms, provisions and conditions not inconsistent with the
Amended 2011 Plan as may be determined by the Administrator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Restricted Stock Awards and Restricted Stock Unit Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards and restricted stock unit awards may be granted under the Amended 2011 Plan pursuant to restricted stock award and
restricted stock unit award agreements. The following is a description of the permissible terms of restricted stock awards and restricted stock unit awards under the Amended 2011 Plan. Individual grants may be more restrictive as to any or all of
the permissible terms described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consideration</I></B>.&nbsp;The Administrator may grant restricted stock awards and
restricted stock unit awards in consideration for past services rendered to the Company or in exchange for any other form of legal consideration acceptable to the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Vesting</I></B>. Shares of stock issued under a restricted stock award agreement may, but need not, be subject to forfeiture to the
Company in accordance with a vesting schedule as determined by the Administrator. Restricted stock unit awards vest and are issued at the rate specified in the restricted stock unit award agreement as determined by the Administrator. However, at the
time of grant, the Administrator may impose additional restrictions or conditions that delay the delivery of stock to be issued in respect of the restricted stock unit award after vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Service</I></B>. Unless the Administrator determines otherwise, the restricted stock purchase agreement shall give the
Company a repurchase option exercisable upon the voluntary or involuntary termination of the purchaser&#146;s employment or consulting relationship with the Company for any reason (including death and disability). The purchase price for any issued
shares repurchased by the Company shall be the original price paid by the purchaser, if any. The repurchase option lapses at a rate determined by the Administrator. Except as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be automatically forfeited upon the participant&#146;s termination of service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Equivalents</I></B>. Dividend equivalent rights may be credited with respect to shares covered by a restricted stock unit
award. However, we do not anticipate paying cash dividends on our common stock for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Performance Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2011 Plan allows the Administrator to issue performance stock awards. Performance stock awards may be granted, vest or be exercised
based upon the attainment during a certain period of time of certain performance goals and will be issued in shares of our common stock, or if determined by the Administrator, cash. All of our employees, consultants and directors are eligible to
receive performance stock awards under the Amended 2011 Plan. The length of any performance period, the performance goals to be achieved during the performance period and the measure of whether and to what degree such performance goals have been
attained shall be determined by the Administrator. The maximum amount to be granted to any individual in any calendar year attributable to such performance stock awards may not exceed 500,000 shares of our common stock. Notwithstanding this limit,
however, in connection with an employee&#146;s initial employment, he or she may be granted stock awards covering up to an additional 500,000 shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In granting a performance stock award, the Administrator will set a period of time, or a performance period, over which the attainment of one
or more goals, or performance goals, will be measured for the purpose of determining whether the stock award recipient has a vested right in or to such performance stock award. With respect to stock awards that are intended to qualify as performance
based compensation for purposes of Section&nbsp;162(m) of the Code, within the time period prescribed by Section&nbsp;162(m) of the Code, the Administrator will establish the performance goals, based upon one or more
<FONT STYLE="white-space:nowrap">pre-established</FONT> criteria, or performance criteria, enumerated in the Amended 2011 Plan and described below. However, in order to qualify as &#147;performance-based compensation&#148; under Section&nbsp;162(m)
of the Code, among other requirements, such awards must be eligible to qualify for the Section&nbsp;162(m) Transition Relief (as described in &#147;Section&nbsp;162(m) Transition Relief for Performance-Based Compensation&#148; above). As soon as
administratively practicable following the end of the performance period, the Administrator will certify (in writing) whether the performance goals have been satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Performance goals under the Amended 2011 Plan shall be established by the Administrator, based on one or more of the following performance
criteria: (i)&nbsp;earnings (including earnings per share and net earnings, in either case before or after any or all of: interest, taxes, depreciation and amortization, legal settlements or other income (expense), or stock-based compensation, other
<FONT STYLE="white-space:nowrap">non-cash</FONT> expenses and changes in deferred revenue); (ii)&nbsp;total stockholder return; (iii)&nbsp;return on equity or average stockholder&#146;s equity; (iv)&nbsp;return on assets, investment, or capital
employed; (v)&nbsp;stock price; (vi)&nbsp;margin (including gross margin); (vii)&nbsp;income (before or after taxes); (viii)&nbsp;operating income; (ix)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(x)&nbsp;pre-tax</FONT>
profit; (xi)&nbsp;operating cash flow; (xii)&nbsp;sales or revenue targets; (xiii)&nbsp;increases in revenue or product revenue; (xiv)&nbsp;expenses and cost reduction goals; (xv)&nbsp;improvement in or attainment of working capital levels;
(xvi)&nbsp;economic value added (or an equivalent metric); (xvii)&nbsp;market share; (xviii)&nbsp;cash flow; (xix)&nbsp;cash flow per share; (xx)&nbsp;cash burn; (xxi)&nbsp;share price performance; (xxii)&nbsp;debt reduction;
(xxiii)&nbsp;implementation or completion of projects or processes (including, without limitation, discovery of a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> drug candidate, recommendation of a drug candidate to enter a clinical trial,
clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals, presentation of studies and
launch of commercial plans, compliance programs or education campaigns); (xxiv)&nbsp;customer satisfaction; (xxv)&nbsp;stockholders&#146; equity; (xxvi)&nbsp;capital expenditures; (xxvii)&nbsp;debt levels; (xxviii)&nbsp;financings;
(xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii)&nbsp;employee hiring; (xxxiv)&nbsp;funds from operations; (xxxv)&nbsp;budget
management; (xxxvi)&nbsp;strategic partnerships or transactions (including acquisitions, joint ventures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or licensing transactions); (xxxvii)&nbsp;engagement of thought leaders and patient advocacy groups; (xxxviii)&nbsp;enhancement of intellectual property portfolio, filing of patent applications
and granting of patents; (xxxix)&nbsp;litigation preparation and management; and (xl)&nbsp;to the extent that an award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by the Administrator, the attainment of performance goals for a performance period will be calculated: (i)&nbsp;to
exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated net sales and operating earnings; (iii)&nbsp;to exclude the
effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that
are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business
divested by the Company achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the
Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or
any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans; (x)&nbsp;to exclude costs incurred in connection
with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally
accepted accounting principles; and (xii)&nbsp;to exclude the effects of the timing of acceptance for review and/or approval of submissions to the FDA or any other regulatory body. In addition, the Administrator retains the discretion to reduce or
eliminate the compensation or economic benefit due upon attainment of performance goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Discretionary</FONT>
Grant Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program under the Amended 2011 Plan provides for the
grant of stock options to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors over their period of service on the Board of Directors. These stock options will be granted as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Initial Option Grant</I></B>. Each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director will, at the time of his or her
initial election or appointment to the Board of Directors, receive an option to purchase a number of shares of the Company&#146;s common stock determined by the Board of Directors (the &#147;initial option grant&#148;). The initial option grant
shall vest monthly with respect to 1/36th of the shares over the three-year period following the date of grant, subject to the director&#146;s continuous service through the applicable vesting dates, so that the initial option grant will be fully
vested on the third anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Option Grant</I></B>. On each annual meeting, each continuing <FONT
STYLE="white-space:nowrap">non-employee</FONT> director will automatically be granted a stock option to purchase a number of shares of our common stock determined by the Board of Directors (the &#147;annual option grant&#148;). The annual option
grant shall vest monthly with respect to 1/12th of the shares over the one year period following the date of grant, subject to the director&#146;s continuous service through the applicable vesting dates, so that the annual option grant will be fully
vested on the first anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General Terms</I></B>. The exercise price of each option granted under the <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> grant program is 100% of the fair market value of the common stock subject to the option on the date of grant. The maximum term of options granted under the
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program is ten years. All other terms of each option granted under the <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program shall be consistent with the terms of the
Amended 2011 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Transaction</I></B>. Each option granted under the
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> grant program shall automatically fully accelerate vesting upon a corporate transaction, subject to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s continuous service
through the date of the corporate transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Other Stock Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator may grant other stock awards that are valued in whole or in part by reference to our common stock. Subject to the provisions
of the Amended 2011 Plan, the Administrator has the authority to determine the persons to whom, and the dates on which, such other stock awards will be granted, the number of shares of common stock (or cash equivalents) to be subject to each award,
and other terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tax Withholding</I></B>. To the extent provided by the terms of any stock award agreement, a participant may satisfy any federal, state
or local tax withholding obligation relating to such stock award by a cash payment, by authorizing the Company to withhold a portion of the stock otherwise issuable to the participant, by withholding from any amounts otherwise payable to the
participant, by a combination of these means, or by such other method as set forth in the stock award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transferability</I></B>. Stock awards may not be sold, pledged, transferred, or disposed of in any manner other than by will or by the
laws of descent and distribution, pursuant to a domestic relations order, or with respect to stock awards other than options or stock appreciation rights, with the Administrator&#146;s consent, and may be exercised, during the lifetime of the
holder, only by the holder or such transferees as have been transferred a stock award with the Administrator&#146;s consent. If the Administrator makes a stock award transferable, such stock award shall contain such additional terms and conditions
as the Administrator deems appropriate and such award will not otherwise be transferred for consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adjustments Upon Changes
in Capitalization</I></B>. In the event any change is made to the outstanding shares of the Company&#146;s common stock without the receipt of consideration (whether through a stock split or other specified change in our capital structure), the
Administrator shall appropriately adjust the number and kind of shares of stock (or other securities or property) subject to the Amended 2011 Plan, the maximum number of shares that may be issued pursuant to the exercise of incentive stock options,
the maximum numbers and/or class of securities for which any one person may be granted appreciation awards, full value stock awards and performance stock awards per calendar year, the number and kind of shares of stock (or other securities or
property) subject to any stock award outstanding under the Amended 2011 Plan, and the exercise or purchase price of any such outstanding stock award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effect of Certain Corporate Events</I></B>. In the event of a dissolution or liquidation of the Company, all outstanding stock awards
under the Amended 2011 Plan shall terminate immediately prior to such dissolution or liquidation. The Amended 2011 Plan further provides that, in the event of a sale, or other disposition of all or substantially all of the Company&#146;s assets or
specified types of mergers or consolidations (each, a &#147;corporate transaction&#148;), any surviving or acquiring corporation shall either assume stock awards outstanding under the Amended 2011 Plan or substitute similar stock awards for those
outstanding under the Amended 2011 Plan. If any surviving corporation declines to assume stock awards outstanding under the Amended 2011 Plan or to substitute similar stock awards, then, with respect to participants whose service with the Company
has not terminated prior to the time of such corporate transaction, the vesting and the time during which such stock awards may be exercised will be accelerated in full, and all outstanding stock awards will terminate if the participant does not
exercise such stock awards at or prior to the corporate transaction. With respect to any stock awards that are held by other participants that terminated service with the Company prior to the corporate transaction, the vesting and exercisability
provisions of such stock awards will not be accelerated and such stock awards will terminate if not exercised prior to the corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment and Termination of the Amended 2011 Plan</I></B>. The Board of Directors may amend, alter, suspend or terminate the Amended
2011 Plan, or any part thereof, at any time and for any reason. Unless sooner terminated, the Amended 2011 Plan will terminate on February&nbsp;20, 2021.&nbsp;However, the Amended 2011 Plan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requires stockholder approval for any amendment to the Amended 2011 Plan to the extent necessary to comply with applicable laws, rules and regulations. No action by the Board of Directors or
stockholders may impair any award previously granted under the Amended 2011 Plan without the consent of the holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Consequences
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Incentive Stock Options</I></B>. An optionee who is granted an incentive stock option does not recognize taxable income at the
time the option is granted or upon its exercise, although the exercise is an adjustment item for alternative minimum tax purposes and may subject the optionee to the alternative minimum tax. Upon a disposition of the shares more than two years after
grant of the option and one year after exercise of the option, any gain or loss is treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee recognizes ordinary income at the time of disposition equal to the
difference between the exercise price and the lesser of (i)&nbsp;the excess of the stock&#146;s fair market value on the date of exercise over the exercise price, or (ii)&nbsp;the participant&#146;s actual gain, if any, on the purchase and sale. Any
gain or loss recognized on such a premature disposition of the shares in excess of the amount treated as ordinary income is treated as long-term or short-term capital gain or loss, depending on the holding period. A different rule for measuring
ordinary income upon such a premature disposition may apply if the optionee is also an officer, director or 10% stockholder of the Company. Unless limited by Section&nbsp;162(m) of the Code, the Company is entitled to a deduction in the same amount
as the ordinary income recognized by the optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nonstatutory Stock Options</I></B>. An optionee does not recognize any taxable
income at the time he or she is granted a nonstatutory stock option. Upon exercise, the optionee recognizes taxable income generally measured by the excess of the then fair market value of the shares over the exercise price. Any taxable income
recognized in connection with an option exercise by an employee of the Company is subject to tax withholding by the Company. Unless limited by Section&nbsp;162(m) of the Code, the Company is entitled to a deduction in the same amount as the ordinary
income recognized by the optionee. Upon a disposition of such shares by the optionee, any difference between the sale price and the optionee&#146;s exercise price, to the extent not recognized as taxable income as provided above, is treated as
long-term or short-term capital gain or loss, depending on the holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights</I></B>. No taxable income
is realized upon the receipt of a stock appreciation right. Upon exercise of the stock appreciation right, the fair market value of the shares (or cash in lieu of shares) received is recognized as ordinary income to the participant in the year of
such exercise. Generally, with respect to employees, we are required to withhold from the payment made on exercise of the stock appreciation right or from regular wages or supplemental wage payments an amount based on the ordinary income recognized.
Subject to the requirement of reasonableness, Section&nbsp;162(m) of the Code and the satisfaction of a reporting obligation, we will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards</I></B>. For federal income tax purposes, if an individual is granted a restricted stock award, the recipient
generally will recognize taxable ordinary income equal to the excess of the common stock&#146;s fair market value over the purchase price, if any. However, to the extent the common stock is subject to certain types of restrictions, such as a
repurchase right in favor of the Company, the taxable event will be delayed until the vesting restrictions lapse unless the recipient makes a valid election under Section&nbsp;83(b) of the Code. If the recipient makes a valid election under
Section&nbsp;83(b) of the Code with respect to restricted stock, the recipient generally will recognize ordinary income at the date of acquisition of the restricted stock in an amount equal to the difference, if any, between the fair market value of
the shares at that date over the purchase price for the restricted stock. If, however, a valid Section&nbsp;83(b) election is not made by the recipient, the recipient will generally recognize ordinary income when the restrictions on the shares of
restricted stock lapse, in an amount equal to the difference between the fair market value of the shares at the date such restrictions lapse over the purchase price for the restricted stock. With respect to employees, the Company is generally
required to withhold from regular wages or supplemental wage payments an amount based on the ordinary income recognized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Generally, the Company will be entitled (subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation) to a
business expense deduction equal to the taxable ordinary income realized by the recipient. Upon disposition of the common stock, the recipient will recognize a capital gain or loss equal to the difference between the selling price and the sum of the
amount paid for such common stock, if any, plus any amount recognized as ordinary income upon acquisition (or the lapse of restrictions) of the common stock. Such gain or loss will be long-term or short-term depending on how long the common stock
was held. Slightly different rules may apply to recipients who are subject to Section&nbsp;16(b) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted
Stock Unit Awards</I></B>. No taxable income is recognized upon receipt of a restricted stock unit award. The participant will recognize ordinary income in the year in which the shares subject to that unit are actually issued to the participant in
an amount equal to the fair market value of the shares on the date of issuance. The participant and the Company will be required to satisfy certain tax withholding requirements applicable to such income. Subject to the requirement of reasonableness,
Section&nbsp;162(m) of the Code and the satisfaction of a tax reporting obligation, we will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued. In general,
the deduction will be allowed for the taxable year in which such ordinary income is recognized by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential
Limitation on Company Deductions</I></B>. Section&nbsp;162(m) of the Code disallows a deduction to any publicly held corporation and its affiliates for certain compensation paid to &#147;covered employees&#148; in a taxable year to the extent that
compensation to a covered employee exceeds $1&nbsp;million. Prior to the recent enactment of the Tax Cuts and Jobs Act, compensation that qualified as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code was not subject
to this deduction limitation. Pursuant to the Tax Cuts and Jobs Act, this exception for &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code was repealed, with respect to taxable years beginning after December&nbsp;31,
2017, except that certain transition relief is provided by the Tax Cuts and Jobs Act for remuneration provided pursuant to a written binding contract which was in effect on November&nbsp;2, 2017 and which was not modified in any material respect on
or after such date. As a result, compensation paid to any of our &#147;covered employees&#148; in excess of $1&nbsp;million per taxable year generally will not be deductible unless, among other requirements, it is intended to qualify, and is
eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act. Because of certain ambiguities and uncertainties as to the application
and interpretation of Section&nbsp;162(m) of the Code and the regulations issued thereunder, including the uncertain scope of the transition relief provided by the Tax Cuts and Jobs Act, no assurance can be given that any award granted under the
Amended 2011 Plan will be eligible for such transition relief and, therefore, eligible for the &#147;performance-based compensation&#148; exception under Section&nbsp;162(m) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The foregoing is only a summary of the effect of federal income taxation upon holders of stock awards and the Company with respect to the
grant and exercise of stock awards under the Amended 2011 Plan. It does not purport to be complete, and does not discuss the tax consequences of the holder&#146;s death or the provisions of the income tax laws of any municipality, state or foreign
country in which the holder may reside. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amended 2011 Plan </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former President, Chief Operating Officer and interim Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group (nine persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group&nbsp;(seven
persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including all current officers who are not executive officers, as a group
(approximately 430 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Coughlin resigned as our Chief Financial Officer effective February&nbsp;15, 2017 (the &#147;Resignation Date&#148;), but he will remain an employee of the Company following the Resignation Date until
May&nbsp;31, 2018 (or such earlier date that Mr.&nbsp;Coughlin and we mutually designate). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gros resigned as our President, Chief Executive Officer and interim Chief Financial Officer effective October&nbsp;19, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Awards granted under the Amended 2011 Plan to our executive officers and other employees are discretionary and are not subject to set benefits or amounts under the terms of the Amended 2011 Plan, and our Board of
Directors and our Compensation Committee have not granted any awards under the Amended 2011 Plan subject to stockholder approval of this Proposal Four. Accordingly, the benefits or amounts that will be received by or allocated to our executive
officers and other employees under the Amended 2011 Plan are not determinable. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;O&#146;Brien resigned as our Chief Medical Officer effective February&nbsp;15, 2018, but remain as an exclusive consultant to the Company. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pursuant to the terms of the Amended 2011 Plan, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
are entitled to receive options as described in <FONT STYLE="white-space:nowrap">&#147;Non-Discretionary</FONT> Grant Program&#148; above. Under our current compensation arrangements for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
and the Amended 2011 Plan, each of our eight current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be automatically granted a nonstatutory stock option to purchase 15,000 (18,000 in the case of our Chairman) shares at the
Annual Meeting and such options will be granted under the Amended 2011 Plan. For additional information regarding our current compensation arrangements for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, please see &#147;Director
Compensation&#148; below. The actual value realized upon exercise of an option will depend on the excess, if any, of the stock price over the exercise prices on the date of exercise. Only
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the Company are eligible to receive <FONT STYLE="white-space:nowrap">non-discretionary</FONT> grants under the Amended 2011 Plan.
All other grants under the Amended 2011 Plan are within the discretion of the Administrator. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for each of the individuals and groups indicated, the total number of shares of our common stock subject to
options and stock awards that have been granted (even if not currently outstanding) under the 2011 Plan through the Record Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2011
Plan </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:63.95pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;shares&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,724,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David- Alexandr&egrave; C. Gros, M.D. (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former President and Chief Operating Officer and interim Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">807,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers as a group (nine persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,621,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors who are not executive officers as a group (seven&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Each nominee for election as a director: (two persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All employees, including all current officers who are not executive officers, as a group
(approximately 430 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,065,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Coughlin resigned as our Chief Financial Officer effective February&nbsp;15, 2017 (the &#147;Resignation Date&#148;), but he will remain an employee of the Company following the Resignation Date until
May&nbsp;31, 2018 (or such earlier date that Mr.&nbsp;Coughlin and the Company mutually designate). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gros resigned as our President, Chief Executive Officer and interim Chief Financial Officer effective October&nbsp;19, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;O&#146;Brien resigned as our Chief Medical Officer effective February&nbsp;15, 2018, but remains as an exclusive consultant to the Company. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A VOTE &#147;FOR&#148; PROPOSAL THREE </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY COMPENSATION PLANS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding all of the Company&#146;s equity compensation plans as of March&nbsp;1, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:49.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities&nbsp;to&nbsp;be<BR>Issued upon<BR>Exercise of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise Price of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Remaining&nbsp;Available<BR>for Future Issuance<BR>Under Equity<BR>Compensation Plans<BR>(Excluding<BR>Securities
Reflected<BR>in Column a)<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders&nbsp;(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,295,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,990,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders&nbsp;(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,588,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,046,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The number of securities remaining available for future issuance under equity compensation plans as of March&nbsp;1, 2018 are from the 2011 Plan. The shares available for issuance under the 2011 Plan may be issued in
the form of option awards, restricted stock awards, restricted stock unit awards or stock bonus awards subject to limitations set forth in the 2011 Plan. In addition to the above, the Company had 1,541,301 restricted stock units outstanding as of
March&nbsp;1, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares of common stock issuable pursuant to employment commencement nonstatutory stock option awards. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL FOUR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVAL OF 2018 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are asking our stockholders to approve the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan, or the ESPP, at the Annual
Meeting. The ESPP was approved by the Board of Directors on February&nbsp;6, 2018, subject to approval by our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of
the ESPP will allow us to provide our employees with the opportunity to acquire an ownership interest in the Company through their participation in the ESPP, thereby encouraging them to remain in our service and more closely aligning their interests
with those of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Proposal Four is approved by our stockholders, the maximum number of shares of our common stock
that may be issued under the ESPP will be 300,000 shares. We do not maintain any other employee stock purchase plans. As of March&nbsp;1, 2018, a total of 89,709,497 shares of our common stock were outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Proposal Four is approved by our stockholders, the ESPP will become effective as of the date of the Annual Meeting. In the event that
our stockholders do not approve this Proposal Four, the ESPP will not become effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the 2018 Employee Stock Purchase Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material features of the ESPP are described below. The following description of the ESPP is a summary only and is qualified in its entirety
by reference to the complete text of the ESPP. Stockholders are urged to read the actual text of the ESPP in its entirety, which is attached hereto as Appendix B. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to
provide a means by which our employees may be given an opportunity to purchase shares of our common stock, to assist us in retaining the services of our employees, to secure and retain the services of new employees and to provide incentives for such
persons to exert maximum efforts for our success. The rights to purchase common stock granted under the ESPP are intended to qualify as options issued under an &#147;employee stock purchase plan&#148; as that term is defined in Section&nbsp;423(b)
of the Internal Revenue Code of 1986, as amended, or the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has the power to administer the ESPP and may also delegate administration of the ESPP to a committee comprised of one or
more members of the Board of Directors. The Board of Directors has delegated administration of the ESPP to the Compensation Committee, but may, at any time, revest in itself some or all of the powers previously delegated to the Compensation
Committee. The Board of Directors and the Compensation Committee are each considered to be a Plan Administrator for purposes of this Proposal Four. The Plan Administrator has the final power to construe and interpret both the ESPP and the rights
granted under it. The Plan Administrator has the power, subject to the provisions of the ESPP, to determine when and how rights to purchase our common stock will be granted, the provisions of each offering of such rights (which need not be
identical), and whether employees of any of our parent or subsidiary companies will be eligible to participate in the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Subject to ESPP
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may be issued
under the ESPP is 300,000 shares. If any rights granted under the ESPP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate without being exercised in full, the shares of common stock not purchased under such rights again become available for issuance under the ESPP. The shares of common stock issuable under
the ESPP will be shares of authorized but unissued or reacquired common stock, including shares repurchased by us on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offerings
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP will be implemented by offerings of rights to purchase our common stock to all eligible employees. The Plan Administrator
will determine the duration of each offering period, provided that in no event may an offering period exceed 27 months. The Plan Administrator may establish separate offerings which vary in terms (although not inconsistent with the provisions of the
ESPP or the requirements of applicable laws). Each offering period will have one or more purchase dates, as determined by the Plan Administrator prior to the commencement of the offering period. The Plan Administrator has the authority to alter the
terms of an offering prior to the commencement of the offering period, including the duration of subsequent offering periods. When an eligible employee elects to join an offering period, he or she is granted a right to purchase shares of our common
stock on each purchase date within the offering period. On the purchase date, all contributions collected from the participant are automatically applied to the purchase of our common stock, subject to certain limitations (which are described further
below under &#147;Eligibility&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan Administrator has the discretion to structure an offering so that if the fair market value
of our common stock on the first trading day of a new purchase period within the offering period is less than or equal to the fair market value of our common stock on the first day of the offering period, then that offering will terminate
immediately as of that first trading day, and the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any individual who is
employed by us (or by any of our parent or subsidiary companies if such company is designated by the Plan Administrator as eligible to participate in the ESPP) may participate in offerings under the ESPP, provided such individual has been employed
by us (or our parent or subsidiary, if applicable) for such continuous period preceding the first day of the offering period as the Plan Administrator may require, but in no event may the required period of continuous employment be equal to or
greater than two years. In addition, the Plan Administrator may provide that an employee will not be eligible to be granted purchase rights under the ESPP unless such employee is customarily employed for more than 20 hours per week and five months
per calendar year. The Plan Administrator may also provide in any offering that certain of our employees who are &#147;highly compensated&#148; as defined in the Code are not eligible to participate in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No employee will be eligible to participate in the ESPP if, immediately after the grant of purchase rights, the employee would own, directly
or indirectly, stock possessing 5% or more of the total combined voting power or value of all classes of our stock or of any of our parent or subsidiary companies, including any stock which such employee may purchase under all outstanding purchase
rights and options. In addition, no employee may purchase more than $25,000 worth of our common stock (determined based on the fair market value of the shares at the time such rights are granted) under all our employee stock purchase plans and any
employee stock purchase plans of our parent or subsidiary companies for each calendar year during which such rights are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of March&nbsp;28, 2018, we had approximately 440 employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Participation in the ESPP </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may enroll in the ESPP by delivering to us, prior to the date selected by the Plan Administrator as the beginning of an
offering period, an agreement authorizing contributions which may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceed the maximum amount specified by the Plan Administrator, but in any case which may not exceed 15% of such employee&#146;s earnings during the offering period. Each participant will be
granted a separate purchase right for each offering in which he or she participates. Unless an employee&#146;s participation is discontinued, his or her purchase right will be exercised automatically at the end of each purchase period at the
applicable purchase price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Price </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price per share at which shares of our common stock are sold on each purchase date during an offering period will not be less than
the lower of (i) 85% of the fair market value of a share of our common stock on the first day of the offering period or (ii) 85% of the fair market value of a share of our common stock on the purchase date. As of March&nbsp;1, 2018, the closing
price of our common stock as reported on the NASDAQ Global Select Market was $84.14 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Payment of Purchase Price; Payroll Deductions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase of shares during an offering period generally will be funded by a participant&#146;s payroll deductions accumulated during the
offering period. A participant may change his or her rate of contributions, as determined by the Plan Administrator in the offering. All contributions made for a participant are credited to his or her account under the ESPP and deposited with our
general funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Limits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with each offering made under the ESPP, the Plan Administrator may specify (i)&nbsp;a maximum number of shares of our common stock that may be purchased by any participant pursuant to such offering, (ii)&nbsp;a maximum number of shares of
our common stock that may be purchased by any participant on any purchase date pursuant to such offering, (iii)&nbsp;a maximum aggregate number of shares of our common stock that may be purchased by all participants pursuant to such offering, and/or
(iv)&nbsp;a maximum aggregate number of shares of our common stock that may be purchased by all participants on any purchase date pursuant to such offering. If the aggregate purchase of shares of our common stock issuable upon exercise of purchase
rights granted under such offering would exceed any such maximum aggregate number, then the Plan Administrator will make a pro rata allocation of available shares in a uniform and equitable manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withdrawal </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants may withdraw
from a given offering by delivering a withdrawal form to us and terminating their contributions. Such withdrawal may be elected at any time prior to the end of an offering, except as otherwise provided by the Plan Administrator. Upon such
withdrawal, we will distribute to the employee his or her accumulated but unused contributions without interest, and such employee&#146;s right to participate in that offering will terminate. However, an employee&#146;s withdrawal from an offering
does not affect such employee&#146;s eligibility to participate in subsequent offerings under the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Employment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant&#146;s rights under any offering under the ESPP will terminate immediately if the participant either (i)&nbsp;is no longer
employed by us or any of our parent or subsidiary companies (subject to any post-employment participation period required by law) or (ii)&nbsp;is otherwise no longer eligible to participate. In such event, we will distribute to the participant his
or her accumulated but unused contributions without interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restrictions on Transfer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rights granted under the ESPP are not transferable except by will, by the laws of descent and distribution, or if permitted by us, by a
beneficiary designation. During a participant&#146;s lifetime, such rights may only be exercised by the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Capitalization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of certain changes in our capitalization, the Plan Administrator will appropriately adjust: (i)&nbsp;the class(es) and maximum
number of securities subject to the ESPP; (ii)&nbsp;the class(es) and number of securities subject to, and the purchase price applicable to outstanding purchase rights; and (iii)&nbsp;the class(es) and number of securities that are the subject of
any purchase limits under each ongoing offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Effect of Certain Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined in the ESPP and described below), (i) any surviving or acquiring corporation (or its parent
company) may assume or continue outstanding purchase rights granted under the ESPP or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the corporate transaction) for such outstanding
purchase rights, or (ii)&nbsp;if any surviving or acquiring corporation (or its parent company) does not assume or continue such outstanding purchase rights or does not substitute similar rights for such outstanding purchase rights, then the
participants&#146; accumulated contributions will be used to purchase shares of our common stock within ten business days prior to the corporate transaction under such purchase rights, and such purchase rights will terminate immediately after such
purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the ESPP, a corporate transaction generally will be deemed to occur in the event of the consummation of:
(i)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 90% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following
which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are
converted or exchanged into other property by virtue of such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duration, Amendment and Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan Administrator may amend or terminate the ESPP at any time. However, except in regard to certain capitalization adjustments, any such
amendment must be approved by our stockholders if such approval is required by applicable law or listing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any outstanding
purchase rights granted before an amendment or termination of the ESPP will not be materially impaired by any such amendment or termination, except (i)&nbsp;with the consent of the employee to whom such purchase rights were granted, (ii)&nbsp;as
necessary to comply with applicable laws, listing requirements or governmental regulations (including Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing or regulatory treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the ESPP or any offering to the contrary, the Plan Administrator will be entitled to: (i)&nbsp;establish the
exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit contributions in excess of the amount designated by a participant in order to adjust for mistakes in the processing of properly completed
contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of our common stock for each participant properly correspond with
amounts withheld from the participant&#146;s contributions; (iv)&nbsp;amend any outstanding purchase rights or clarify any ambiguities regarding the terms of any offering to enable such purchase rights to qualify under and/or comply with
Section&nbsp;423 of the Code; and (v)&nbsp;establish other limitations or procedures as the Plan Administrator determines in its sole discretion advisable that are consistent with the ESPP. Any such actions by the Plan Administrator will not be
considered to alter or impair any purchase rights granted under an offering as they are part of the initial terms of each offering and the purchase rights granted under each offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following is a summary of the principal United States federal income taxation consequences to participants and us with respect to participation in the ESPP. This summary is not intended to be exhaustive and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is
subject to change when those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local, and
other tax consequences of the grant or exercise of a purchase right or the sale or other disposition of common stock acquired under the ESPP. The ESPP is not qualified under the provisions of Section&nbsp;401(a) of the Code and is not subject to any
of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rights granted under the ESPP are intended to
qualify for favorable federal income tax treatment associated with rights granted under an employee stock purchase plan which qualifies under the provisions of Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will be taxed on amounts withheld for the purchase of shares of our common stock as if such amounts were actually received.
Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a purchase right until a sale or other disposition of the acquired shares. The taxation upon such sale or other disposition will depend upon the holding
period of the acquired shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shares are sold or otherwise disposed of more than two years after the beginning of the offering
period and more than one year after the shares are transferred to the participant, then the lesser of the following will be treated as ordinary income: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or other
disposition over the purchase price; or (ii)&nbsp;the excess of the fair market value of the shares as of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period). Any further gain or any
loss will be taxed as a long-term capital gain or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the shares are sold or otherwise disposed of before the expiration of either
of the holding periods described above, then the excess of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of such sale or other disposition. The balance of any gain
will be treated as capital gain. Even if the shares are later sold or otherwise disposed of for less than its fair market value on the purchase date, the same amount of ordinary income is attributed to the participant, and a capital loss is
recognized equal to the difference between the sales price and the fair market value of the shares on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no federal income tax consequences to us by reason of the grant or exercise of rights under the ESPP. We are entitled to a deduction
to the extent amounts are taxed as ordinary income to a participant for shares sold or otherwise disposed of before the expiration of the holding periods described above (subject to the requirement of reasonableness and the satisfaction of tax
reporting obligations). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participation in the ESPP is voluntary and each eligible employee will make his or her own decision regarding whether and to what extent to
participate in the ESPP. In addition, the Board of Directors and the Compensation Committee have not granted any purchase rights under the ESPP that are subject to stockholder approval of this Proposal Four. Accordingly, the benefits or amounts that
will be received by or allocated to our executive officers and other employees under the ESPP, as well as the benefits or amounts which would have been received by or allocated to our executive officers and other employees for fiscal year 2017 if
the ESPP had been in effect, are not determinable. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will not be eligible to participate in the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, the
stockholders are being asked to approve the ESPP. The affirmative vote of the holders of a majority of the shares represented in person or by proxy at the Annual Meeting and entitled to vote on the item will be required to approve the ESPP. <B>The
Board of Directors recommends voting &#147;FOR&#148; the approval of the ESPP.</B><B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROPOSAL&nbsp;FIVE: RATIFICATION OF APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected
Ernst&nbsp;&amp; Young LLP to audit the financial statements of the Company for the current fiscal year ending December&nbsp;31, 2018. Ernst&nbsp;&amp; Young LLP has audited the Company&#146;s financial statements since 1992. Representatives of
Ernst&nbsp;&amp; Young LLP are expected to be present at the Annual Meeting, will have the opportunity to make a statement if they so desire, and are expected to be available to respond to appropriate questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders are not required to ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public
accounting firm. However, the Audit Committee is submitting the selection of Ernst&nbsp;&amp; Young LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit
Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in their discretion may direct the selection of a different independent registered public accounting firm at any time during the
year if they determine that such a change would be in the best interests of the Company and its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the&nbsp;shares represented in person or by proxy at the Annual Meeting and entitled to
vote on the item will be required to approve and ratify the Audit Committee&#146;s selection of Ernst&nbsp;&amp; Young LLP.<B> The Board of Directors unanimously recommends voting &#147;FOR&#148; approval and ratification of such
selection.</B>&nbsp;In the event of a negative vote on such ratification, the Audit Committee will reconsider its selection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Record Date, our executive officers were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Position</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle W. Gano, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dimitri E. Grigoriadis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Research Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Darin M. Lippoldt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Legal&nbsp;Officer&nbsp;and&nbsp;Corporate&nbsp;Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Malcolm C. Lloyd-Smith</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Regulatory Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eiry W. Roberts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See above for biographical information concerning Kevin C. Gorman,&nbsp;Ph.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew C. Abernethy</I></B><B> </B>was appointed Chief Financial Officer in November 2017 and is responsible for leading corporate
finance activities and commercial supply chain operations, as well as information technology and investor relations functions at Neurocrine. Mr.&nbsp;Abernethy has nearly 15 years of experience in the financial sector and investor relations with
expertise in the healthcare industry. He joined Neurocrine from Zimmer Biomet, where he held various positions from February 2009 to November 2017, including most recently, Vice President, Investor Relations and Treasurer and Vice President of
Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr.&nbsp;Abernethy earned bachelor&#146;s degrees in Accounting and Business Administration from Grace College and an MBA
from the University of Chicago. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Benevich </I></B>was appointed Chief Commercial Officer in May 2015 and is responsible for all
aspects of commercial development, marketing and sales of the Neurocrine product portfolio.&nbsp;Previously, Mr.&nbsp;Benevich was at Avanir Pharmaceuticals, Inc., from 2005 to 2015, serving most recently as Vice President of Marketing where he was
responsible for NUEDEXTA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and commercialization of their CNS pipeline. Mr.&nbsp;Benevich has over 20&nbsp;years of experience in the pharmaceutical industry and previously served in various
positions of increasing responsibility at Peninsula Pharmaceuticals Inc., Amgen and AstraZeneca in the sales and marketing of drugs such as Enbrel<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Epogen<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Prilosec<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Mr.&nbsp;Benevich has a BBA in International Business from Washington State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Haig P. Bozigian,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B> was appointed Chief Development Officer in December 2006 after having
served as Senior Vice President of Pharmaceutical and Preclinical Development. He is responsible for all preclinical development, chemistry manufacturing and controls (CMC) and clinical pharmacology. Dr.&nbsp;Bozigian joined Neurocrine in 1997. With
extensive expertise in CNS related new product development, Dr.&nbsp;Bozigian has participated in research and development for approximately 30&nbsp;years. Prior to joining Neurocrine, Dr.&nbsp;Bozigian served as Director of Pharmaceutical
Development at Procyte Corporation, Associate Director of Pharmacokinetics and Drug Metabolism at Sphinx Pharmaceuticals Corporation and as a Clinical Pharmacokineticist at GlaxoSmithKline. Dr.&nbsp;Bozigian earned his B.S. in Microbiology from the
University of Massachusetts, his M.S. in Pharmacodynamics and Toxicology from the University of Nebraska Medical Center, and earned his Ph.D. in Pharmaceutical Sciences from the University of Arizona. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kyle W. Gano, Ph.D.</I></B> was appointed Chief Business Development Officer in 2011 and is responsible for all business and corporate
development activities, including the management of ongoing collaborations with AbbVie, Mitsubishi Tanabe Pharma and Sumitomo Dainippon Pharma. From 2001 to 2011, Dr.&nbsp;Gano held several positions of increasing responsibility at Neurocrine
spanning marketing analytics to business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development. Dr.&nbsp;Gano received his B.S. in Chemistry from the University of Oregon, B.S. in Biochemistry from the University of Washington, and his Ph.D. in Organic Chemistry and M.B.A in
Finance from the University of California, Los Angeles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dimitri E. Grigoriadis, Ph.D. </I></B>became Chief Research Officer in
January 2007 and oversees all research functions, including drug discovery, biology and chemistry. Dr.&nbsp;Grigoriadis joined Neurocrine in 1993, established the pharmacology and drug screening groups and was most recently a Neurocrine Fellow and
Vice President of Discovery Biology. Prior to joining Neurocrine, he was a Senior Scientist in the Neuroscience group at the DuPont Pharmaceutical Company from 1990 to 1993. Dr.&nbsp;Grigoriadis received his B.Sc. from the University of Guelph in
Ontario, Canada, and his M.Sc. and Ph.D. in Pharmacology from the University of Toronto, Ontario, Canada. He conducted his postdoctoral research at the National Institute on Drug Abuse from 1987 to 1990. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Darin M. Lippoldt</I></B> was appointed Chief Legal Officer and Corporate Secretary in October 2014 and has oversight of all corporate
legal matters, intellectual property, compliance, and government relations. Prior to joining Neurocrine, Mr.&nbsp;Lippoldt served as Executive Vice President, General Counsel, and Chief Compliance Officer of Volcano Corporation, a company he joined
in 2010. Prior to Volcano, Mr.&nbsp;Lippoldt served as Associate General Counsel at Amylin Pharmaceuticals, Inc. since 2003. He previously practiced corporate and securities law with the law firms of Fulbright&nbsp;&amp; Jaworski LLP and Matthews
and Branscomb, P.C. Mr.&nbsp;Lippoldt received a B.B.A. in Finance, an M.A. in International Relations and a J.D. from St. Mary&#146;s University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Malcolm C. Lloyd-Smith</I></B> was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and
quality assurance. Prior to joining Neurocrine, Mr.&nbsp;Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice
President, Regulatory Affairs and Quality Assurance from August 2008. Mr.&nbsp;Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the
United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr.&nbsp;Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA
and UK. Mr.&nbsp;Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eiry W. Roberts, M.D.,</I></B> was appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and
medical affairs activities at Neurocrine. Dr.&nbsp;Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic
areas, including neuroscience, inflammation, oncology and metabolic diseases. She joined Neurocrine from Eli Lilly and Company where she held various positions during her tenure, including Vice President, Clinical Pharmacology and Vice President of
R&amp;D, BioMedicines Business Unit. Dr.&nbsp;Roberts was the Chair of the Medical Review Committee, where she was responsible for review and approval of all the integrated clinical plans for molecules in the Lilly portfolio. Dr.&nbsp;Roberts was
accountable for early clinical development programs across all therapeutic areas within Lilly, as well as registration for new chemical entities and biproducts in Phase III development. During her time at Lilly, Dr.&nbsp;Roberts established a new
therapeutic area, which resulted in the development of five potential novel medicines from Phase I through to approval, with two of them successfully receiving regulatory approval. Dr.&nbsp;Roberts also has extensive leadership and business
development experience, including the management of strategic alliances, business partnerships and venture capital collaborations. Dr.&nbsp;Roberts is a physician who trained in pharmacology and medicine in the UK, qualifying from the University of
London in 1987. Her post-graduate clinical training was in clinical pharmacology and cardiology at St. Bartholomew&#146;s Hospital and the Royal London Hospital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Compensation Discussion and Analysis describes Neurocrine&#146;s executive compensation program for 2017 and certain elements of our 2018
program. It provides qualitative information on the factors relevant to these decisions and the manner in which compensation is awarded to the following individuals who are our Named Executive Officers (&#147;NEOs&#148;) for 2017:<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Chief Executive Officer, Kevin C. Gorman, Ph.D.&nbsp;(1); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Former Chief Financial Officer, Timothy P. Coughlin&nbsp;(2); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Former President, Chief Operating Officer and interim Chief Financial Officer, David-Alexandr&egrave; C. Gros, M.D. (3); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Chief Financial Officer, Matthew C. Abernethy (4); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Chief Development Officer, Haig P. Bozigian, Ph.D.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Chief Commercial Officer, Eric Benevich; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Former Chief Medical Officer, Christopher F. O&#146;Brien, M.D (5). </TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gorman also served as our interim Chief Financial Officer from October&nbsp;19, 2017 until November&nbsp;29, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Coughlin resigned as our Chief Financial Officer effective February&nbsp;15, 2017 (the &#147;Resignation Date&#148;), but he will continue to be employed by the Company following the Resignation Date until
May&nbsp;31, 2018 (or such earlier date that Mr.&nbsp;Coughlin and the Company mutually designate). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gros began serving as our President and Chief Operating Officer on January&nbsp;9, 2017. Dr.&nbsp;Gros was also appointed as our interim Chief Financial Officer effective February&nbsp;15, 2017. Dr.&nbsp;Gros
resigned as our President, Chief Operating Officer and interim Chief Financial Officer effective as of October&nbsp;19, 2017, but remained employed by the Company until December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Abernethy joined the Company as our Chief Financial Officer on November&nbsp;29, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;O&#146;Brien retired from his role as our Chief Medical Officer on February&nbsp;15, 2018, but remains as an exclusive consultant to the Company. Eiry W. Roberts, M.D., joined the Company as Chief Medical
Officer, effective January&nbsp;8, 2018. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Summary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a company
focused on discovering, developing, and commercializing innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through our novel R&amp;D platform, focused on neurological and endocrine based diseases and disorders.
Our portfolio of products and product candidates is led by INGREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (valbenazine), a vesicular monoamine transporter&nbsp;2 (VMAT2) inhibitor for the treatment of movement disorders which was
approved by the FDA on April&nbsp;11, 2017 for the treatment of tardive dyskinesia (TD). Our three lead late-stage clinical programs are INGREZZA (valbenazine) for Tourette syndrome, elagolix, a gonadotropin-releasing hormone antagonist for
women&#146;s health that is partnered with AbbVie Inc., and opicapone, a highly-selective <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">catechol-O-methyltransferase</FONT></FONT> inhibitor that is an adjunct therapy to
preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson&#146;s disease and was <FONT STYLE="white-space:nowrap">in-licensed</FONT> from BIAL &#150; Portela&nbsp;&amp; CA, S.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Corporate Performance Highlights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2017 was a year of significant achievement for the Company as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieved FDA approval of INGREZZA for the treatment of TD; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully launched INGREZZA for the treatment of TD; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully completed a $517.5&nbsp;million convertible debt offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanded our <FONT STYLE="white-space:nowrap">mid-and</FONT> late-stage pipeline; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintained our strong capital structure; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">secured a physical facility that is suitable for our future growth. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pay for Performance/At Risk Pay
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive compensation program is designed to reward achievement of the specific strategic goals that we believe will advance
our business strategy and create long-term value for our stockholders. Consistent with our goal of attracting, motivating and retaining a high-caliber executive team, our executive compensation program is designed to pay for performance. We utilize
compensation elements that meaningfully align our NEOs&#146; interests with those of our stockholders to create long-term value. As such, a significant portion of our CEO&#146;s and other executive officers&#146; compensation is <FONT
STYLE="white-space:nowrap">&#147;at-risk,&#148;</FONT> performance-based compensation, in the form of long-term equity awards, and annual cash incentives that are only earned if we achieve multiple corporate metrics. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CEO 2017 Compensation Mix</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>All Other NEO 2017</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Compensation Mix</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g474270g31f09.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g474270g32t06.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g474270g08k92.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Compensation Practices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are key elements of our compensation program, as well as problematic pay practices that we avoid: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>What We Do</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>What We Don&#146;t Do</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Heavily weight our NEO compensation toward &#147;at risk,&#148; performance-based
compensation</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B> Allow for the repricing of stock options without stockholder approval</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Use multi-year vesting for all executive officer equity awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B> </B>Pay dividends or dividend equivalents on unearned shares</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Have an incentive compensation recoupment, or clawback, policy</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Structure our executive
compensation program to minimize inappropriate risk-taking</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B> </B>Permit hedging or other forms of speculative transactions by
executive officers, members of management and directors</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>&times;</I></B><B> </B>Provide single-trigger change in control benefits</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Cap annual cash incentives at a maximum payout amount</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Select peer companies that we compete with for executive talent, have a similar
business and are of similar size as us, and review their pay practices</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Solicit advice from the Committee&#146;s independent compensation consultant</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Have meaningful stock ownership guidelines for NEOs</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#10003;<B> </B>Have three or more independent
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors serve on the Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in greater detail below, the Compensation Committee of our Board of Directors (the &#147;Committee&#148;) takes into consideration
peer groups, survey data and advice from an independent compensation consultant when setting the compensation structure and compensation philosophy for the Company. The Committee&#146;s complete roles and responsibilities are set forth in a written
charter which was adopted by the Board of Directors and is available at<I>&nbsp;www.neurocrine.com</I>. Some of the significant roles and responsibilities of the Committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and, if necessary, revising the compensation philosophy of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving corporate goals and objectives relating to the compensation of the Company&#146;s employees, including executive officers, and evaluating the performance of the Company, and its executive
officers, in light of these corporate goals and objectives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving compensation for all executive officers, including perquisite benefits, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving all employment agreements for executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving all promotions to executive officer positions and all new hires of executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing director compensation and making recommendations to the Board of Directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving guidelines for salaries, merit salary increases, cash incentive payments, stock based grants and performance-based stock grants for all <FONT STYLE="white-space:nowrap">non-executive</FONT>
officer employees of the Company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving equity grants to <FONT STYLE="white-space:nowrap">non-employees</FONT> of the Company, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">making recommendations to the Board of Directors with regard to equity incentive plans and administering the Company&#146;s equity incentive plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and taking into consideration stockholder feedback regarding compensation matters, including our annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT>
vote; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">retaining independent compensation consultant and advisors when appropriate to advise the Committee on compensation policies and plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complying with requirements established by the SEC, assessing the risks arising from the Company&#146;s compensation policies and taking any actions required as a result thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing executive officer compliance with our Stock Ownership Guidelines; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing and approving the Compensation Discussion and Analysis to be included as part of the Company&#146;s annual proxy statement. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committee Actions in Connection with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT> Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Committee is committed to ensuring that our executive compensation program is effective and aligned with our stockholders&#146; interests
and concerns. Accordingly, a critical component of our Committee&#146;s process has been to continue to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review emerging compensation &#147;best practices&#148; in the U.S., with a focus toward companies of similar size; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">solicit advice from our Committee&#146;s independent compensation consultant. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we
sought an advisory vote from our stockholders regarding our executive compensation program and received a 99.5% favorable vote supporting the program. Each year, the Committee considers the results of the advisory vote as it completes its annual
review of each pay element and the compensation provided to our NEOs and other executives. Given the significant level of stockholder support, the Committee concluded that our executive compensation program continues to align executive pay with
stockholder interests and provides competitive pay that encourages retention and effectively incentivizes performance of talented NEOs and executives. Accordingly, the Committee is determined not to make any significant changes to our programs as a
result of the vote. The Committee will continue to consider the outcome of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> votes and our stockholders&#146; views when making future compensation
decisions for the NEOs and executives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Philosophy and Overall Compensation Determination Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that in order to create value for our stockholders, it is critical to attract, motivate and retain key executive talent by providing
competitive compensation packages. Accordingly, we design our executive compensation programs to attract, motivate and retain executives with the skills and expertise to execute our business plans, and reward those executives fairly over time for
actions consistent with creating long-term stockholder value. The market for talented individuals in the life sciences industry is highly competitive and becoming more challenging for employers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation philosophy for executive officers provides that cash compensation should be structured such that at least <FONT
STYLE="white-space:nowrap">one-third</FONT> of each executive officer&#146;s total cash compensation, consisting of base salary and target cash incentives, is at risk and dependent upon the Company&#146;s performance.
<FONT STYLE="white-space:nowrap">Non-cash</FONT> long-term equity compensation for executive officers is generally a combination of performance-based and time-based vesting, and is designed to motivate executive officers to increase long-term
stockholder value as well as reward and retain key employees. The Committee believes that this approach provides an appropriate blend of short-term and long-term incentives to maximize stockholder value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of the compensation philosophy is carried out under the supervision of the Committee. The Committee uses the services of an
independent compensation consultant who is retained by, and reports </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directly to, the Committee. Management, under guidelines and procedures approved by the Committee, determines the compensation of our <FONT STYLE="white-space:nowrap">non-executive</FONT> officer
employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the early part of each year, the Committee, without the presence of our Chief Executive Officer, deliberates and makes
decisions regarding the base salary, target cash incentives and long-term equity award components of compensation to be awarded to our Chief Executive Officer for the new fiscal year, as well as performance-based compensation payouts for the prior
fiscal year. In setting compensation for our other NEOs, the Committee solicits the input of our Chief Executive Officer, who recommends to the Committee the base salary, target cash incentives and long-term equity award components of compensation
to be awarded to our NEOs for the new fiscal year, as well as performance-based compensation payouts for the prior fiscal year. The Committee remains solely responsible for making the final decisions on compensation for all of our NEOs. Our NEOs are
not present during discussions of their compensation packages nor do they participate in approving any portion of their own compensation packages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Executive Officer annually reviews the performance of each NEO (other than himself) and discusses these performance reviews with the
Committee. These recommendations reflect his consideration of the market data, the performance of each NEO, internal pay equity among individuals (including qualifications and contributions to meeting our corporate objectives), criticality and scope
of job function and our Chief Executive Officer&#146;s extensive industry experience. The Committee reviews and considers the market data, our Chief Executive Officer&#146;s recommendations on specific pay levels for each NEO and Radford&#146;s
recommendations on compensation policy determinations for the executive officer group, and also reviews internal pay equity among individuals and positions, criticality and scope of job function, retention risk, Company performance and individual
performance (including qualifications and contributions to meeting our corporate objectives), total targeted and historical compensation for each individual NEO and any other factors the Committee determines important. The Committee uses all of
these factors to set the compensation of our NEOs at levels that the Committee considers to be competitive and appropriate for each NEO, using the Committee&#146;s professional experience and judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee generally meets at least six times per year. In the first quarter of the year, the performance of each executive officer for the
prior year and peer group compensation data are reviewed by the Committee, and base salary adjustments, cash incentive payouts, following year targets and annual equity grants are discussed and approved. Also during the first quarter of the year,
Company-wide performance goals for the then current year are finalized by the Committee and the Board of Directors. At <FONT STYLE="white-space:nowrap">mid-year</FONT> meetings, the Committee reviews the Company&#146;s compensation philosophy,
policies and procedures. Meetings in the fourth quarter of the year generally focus on Company goal achievement, selection of the peer group for the following year and the structure of executive officer performance reviews. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Consultants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee
uses the services of an independent compensation consultant who is retained by, and reports directly to, the Committee to provide the Committee with an additional external perspective with respect to its evaluation of relevant market and industry
practices. The Committee continued to select Radford, an AON Hewitt Company, as a third-party compensation consultant to assist the Committee in establishing 2017 and 2018 overall compensation levels. Radford conducted analyses and provided advice
on, among other things, the appropriate peer group, executive compensation for our executive officers and compensation trends in the life sciences industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In weighing its recommendations for executive compensation for the fiscal year 2017, the
Committee directed Radford to advise the Committee on both best practices and peer practices when designing and modifying our compensation program for executive officers in order to achieve our objectives. As part of its duties, Radford provided the
Committee with the following services with respect to 2017 compensation decisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">carried out a comprehensive review of our peer group for use in making 2017 executive compensation decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provided compensation data for the peer group and relevant executive pay survey data and an analysis of the compensation of the Company&#146;s executive officers as compared to this market data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provided a competitive assessment of, and comparison to, incentive design and executive pay program structure based on peer group data; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conducted a comprehensive pay for performance assessment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provided recommendations regarding the annual cash incentive and long-term equity incentive program design for 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assisted the Committee with the design of 2017 pay programs consistent with the Company&#146;s business strategy and pay philosophy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provided background information and data for 2017 adjustments to the Company&#146;s executive compensation program consistent with good governance practices and the Company&#146;s objectives; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prepared an analysis of the Board&#146;s 2017 compensation program. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee annually
assesses whether the work of Radford as a compensation consultant has raised any conflict of interest, taking into consideration the following factors: (i)&nbsp;the provision of other services to the Company by Radford; (ii)&nbsp;the amount of fees
the Company paid to Radford as a percentage of the firm&#146;s total revenue; (iii)&nbsp;Radford&#146;s policies and procedures that are designed to prevent conflicts of interest; (iv)&nbsp;any business or personal relationship of Radford or the
individual compensation advisors employed by the firm with an executive officer of the Company; (v)&nbsp;any business or personal relationship of the individual compensation advisors with any member of the Committee and (vi)&nbsp;any stock of the
Company owned by Radford or the individual compensation advisors employed by the firm. The Committee has determined, based on its analysis of the above factors, that the work of Radford and the individual compensation advisors employed by Radford as
compensation consultants to the Company has not created any conflict of interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Peer Group </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When developing a proposed list of our peer group companies to be used in connection with making compensation decisions for 2017, Radford
reexamined our compensation philosophy and peer group and recommended changes to our 2016 peer group company list to reflect our growth, market capitalization and the stage of our commercial development.&nbsp;Radford suggested biopharmaceutical
companies that were in late stage <FONT STYLE="white-space:nowrap">pre-commercial</FONT> (Phase III or recently commercial companies with revenue generally less than $300 million), had market values of approximately one half (0.5x) to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-and-a-half</FONT></FONT></FONT> (2.5x)&nbsp;our market capitalization at the time (resulting in a range of between $2&nbsp;billion to $10&nbsp;billion
in market capitalization) and had headcounts of generally between 50 to 600.&nbsp;Based on these criteria, Radford recommended, and our Committee approved, removing Clovis Oncology, Inc., Novavax, Inc. and Portola Pharmaceuticals, Inc. (which no
longer met the criteria described above), Anacor Pharmaceuticals, Inc. and Dyax Corp. (which were acquired since the 2016 peer group company list was approved) and adding ARIAD Pharmaceuticals, Inc., Exelixis, Inc., Ironwood Pharmaceuticals, Inc.,
Nektar Therapeutics, Seattle Genetics, Inc. and The Medicines Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2017 Peer Group</I>. Based on these parameters, in November
2016 our Committee approved the following companies as our peer group for 2017: ACADIA Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alnylam </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc., bluebird bio, Inc., Exelixis, Inc., Intercept Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Juno
Therapeutics, Inc., Kite Pharma, Inc., Nektar Therapeutics, Puma Biotechnology, Inc., Sarepta Therapeutics, Inc., Seattle Genetics, Inc., TESARO, Inc., The Medicines Company and Ultragenyx Pharmaceutical Inc. In determining executive compensation
for 2017, the Committee reviewed data from this group of peer companies.&nbsp;At the time of approval of our 2017 peer group, our Company was approximately in the 89<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile of the peer group
for market capitalization and 33<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> percentile of the peer group for revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
early 2017, Radford completed an assessment of executive compensation based on the 2017 peer group to inform the Committee&#146;s determinations of executive compensation for 2017. This market data was compiled from multiple sources, including:
(i)&nbsp;the 2017 peer group companies&#146; publicly disclosed information, or public peer data and (ii)&nbsp;data from public biotechnology and pharmaceutical companies in the Radford Global Life Sciences Survey that had market values between
$2&nbsp;billion and $10&nbsp;billion. The components of the market data were based on the availability of sufficient comparative data for an executive officer&#146;s position. The general survey data and the public peer data, collectively referred
to in this proxy statement together as market data, were reviewed by the Committee, with the assistance of Radford, and used as one reference point, in addition to other factors, in setting our executive officers&#146; compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee generally reviews total direct compensation, comprising both target cash compensation and equity compensation, against the
market data described above primarily to ensure that our executive compensation program as a whole is positioned competitively to attract and retain the highest caliber executive officers and that the total direct compensation opportunity for the
executive officer group is aligned with our corporate objectives and strategic needs.&nbsp;The Committee does not have a specific target compensation level for the NEOs; rather, the Committee reviews a range of market data reference points
(generally at the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>, 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;and 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;percentiles of the market data) with
respect to total direct compensation, total target cash compensation (including both base salary and the target annual cash incentive) and equity compensation (valued based on an approximation of grant date fair value). In making compensation
determinations, the Committee considers a variety of factors, which may include market data and a particular executive officer&#146;s experience, overall qualifications and criticality of skills to the future performance of our Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2018 Peer Group. </I>In November 2017, when developing a proposed list of our peer group companies to be used in connection with making
compensation decisions for 2018, Radford selected primarily recently commercial or commercial biopharmaceutical companies with revenue generally less than $300&nbsp;million, market values of approximately one half (0.5x) to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">two-and-a-half</FONT></FONT></FONT> (2.5x)&nbsp;our market capitalization at the time (resulting in a range of between $2&nbsp;billion to $12&nbsp;billion
in market capitalization) and headcounts of generally between 200 to 1,000. Based on these criteria, Radford&#146;s recommendation, and any acquisitions of peer group companies, our Committee removed ARIAD Pharmaceuticals, Inc., Intercept
Pharmaceuticals, Inc. and Kite Pharma, Inc. and added Clovis Oncology, Inc., Halozyme Therapeutics, Inc. and Portola Pharmaceuticals, Inc. to the remaining 2017 peers to form the final 2018 list of peer companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee considers each executive officer&#146;s performance, contribution to Company goals, responsibilities, experience, qualifications,
and where in the competitive range the executive officer&#146;s compensation compares to the Company&#146;s identified peer group when determining the appropriate compensation for each executive officer. The Committee considers each component of
compensation independently and each component in the context of each executive officer&#146;s total compensation. Compensation for our NEOs currently consists of three key elements that are designed to reward performance in a simple and
straightforward manner: base salaries, annual performance-based cash incentives and long-term equity awards, which generally include restricted stock unit awards (&#147;RSUs&#148;) and stock options, which both vest based on continued service over
time, and in some years include performance restricted stock units (&#147;PRSUs&#148;), which vest upon achievement of key corporate metrics that we believe will create shareholder value. The purpose and key characteristics of each of these elements
are summarized below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Base Salary</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Designed to compensate competitively at levels necessary to attract and retain qualified executives in the life sciences industry; generally based on the scope of each executive officer&#146;s responsibilities, as well as his/her
qualifications, breadth of experience, performance record and depth of applicable functional expertise; established and adjusted to be within the range of the applicable peer group, enabling the Company to attract, motivate, reward and retain highly
skilled executives; gives executives a degree of certainty in light of having a majority of their compensation at risk.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fixed compensation where <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> adjustments to each
executive officer&#146;s base salary are based upon sustained superior performance, changes in the general level of base salaries of persons in comparable positions within our industry, and the average merit salary increase for such year for all
employees of the Company established by the Committee, as well as other factors the Committee judges to be pertinent during an assessment period.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making base salary decisions, the Committee exercises its judgment to determine the appropriate weight to be given to each of these factors. Adjustments may
also be made during the fiscal year for promotions, highly urgent retention reasons, superior performance in response to changed or challenging circumstances, and similar special circumstances.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual&nbsp;Cash&nbsp;Incentives</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Motivates executive officers to achieve our short-term strategic plan and milestones that are designed to drive long-term growth and performance while providing flexibility to respond to opportunities and changing market
conditions.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual cash award based on corporate performance compared to <FONT STYLE="white-space:nowrap">pre-established</FONT> corporate goals with <FONT
STYLE="white-space:nowrap">pre-established</FONT> target payouts for each executive officer.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash incentive program, including corporate goals and target payouts, are reviewed and approved by the Committee annually and may include individual
performance targets for each executive officer. The corporate goals are prepared in an interactive process between management and the Board of Directors based on the Company&#146;s business plan and budget for the year. Cash incentive payments are
linked to the attainment of overall corporate goals and may include individual performance targets for each executive officer. The Committee establishes the target and maximum potential amount of each executive officer&#146;s cash incentive payment
annually.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Long-Term Equity Incentives (RSUs)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Motivates executive officers to achieve our business objectives by tying compensation to the performance of our common stock over the long
term; motivates our executive officers to remain with the Company by mitigating swings in incentive values during periods when market volatility impacts our stock price; directly motivate an executive officer to maximize long-term stockholder value
and serve as an effective tool for incentivizing and retaining those executive officers who are most responsible for influencing stockholder value.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">RSUs generally vest on an annual basis, ratably over four years for executive-level grants; the ultimate value realized varies with our common stock price.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Long-Term Equity Incentives (Stock Options)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long term.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options with an exercise price equal to the fair market value on the date of grant generally vesting monthly over four years for
executive-level grants; the ultimate value realized, if any, depends on the appreciation of our common stock price from the date of grant.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Long-Term&nbsp;Equity&nbsp;Incentives</FONT>
(PRSUs)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Creates a strong link to the Company&#146;s long-term performance, creates an ownership culture and closely aligns the interests of our
executive officers with those of our stockholders because the value that the grants deliver are directly dependent on our performance goal attainment.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PRSUs only vest upon achievement of objectively measurable performance goals that focus executives on achieving specific longer-term Company performance goals and increasing stockholder value.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Provides benefits that promote employee health and welfare, which assists in attracting and retaining our executive officers; certain additional benefits reflect market standards and are reasonable and necessary to attract and/or
retain each of our executive officers and allow the executive officers to realize the full benefit of the other elements of compensation we provide.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive officers are eligible to participate in the Company&#146;s employee benefit plans on the same terms as all other full-time
employees. These plans include medical, dental and life insurance. Additional benefits include disability insurance premiums, an annual physical examination and financial planning services.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Company&#146;s 401(k) Savings Plan (the &#147;401(k) Plan&#148;)
provide for executive officer and broad-based employee participation on the same general terms. Under the 401(k) Plan, all Company employees are eligible to receive basic matching contributions from the Company that vest three years from date of
hire and monthly thereafter.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="34%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:28.40pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purpose</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Characteristics</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Severance and Change in Control Benefits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Serves our retention objectives by helping our NEOs maintain continued focus and dedication to their responsibilities to maximize stockholder value, including in the event of a transaction that could result in a change in control of
the Company.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provides protection in the event of a termination of employment under specified circumstances, including following a change in control of the
Company as described below under &#147;Potential Payments Upon Termination or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control&#148;.</FONT></FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation components for executive officers in the event of a termination by the
Company without cause or termination by the executive officer due to constructive termination within six months after the consummation of a change in control include payments for accrued annual base salary, a cash compensation payment, cash
compensation for the value of all outstanding stock awards, limited Company-paid health insurance benefits, and any accrued vacation and any accrued benefits under any plans of the Company in which the executive officer is a participant. Eligibility
for these benefits requires a signed release agreement by the executive officer.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Certain individuals whose offer letters were entered into in or before 2007, including Dr.&nbsp;Gorman, are entitled to tax
<FONT STYLE="white-space:nowrap">gross-ups</FONT> in the event of a change in control. We have not entered into any new change in control <FONT STYLE="white-space:nowrap">gross-ups</FONT> for executive officers since 2007, nor does the Company
intend to enter into any new agreements containing such <FONT STYLE="white-space:nowrap">gross-ups.</FONT> Accordingly, Mr.&nbsp;Benevich&#146;s and Mr.&nbsp;Abernethy&#146;s employment agreements do not provide for a tax <FONT
STYLE="white-space:nowrap">gross-up.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Executive Compensation Decisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, our
Committee reviewed and determined the 2017 base salaries for each of the NEOs as set forth in the table below, except for Dr.&nbsp;Gros&#146; and Mr.&nbsp;Abernethy&#146;s base salaries, which were determined in connection with their commencement of
employment with us. In making these 2017 decisions, the Committee considered the positioning of each individual&#146;s salary as compared to the peer data, as well as the individual&#146;s historical salary levels, our then-current budget for
employee salary adjustments and anticipated role and responsibilities for the coming year. Although the Committee does not have a specific target compensation level for each NEO, the NEOs&#146; salaries are generally within the 25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> to 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles of the peer data. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.65pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%<BR>Change<BR>from&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-28.69</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to a transition agreement with the Company, Mr.&nbsp;Coughlin&#146;s base salary decreased from $434,700 to $310,000 effective as of the Resignation Date. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Incentives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, the Committee approved the Company&#146;s executive officer cash incentive target percentages and performance goals for 2017,
with the exception of Dr.&nbsp;Gros&#146; and Mr.&nbsp;Abernethy&#146;s percentages, which were determined in connection with their commencement of employment with us. The table below sets forth the targets for our Chief Executive Officer and other
NEOs for 2017. The target percentage is paid as a percentage of such executive officer&#146;s base salary. For example, if 100% of the Company&#146;s performance goals are achieved for 2017, this would yield our Chief Executive Officer a cash
incentive award of 70% of his 2017 base salary. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:59.65pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Executive Officer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Percentage&nbsp;of<BR>Base Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President/Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In early 2017, the Committee established the corporate goals described below. Our objective
corporate goals are directly aligned with our specific strategic goals, including advancing our development programs, our research function, our clinical activities, commercialization activities and certain corporate and financial goals, which we
believe will create long-term value for stockholders. The Board of Directors and the Committee did not assign specific relative weightings to the goals for 2017. The maximum corporate achievement for 2017 was 120% of our 2017 corporate goals. In
February 2018, the Committee evaluated the accomplishments and performance of the Company against such corporate goals. After its consideration of the Company&#146;s performance, as more specifically described below, the Committee rated our 2017
corporate achievement at 115% of our 2017 corporate goals. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Corporate Goal</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Corporate Achievement</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obtain FDA approval for INGREZZA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Approval obtained April&nbsp;11, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meet sales revenue goal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Surpassed</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expand product candidate pipeline</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-licensed</FONT> Phase 3 opicapone</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moved second CAH compound into clinical trials</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenced Phase 2b
study in Tourette syndrome</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of research compound</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Secure facility suitable for future growth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Renewed lease for corporate headquarters</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital raise</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$517.5&nbsp;million convertible debt offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maintained strong capital structure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Achieved</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, after making these determinations regarding level of corporate performance achieved against
the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, the Committee reviewed and approved corporate cash incentives as set forth in the table below. Dr.&nbsp;Gros was not eligible to receive a cash incentive award because he
left the Company prior to the payment date. The Committee may, in its sole discretion, eliminate any individual cash incentive or reduce or increase the amount of compensation payable with respect to any individual cash incentive. The Committee
exercised its discretion to increase the amount of individual cash incentives with respect to each of our NEOs for 2017 by paying their cash incentives at the rates noted below due to their significant individual performances related to the
Company&#146;s performance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:121.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017&nbsp;Target&nbsp;Annual&nbsp;Cash&nbsp;Incentive</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017&nbsp;Actual&nbsp;Annual&nbsp;Cash&nbsp;Incentive&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Base&nbsp;Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of&nbsp;Target&nbsp;Annual&nbsp;Cash<BR>Incentive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">515,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In determining Mr.&nbsp;Coughlin&#146;s bonus for 2017 the Compensation Committee determined that the contributions made by Mr.&nbsp;Coughlin following the Resignation Date were significantly higher than had been
predicted, and therefor Mr.&nbsp;Coughlin&#146;s target bonus at 50% of his salary prior to the Resignation Date, which was $434,700. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Abernethy&#146;s award was <FONT STYLE="white-space:nowrap">pro-rated</FONT> due to his commencement of employment with us in November 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Term Equity Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Size of Equity Awards</I>. In determining the size of the total equity compensation opportunity in 2017, the Committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aimed to have the aggregate target award value result in target total direct compensation at a level that is competitive in the marketplaces in which we compete; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">focused a larger portion of total direct compensation in the form of long-term and performance-based equity awards intended to drive long-term differentiated value relative to our peers and maximize long-term
stockholder value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aimed to structure a substantial portion of equity opportunity in the form of awards that vest based on achievement of performance goals to better align our executives&#146; long-term compensation opportunity with our
stockholders&#146; interests; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">considered the recommendations of Dr.&nbsp;Gorman for the other NEOs. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Award
Mix</I>. The Committee determined that the equity awards granted to the NEOs on February&nbsp;6, 2017 should consist of stock options and time-vesting RSU grants as set forth in the table below. The Committee determined these two types of equity
awards provided the appropriate balance of long-term incentives for our executive officers. Specifically, RSUs that vest over time provide tangible value to executive officers and serve as an incentive and retention tool during a difficult operating
or volatile business environment, while still being tied to our stockholder value. It is the Committee&#146;s view that stock options are inherently performance oriented because the executive realizes no value from stock options unless and until the
Company&#146;s stock price increases over the strike price. The Committee believes it is important to evaluate the equity award mix each year to determine what types of equity awards should be granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In setting the mix of the two types of equity awards granted on February&nbsp;6, 2017, the Committee determined that the equity grants should
consist of awards that vest based on continued service over time. The mix between the two types of awards was determined based on market data of the equity award practices of peer group companies provided by the Committee&#146;s consultant.
Accordingly, the Committee structured the mix of equity such that the baseline award of options and RSUs would generally deliver value, as determined by the Black-Scholes value of stock options and the value of RSUs as if they were fully vested, to
NEOs between approximately the 75<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> and 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentiles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:70.95pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Executive Officer (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSU&nbsp;&#150;&nbsp;Time&nbsp;Vesting</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gros and Mr.&nbsp;Abernethy received grants in connection with their commencement of employment with us, as further described under &#147;New Hire Awards&#148; below. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Coughlin resigned as the Company&#146;s Chief Financial Officer effective February&nbsp;15, 2017, and pursuant to his Transition Agreement with the Company Mr.&nbsp;Coughlin did not receive a stock grant in
2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2017 Award Vesting Criteria</I>. The Committee, in consultation with the independent members of the Board of
Directors, determined with respect to the February&nbsp;6, 2017 equity grants that the use of both stock options which vest monthly, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period and RSUs which vest annually,
on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period were the appropriate equity compensation vehicles. The Committee and Board of Directors believe that the long-term equity based compensation awards closely align
stockholder and management interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>New Hire Awards</I>. In connection with his commencement of employment, (i)&nbsp;on
February&nbsp;1, 2017, Dr.&nbsp;Gros was granted an initial stock option to purchase up to 350,000 shares of the Company&#146;s common stock, 25% of which will vest on the first anniversary of the grant date, and the remainder of which will vest in
equal monthly installments thereafter over three years and (ii)&nbsp;on February&nbsp;6, 2017, Dr.&nbsp;Gros was granted an RSU award covering 25,000 shares of the Company&#146;s common stock which vests in equal annual installments over four years.
In connection with his commencement of employment, on December&nbsp;1, 2017, Mr.&nbsp;Abernethy was granted (i)&nbsp;an initial stock option to purchase up to 60,000 shares of the Company&#146;s common stock, 25% of which will vest on the first
anniversary of the grant date, and the remainder of which will vest in equal monthly installments thereafter over three years and (ii)&nbsp;an RSU award covering 12,500 shares of the Company&#146;s common stock, 25% of which will vest on each
anniversary of the grant date. The Committee and Board of Directors structures the vesting schedules for new hire awards in order to serve as an effective tool for incentivizing and retaining our NEOs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Benefits </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s matching contribution to the 401(k) Plan for 2017 was 50% of eligible participant contributions, subject to applicable federal limits. The Company made no additional discretionary contributions to the 401(k) Plan in 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Ownership Guidelines </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
March 2014, the Committee approved equity ownership guidelines for our executive officers. The equity ownership guidelines are designed to further align the interests of the executive officers with those of our stockholders by ensuring that our
executive officers have a meaningful financial stake in the Company&#146;s long-term success. The equity ownership guidelines establish a minimum equity ownership level by position, with such values determined based on the value of our common stock
owned by such persons as of certain measurement dates. All shares directly or beneficially owned by the executive officer, including the net exercisable value of outstanding vested stock options (where the market price of our common stock exceeds
the strike price of such option) are included in determining the value of equity owned under our equity ownership guidelines. The equity ownership requirements are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;times&nbsp;base&nbsp;salary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other executive officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;times&nbsp;base&nbsp;salary</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New executive officers are granted a five-year period to reach the equity ownership requirements set forth in
the guidelines and are expected to make annual progress toward the equity ownership requirements during this five-year period. When an executive officer does not meet the equity ownership requirements set forth in the guidelines, he/she is
restricted from selling any held shares until such requirements are met. Additionally, should an executive officer who does not meet the equity ownership requirements choose to exercise a stock option or vest in any RSUs, he or she is required to
retain all shares acquired through those transactions, aside from any shares necessary to fulfill such transaction related tax obligations, until full compliance with the equity ownership guidelines is attained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual compliance with the equity ownership guidelines is assessed during the first quarter of each year. As of March&nbsp;1, 2018, each of
our NEOs is in compliance with the equity ownership guidelines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Trading Policies and Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has policies and procedures to prohibit direct or indirect participation by employees of the Company in transactions involving
trading activities in Company common stock which by their aggressive or speculative nature may give rise to an appearance of impropriety. Such prohibited activities would include the purchase of put or call options, or the writing of such options as
well as short sales, hedging transactions such as &#147;cashless&#148; collars, forward sales, equity swaps and other related arrangement which may indirectly involve short-sale and any other transactions designed for profit from short-term movement
in the Company&#146;s stock price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the Company&#146;s knowledge, there were no transactions involving hedging, pledging or
margining Company common stock during 2017, nor were there any such transactions as of the Record Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also requires
executive officers to complete all equity related open-market purchase and sale transactions via a <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan. The <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans typically cover, among other
transactions, direct sales and purchases of Company stock, as well as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">same-day-sales</FONT></FONT> related to option exercises and sales of stock for tax payments upon the vesting of
restricted stock units. All <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans are required to have a <FONT STYLE="white-space:nowrap">90-day</FONT> waiting period from the election date to the date of the first transaction. Additionally, Company
policy restricts the executive officers from amending, canceling, suspending or otherwise modifying any <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plan subsequent to adoption of the plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Recovery Policy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2017, we adopted a clawback policy, even though the SEC has not yet issued final rules implementing the Dodd-Frank Wall Street Reform and Consumer Protection Act requirement. Our policy currently provides that, in the event that (i)&nbsp;we
are required to prepare an accounting restatement for any fiscal quarter or year due to our material noncompliance with any financial reporting requirement and (ii)&nbsp;it is determined that misconduct contributed to the noncompliance that resulted
in the obligation to restate our financial statements, we may take action to recover from any officer whose misconduct contributed to the noncompliance which resulted in the obligation to restate our financial statements, the incentive compensation
that was paid or vested to such officer during the twelve-month period preceding the restatement obligation. We will also comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and will modify our policy to the
extent required by law once the SEC adopts final regulations on the subject. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Internal Revenue Code Section&nbsp;162(m) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;162(m) of the Code disallows a deduction to any publicly held corporation and its affiliates for certain compensation paid to
&#147;covered employees&#148; in a taxable year to the extent that compensation to a covered employee exceeds $1&nbsp;million. Prior to the recent enactment of the Tax Cuts and Jobs Act, compensation that qualified as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code was not subject to this deduction limitation. Pursuant to the Tax Cuts and Jobs Act, this exception for &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code was
repealed, with respect to taxable years beginning after December&nbsp;31, 2017, except that certain transition relief is provided by the Tax Cuts and Jobs Act for remuneration provided pursuant to a written binding contract which was in effect on
November&nbsp;2, 2017 and which was not modified in any material respect on or after such date. As a result, compensation paid to any of our &#147;covered employees&#148; in excess of $1&nbsp;million per taxable year generally will not be deductible
unless among other requirements, it is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act.
Because of certain ambiguities and uncertainties as to the application and interpretation of Section&nbsp;162(m) of the Code and the regulations issued thereunder, including the uncertain scope of the transition relief provided by the Tax Cuts and
Jobs Act, no assurance can be given that any compensation paid by the Company will be eligible for such transition relief and, therefore, eligible for the &#147;performance-based compensation&#148; exception under Section&nbsp;162(m) of the Code.
The Committee will continue to monitor the applicability of Section&nbsp;162(m) of the Code to its ongoing compensation arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Internal
Revenue Code Section&nbsp;409A </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;409A governs deferred compensation arrangements. The Committee structures our deferred
compensation programs with the assistance of our external counsel to be exempt from, or compliant with, Section&nbsp;409A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for equity compensation paid to our employees under the FASB ASC Topic 718, which requires us to estimate and record an
expense over the service period of the equity award. Our cash compensation is recorded as an expense at the time the obligation is incurred. The accounting impact of our compensation programs are one of many factors that the Committee considers in
determining the structure and size of our executive compensation programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk Analysis of Our Compensation Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage
excessive or inappropriate risk taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on the Company. As part of its assessment, the Committee considered, among other factors, the
allocation of compensation among base salary and short- and long-term compensation, our approach to establishing Company-wide and individual financial, operational and other performance targets, our bonus structure of payouts at multiple levels of
performance (including maximum payout caps and payments for performance below target levels) and the nature of our key performance metrics. We believe these practices encourage our employees to focus on sustained, long-term Company growth, which we
believe will ultimately contribute to the creation of stockholder value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE COMPENSATION AND OTHER INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Summary Compensation Table</I></B><B><I></I></B>&nbsp;The following table sets forth the compensation paid by the Company for the fiscal
years ended December&nbsp;31, 2015, 2016 and 2017 to the NEOs named below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:109.20pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All<BR>Other<BR>Compensation<BR>($)(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">575,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">345,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">824,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,011,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">592,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">337,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,202,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,114,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,289,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">515,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,929,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,556,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">422,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,720,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,785,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">434,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,364,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,281,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">325,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">609,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher&nbsp;F.&nbsp;O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">472,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,612,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,744,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief&nbsp;Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,223,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,558,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,540,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">288,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,103,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">381,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">190,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,397,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">362,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,371,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">979,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,104,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,716,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,969,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,648,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,044,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,242,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">376,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">831,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,050,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,490,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,977,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">920,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">394,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,789,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">513,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,562,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,357,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Former President, Chief Operating Officer and interim Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The titles and capacities set forth in the table above are as of March&nbsp;1, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Salary and bonus figures represent amounts earned during each respective fiscal year, regardless of whether part or all of such amounts were paid in subsequent fiscal year(s). Bonuses are awarded pursuant to a bonus
program. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown are the full grant date fair value in accordance with Accounting Standards Codification <FONT STYLE="white-space:nowrap">718-10,</FONT> Compensation&#151;Stock Compensation (ASC 718). The assumptions
used to calculate the grant date fair value of stock awards are set forth under Note 9 of the Notes to the Consolidated Financial Statements included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2017 filed with the SEC on February&nbsp;13, 2018. The grant date fair values of option awards for 2015, 2016 and 2017 (other than Mr.&nbsp;Benevich&#146;s 2015 option award and each of Mr.&nbsp;Abernethy&#146;s and
Dr.&nbsp;Gros&#146; 2017 option award) are based on per share Black-Scholes values of $21.50, $20.19 and $23.77, respectively. Mr.&nbsp;Benevich&#146;s 2015 option awards are based on per share Black-Scholes value of $27.47,
Mr.&nbsp;Abernethy&#146;s 2017 option awards are based on per share Black-Scholes value of $40.28 and Dr.&nbsp;Gros&#146; 2017 option awards are based on per share Black-Scholes value of $23.43. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The amounts shown are the full grant date fair value in accordance with Accounting Standards Codification <FONT
STYLE="white-space:nowrap">718-10,</FONT> Compensation&#151;Stock Compensation (ASC 718). The assumptions used to calculate the grant date fair value of stock awards are set forth under Note 9 of the Notes to the Consolidated Financial Statements
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 filed with the SEC on February&nbsp;13, 2018. The fair
values of restricted stock units granted in 2015, 2016 and 2017 are based on the Company&#146;s closing market price per share on the grant date, which was $32.99 for all 2015 grants (other than Mr.&nbsp;Benevich&#146;s grant, for which it was
$41.78), and which was $35.99 for all 2016 grants, and which was $43.24 for all 2017 grants (other than Mr.&nbsp;Abernethy&#146;s grant, for which it was $73.60). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes all other compensation as described in the table below. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>All Other Compensation
Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>401(k)<BR>Employer<BR>Match</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Insurance<BR>Premiums<BR>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Severance<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Inducement<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Relocation<BR>Expense</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Other</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">394,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,131,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">402,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,562,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the costs for medical insurance for Company-wide plans, as well as disability insurance premiums and related tax <FONT STYLE="white-space:nowrap">gross-up</FONT> amounts.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Plan-Based Awards During the Fiscal Year Ended December&nbsp;31, 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding plan based-awards granted by the Company during the year ended December&nbsp;31, 2017 to the NEOs
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Stock<BR>Awards:&nbsp;Number&nbsp;of<BR>Shares of Stock or<BR>Units<BR>(#)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Option<BR>Awards:&nbsp;Number<BR>of Securities<BR>Underlying<BR>Options (#)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;or&nbsp;Base<BR>Price of Awards<BR>($/Sh)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair&nbsp;Value&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,929,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">458,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,825,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">920,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,200,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">All options and restricted stock units were granted and approved on the same date with option awards having an exercise price equal to the closing market price of the Company&#146;s common stock on the date of grant.
All option awards are time-based awards, which vest monthly, on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over four years and have an option term of ten years. These RSUs vest annually, on a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> basis, over a four-year period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Reflects the grant date per share Black-Scholes value of $23.77 for option awards and the grant date per share value of $43.24 for restricted stock units, each granted on February&nbsp;6, 2017 (other than with respect
to Dr.&nbsp;Gros&#146; option award) which was calculated in accordance with ASC 718. The grant date per share Black-Scholes value for Dr.&nbsp;Gros&#146; option awards and restricted stock units was $23.43 and $43.24, respectively. The grant date
per share Black-Scholes value for Mr.&nbsp;Abernethy&#146;s option awards and restricted stock units was $40.28 and $73.60, respectively. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Coughlin resigned as the Company&#146;s Chief Financial Officer effective February&nbsp;15, 2017, and pursuant to his Transition Agreement with the Company Mr.&nbsp;Coughlin did not receive a stock grant in
2017. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kevin C. Gorman,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B> has an employment contract that provides that: (i)&nbsp;Dr.&nbsp;Gorman
will serve as the Company&#146;s Executive Vice President and Chief Operating Officer commencing on August&nbsp;1, 2007 at an initial annual salary of $400,000, subject to annual adjustment by the Board of Directors (subsequent to entering into the
employment contract, Dr.&nbsp;Gorman became Chief Executive Officer and his annual base salary for 2017 is $640,000); (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive
termination or voluntary resignation; (iii)&nbsp;Dr.&nbsp;Gorman is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;each year starting in 2007 and
continuing for the term of the agreement, Dr.&nbsp;Gorman will be eligible to receive equity awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew C. Abernethy</I></B> has an employment contract that provides that: (i)&nbsp;Mr.&nbsp;Abernethy will be entitled to receive an
initial base salary of $420,000 per year, subject to future adjustments; (ii)&nbsp;the agreement terminates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation; (iii)&nbsp;Mr.&nbsp;Abernethy is eligible for a discretionary annual
bonus as determined by the Board of Directors, based upon achieving certain performance criteria; (iv)&nbsp;Mr.&nbsp;Abernethy is eligible to receive equity awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be
determined by the Board of Directors; (v)&nbsp;Mr.&nbsp;Abernethy is entitled to receive a <FONT STYLE="white-space:nowrap">one-time</FONT> cash inducement advance in the amount of $180,000, which will be deemed earned when Mr.&nbsp;Abernethy
completes two full years of employment with the Company; and (vi)&nbsp;Mr.&nbsp;Abernethy is entitled to receive relocation benefits, including a <FONT STYLE="white-space:nowrap">one-time</FONT> cash relocation advance in the amount of $140,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Timothy P. Coughlin</I></B> has an employment contract that provides that: (i)&nbsp;Mr.&nbsp;Coughlin will serve as the
Company&#146;s Vice President and Chief Financial Officer commencing on August&nbsp;1, 2007 at an initial annual salary of $275,000, subject to annual adjustment by the Board of Directors; (ii)&nbsp;the agreement terminates upon death, disability,
termination by the Company with or without cause, constructive termination or voluntary resignation; (iii)&nbsp;Mr.&nbsp;Coughlin is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain
performance criteria; and (iv)&nbsp;each year starting in 2007 and continuing for the term of the agreement, Mr.&nbsp;Coughlin will be eligible to equity awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be determined
by the Board of Directors. In late 2016, Mr.&nbsp;Coughlin and the Company entered into a transition agreement that provides that: (i)&nbsp;from December&nbsp;20, 2016 until February&nbsp;15, 2017 (the &#147;Resignation Date&#148;),
Mr.&nbsp;Coughlin continued to receive his 2016 base salary of $434,700; (ii)&nbsp;from the Resignation Date until May&nbsp;31, 2018 (or such earlier date that Mr.&nbsp;Coughlin and the Company mutually designate), Mr.&nbsp;Coughlin will remain
employed by the Company (the &#147;Employment Termination Date&#148;). During the period between the Resignation Date and the Employment Termination Date (the &#147;Transition Period&#148;), Mr.&nbsp;Coughlin will continue to serve as an employee of
the Company as a Vice President, but will no longer have the powers, duties and responsibilities commensurate with the position of Chief Financial Officer. During the Transition Period, Mr.&nbsp;Coughlin will (i)&nbsp;receive a reduced base salary
of $310,000; (ii)&nbsp;continue to remain eligible for vacation and other benefits and expense reimbursement pursuant to the terms of his employment agreement; (iii)&nbsp;continue to remain eligible to receive his annual cash incentive bonus payment
for 2016, with a target bonus percentage of 50% and a maximum bonus percentage of 60%, as determined by the Board of Directors and/or its Compensation Committee; and (iv)&nbsp;remain eligible to participate in the Company&#146;s cash incentive bonus
program for 2017, as determined by the Board of Directors snd/or its Compensation Committee, with a reduced target bonus percentage of 40%. Pursuant to the transition agreement, Mr.&nbsp;Coughlin is not entitled to any further stock awards or equity
grants from the Company but any stock awards and equity grants previously granted to Mr.&nbsp;Coughlin will continue to vest and become exercisable during the Transition Period in accordance with their terms. The equity awards previously granted to
Mr.&nbsp;Coughlin under the 2011 Plan and then held by him, other than certain performance-based restricted stock units granted to Mr.&nbsp;Coughlin in February 2016 (collectively, the &#147;Covered Awards&#148;), shall continue to vest and become
exercisable following the Employment Termination Date, and any such equity award that is a stock option shall remain exercisable until three months following the last vesting date with respect to any of the Covered Awards, but no later than the end
of the original full term of such stock option. Except as modified by the transition agreement, Mr.&nbsp;Coughlin&#146;s employment agreement remains in full force and effect until the Employment Termination Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher F. O&#146;Brien, M.D.</I></B> had an employment contract that provided that: (i)&nbsp;Dr.&nbsp;O&#146;Brien served as the
Company&#146;s Senior Vice President, Clinical Development and Chief Medical Officer commencing on August&nbsp;1, 2007 at an initial annual salary of $350,000, subject to annual adjustment by the Board of Directors (Dr.&nbsp;O&#146;Brien&#146;s
annual base salary for 2017 is $501,600); (ii)&nbsp;the agreement terminated upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation; (iii)&nbsp;Dr.&nbsp;O&#146;Brien was eligible
for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;Dr.&nbsp;O&#146;Brien was eligible to receive equity awards with the number of&nbsp;shares, vesting terms, and
exercise price as was determined by the Board of Directors. On February&nbsp;5, 2018, the Compensation Committee approved a consulting arrangement with Dr.&nbsp;O&#146;Brien that became effective February&nbsp;28, 2018, the date of
Dr.&nbsp;O&#146;Brien&#146;s retirement from the Company. Under the consulting arrangement, Dr.&nbsp;O&#146;Brien provides consulting services exclusively to the Company for a minimum period of three years.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;O&#146;Brien will receive $20,000 per quarter as payment for these services. The equity awards previously granted to Dr.&nbsp;O&#146;Brien under the 2011 Plan, other than any
performance-based restricted stock units, shall continue to vest and become exercisable during the term of the consulting agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Haig P. Bozigian,</I></B><B><I></I></B><B><I>&nbsp;Ph.D.</I></B> has an employment contract that provides that:
(i)&nbsp;Dr.&nbsp;Bozigian will serve as the Company&#146;s Senior Vice President, Pharmaceutical and Preclinical Development commencing on August&nbsp;1, 2007 at an initial annual salary of $260,000, subject to annual adjustment by the Board of
Directors (Dr.&nbsp;Bozigian&#146;s annual base salary for 2017 is $408,800); (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation;
(iii)&nbsp;Dr.&nbsp;Bozigian is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;Dr.&nbsp;Bozigian is eligible to receive stock option awards with the
number of&nbsp;shares and exercise price as shall be determined by the Board of Directors. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eric Benevich</I></B> has
an employment contract that provides that: (i)&nbsp;Mr.&nbsp;Benevich will serve as the Company&#146;s Chief Commercial Officer commencing on May&nbsp;26, 2015 at an initial annual salary of $365,000, subject to annual adjustment by the Board of
Directors (Mr.&nbsp;Benevich&#146;s annual base salary for 2017 is $410,000); (ii)&nbsp;the agreement terminates upon death, disability, termination by the Company with or without cause, constructive termination or voluntary resignation;
(iii)&nbsp;Mr.&nbsp;Benevich is eligible for a discretionary annual bonus as determined by the Board of Directors, based upon achieving certain performance criteria; and (iv)&nbsp;Mr.&nbsp;Benevich is eligible to receive stock option awards with the
equity awards with the number of&nbsp;shares, vesting terms, and exercise price as shall be determined by the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End.</FONT></I></B>&nbsp;The
following table sets forth the outstanding equity awards held by the NEOs at December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="20" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="12" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:17.50pt; display:inline; font-size:7pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Award<BR>Grant and<BR>Commencement<BR>of Vesting Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan <BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Shares<BR>or&nbsp;Units<BR>of<BR>Stock<BR>That<BR>Have<BR>Not</B><br><B>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares<BR>or Units<BR>of&nbsp;Stock<BR>That<BR>Have&nbsp;Not<BR>Vested<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout</B><br><B>Value of<BR>Unearned<BR>Shares,</B><br><B>Units
or<BR>Other<BR>Rights<BR>That<BR>Have Not<BR>Vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/25/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/10/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/10/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/16/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">581,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/3/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/5/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,338,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,773,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/6/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,560,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/16/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/3/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/5/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/10/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/10/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/16/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/3/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/5/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">744,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,366,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/6/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8/25/2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/25/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/12/2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/12/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/10/2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/10/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1/16/2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/16/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/3/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/5/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">593,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/6/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6/1/2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,939,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/5/2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,590,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/6/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/1/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/31/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2/6/17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12/1/2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">969,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over four years, subject to an initial <FONT STYLE="white-space:nowrap">one-year</FONT> &#147;cliff.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over four years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 35,750 Performance Restricted Stock Units (PRSUs) for Dr.&nbsp;Gorman, 30,500 PRSUs for Dr.&nbsp;O&#146;Brien and 20,500 PRSUs each for Mr.&nbsp;Coughlin, Mr.&nbsp;Benevich and Dr.&nbsp;Bozigian. These PRSUs
vest upon the Company obtaining positive pivotal data in Tourette syndrome and filing of a NDA for valbenazine in Tourette syndrome. The PRSUs have a limited term of four years to file the NDA. Additionally, Dr.&nbsp;Gorman has 17,250 restricted
stock unit (RSU) awards, Dr.&nbsp;O&#146;Brien has 9,600 RSUs, Mr.&nbsp;Coughlin and Dr.&nbsp;Bozigian each have 7,650 RSUs and Mr.&nbsp;Benevich has 6,525 RSUs. These RSUs are time-based and vest annually, on a
<FONT STYLE="white-space:nowrap">pro-rata</FONT> basis over four years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Vests monthly over three years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Vests after a three-year &#147;cliff&#148; vesting period. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Vests annually over four years. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to Dr.&nbsp;Gros&#146; employment agreement dated January&nbsp;4, 2017, all outstanding stock awards held by Dr.&nbsp;Gros on the date of his termination of employment with the Company on December&nbsp;31, 2017
were accelerated so that the number of shares which would have vested if Dr.&nbsp;Gros had continued to render services to the Company for 15 months after Dr.&nbsp;Gros&#146; termination of employment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Exercises and Stock Vested During the Year.</I></B> The following table sets forth the options
exercised and stock awards that vested during fiscal 2017 along with their respective values at December&nbsp;31, 2017 for the NEOs: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Option Exercises and Stock Vested Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Exercise (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized on<BR>Exercise&nbsp;($)&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Vesting (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized&nbsp;on<BR>Vesting&nbsp;($)&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,748,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,699,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,403,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,568,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,488,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,596,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,157,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,537,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David-Alexandr&egrave; C. Gros, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Information relates to stock option exercises during 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Information relates to restricted stock units and performance restricted stock units that vested during 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Calculated by multiplying the number of shares acquired upon exercise of stock options by the difference between the exercise price and the market price of the Company&#146;s common stock at the time of exercise.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Calculated by multiplying the number of shares acquired upon vesting of restricted stock units by the average price of shares sold for purposes of satisfying federal and state income tax liabilities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Payments Upon Termination or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control.</FONT></FONT></I></B><B><I></I></B>&nbsp;The following tables set forth the potential severance benefits payable to the NEOs in the event of a termination prior to
or following a change in control, assuming such event occurred on December&nbsp;31, 2017: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination Table*
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">560,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,531,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,006,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">387,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,908,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,556,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,966,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,542,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,939,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,611,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">963,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Reflects a termination without cause or due to a constructive termination, or deemed termination, prior to a change in control. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on salary as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on bonus targets established by the Board of Directors for 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the intrinsic value of <FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2017 that would vest in
accordance with the executive officers&#146; employment agreements. Values were derived using the closing price of the Company&#146;s common stock on December&nbsp;29, 2017 of $77.59. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Medical is comprised primarily of health insurance premiums for the period specified in each executive officer&#146;s employment contract. </TD></TR></TABLE>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Change-in-Control</FONT></FONT> Table* </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Severance&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,484,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,802,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">620,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,158,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,177,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Christopher&nbsp;F.&nbsp;O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">752,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">376,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,204,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,372,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">613,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,803,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,821,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">615,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">307,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,681,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,679,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,209,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,199,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Reflects benefits to be provided upon a termination without cause, or due to a constructive termination, within a specified time following a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control.</FONT></FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on salary as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on bonus targets established by the Board of Directors for 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the intrinsic value of <FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2017 that would vest in
accordance with the executive officers&#146; employment agreements. Values were derived using the closing price of the Company&#146;s common stock on December&nbsp;29, 2017 of $77.59. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Medical is comprised primarily of health insurance premiums for the period specified in each executive officer&#146;s employment contract. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination by Disability Table* </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Medical&nbsp;(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,531,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,894,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">387,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,908,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,517,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">501,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,966,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,542,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,939,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,611,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">963,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Reflects a termination due to disability. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on salary as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on bonus targets established by the Board of Directors for 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the intrinsic value of <FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2017 that would vest in
accordance with the executive officers&#146; employment agreements. Values were derived using the closing price of the Company&#146;s common stock on December&nbsp;29, 2017 of $77.59. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Medical is comprised primarily of health insurance premiums for the period specified in each executive officer&#146;s employment contract. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Payment upon Termination by Death Table* </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accrued<BR>Compensation&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">448,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,531,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,049,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timothy P. Coughlin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,908,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,094,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher F. O&#146;Brien, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,439,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haig P. Bozigian, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,848,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,096,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Benevich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,939,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,165,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew C. Abernethy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">515,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Reflects a termination due to death. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Based on bonus targets established by the Board of Directors for 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Accrued compensation is comprised of vacation pay earned and unpaid as of December&nbsp;31, 2017 and a <FONT STYLE="white-space:nowrap">one-time</FONT> additional <FONT STYLE="white-space:nowrap">two-week</FONT>
vacation benefit for eligible employees. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the intrinsic value of <FONT STYLE="white-space:nowrap">&#145;in-the</FONT> money&#146; unvested options and restricted stock units as of December&nbsp;31, 2017 that would vest in
accordance with the executive officers&#146; employment agreements. Values were derived using the closing price of the Company&#146;s common stock on December&nbsp;29, 2017 of $77.59. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the arrangements under which the NEOs may be entitled to potential payments upon a termination without cause
or resignation due to a constructive termination (including following a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control)</FONT></FONT> or upon disability or death. Resignation due to constructive termination may
include an executive&#146;s resignation following one or more of the following material adverse changes in the nature of such executive&#146;s employment, as specified in the agreement, which is not cured following notification: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a significant reduction in the executive or the executive supervisor&#146;s duties or responsibilities, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material reduction in base salary, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material relocation, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material breach of the executive&#146;s employment agreement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Gorman</I></B> is entitled to 1.25 times the amount of his annual base salary and target annual
bonus to be paid equally over 15&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 15 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of
15&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months after the consummation of a change of
control, Dr.&nbsp;Gorman is entitled to 2 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding stock awards, and
payment of COBRA benefits to continue then-current coverage for a period of 24&nbsp;months following termination. In addition, the Company has agreed to reimburse Dr.&nbsp;Gorman for the increase in federal and state income taxes payable by him by
reason of the benefits provided in connection with such a termination in connection with a change in control if the total payment exceeds 2.99 times his base amount by more than 15%. In the event of termination due to disability, Dr.&nbsp;Gorman is
entitled to 15&nbsp;months of base salary paid semi-monthly over 15&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Gorman in the
fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 15&nbsp;continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a
period of 15&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;Gorman&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 15
continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Gorman in the fiscal year and the denominator
of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Coughlin</I></B> is entitled to 1.25 times the
amount of his annual base salary and target annual bonus to be paid equally over 15&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 15 continuous months after the date of termination, and payment of COBRA
benefits to continue then-current coverage for a period of 15&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination
within six months after the consummation of a change of control, Mr.&nbsp;Coughlin is entitled to 2 times his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and
all vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 24&nbsp;months following termination. In addition, the Company has agreed to reimburse Mr.&nbsp;Coughlin for the increase in
federal and state income taxes payable by him by reason of the benefits provided in connection with such a termination in connection with a change in control if the total payment exceeds 2.99 times his base amount by more than 15%. In the event of
termination due to disability, Mr.&nbsp;Coughlin is entitled to 15&nbsp;months of base salary paid semi-monthly over 15&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of
full months of employment by Mr.&nbsp;Coughlin in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 15&nbsp;continuous months after the date of termination, and payment of
COBRA benefits to continue then-current coverage for a period of 15&nbsp;months following termination. In the event of a termination due to Mr.&nbsp;Coughlin&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of
unvested&nbsp;shares that would have vested over the 15 continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by
Mr.&nbsp;Coughlin in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;O&#146;Brien</I></B> is entitled to 1.0 times the amount of his annual base salary and target
annual bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a
period of 12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months after the consummation of a
change of control, Dr.&nbsp;O&#146;Brien is entitled to 1.5 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding
stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination. In addition, the Company has agreed to reimburse Dr.&nbsp;O&#146;Brien for the increase in federal and state income
taxes payable by him by reason of the benefits provided in connection with such a termination in connection with a change in control if the total payment exceeds 2.99 times his base amount by more than 15%. In the event of termination due to
disability, Dr.&nbsp;O&#146;Brien is entitled to 12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction of the numerator of which is the number of full months
of employment by Dr.&nbsp;O&#146;Brien in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 12&nbsp;continuous months after the date of termination, and payment of COBRA
benefits to continue then-current coverage for a period of 12&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;O&#146;Brien&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of
unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by
Dr.&nbsp;O&#146;Brien in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Bozigian</I></B> is entitled to 1.0 times the amount of his annual base salary and target annual
bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of
12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months after the consummation of a change of
control, Dr.&nbsp;Bozigian is entitled to 1.5 times the amount of his annual base salary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all vested and outstanding stock awards, and payment of COBRA benefits to
continue then-current coverage for a period of 18&nbsp;months following termination. In addition, the Company has agreed to reimburse Dr.&nbsp;Bozigian for the increase in federal and state income taxes payable by him by reason of the benefits
provided in connection with such a termination in connection with a change in control if the total payment exceeds 2.99 times his base amount by more than 15%. In the event of termination due to disability, Dr.&nbsp;Bozigian is entitled to
12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Bozigian in the fiscal
year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 12&nbsp;continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of
12&nbsp;months following termination. In the event of a termination due to Dr.&nbsp;Bozigian&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months
after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Dr.&nbsp;Bozigian in the fiscal year and the denominator of which is 12
and any accrued and unpaid compensation on the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Benevich</I></B> is
entitled to 1.0 times the amount of his annual base salary and target annual bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination,
and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event
of such termination within six months after the consummation of a change of control, Mr.&nbsp;Benevich is entitled to 1.5 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value
of all unvested stock awards and all vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination; provided, however, in the event such payment to
Mr.&nbsp;Benevich after a change of control is subject to a <FONT STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT STYLE="white-space:nowrap">best-after-tax</FONT> provision provides that if the change of control
payment due to Mr.&nbsp;Benevich would be subject to the excise tax provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce the change of control payments to Mr.&nbsp;Benevich if, after all applicable taxes, the final
payments would be larger than if the change of control payments were not reduced and therefor subject to an excise tax. In the event of termination due to disability, Mr.&nbsp;Benevich is entitled to 12&nbsp;months of base salary paid semi-monthly
over 12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Benevich in the fiscal year and the denominator of which is 12, an
acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue then-current coverage for a period of 12&nbsp;months following termination. In the
event of a termination due to Mr.&nbsp;Benevich&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, a lump sum
amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Benevich in the fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on
the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mr.</I></B><B><I></I></B><B><I>&nbsp;Abernethy </I></B>is entitled to 1.0 times the amount of his annual
base salary and target annual bonus to be paid equally over 12&nbsp;months, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to continue
then-current coverage for a period of 12&nbsp;months following termination in the event that the Company terminates his employment without cause, or he resigns due to a constructive termination. In the event of such termination within six months
after the consummation of a change of control, Mr.&nbsp;Abernethy is entitled to 1.5 times the amount of his annual base salary and annual target bonus to be paid in one lump sum, a cash amount equal to the value of all unvested stock awards and all
vested and outstanding stock awards, and payment of COBRA benefits to continue then-current coverage for a period of 18&nbsp;months following termination; provided, however, in the event such payment to Mr.&nbsp;Abernethy after a change of control
is subject to a <FONT STYLE="white-space:nowrap">&#147;best-after-tax&#148;</FONT> provision. The <FONT STYLE="white-space:nowrap">best-after-tax</FONT> provision </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides that if the change of control payment due to Mr.&nbsp;Abernethy would be subject to the excise tax provisions of Section&nbsp;280G of the Internal Revenue Code, the Company may reduce
the change of control payments to Mr.&nbsp;Abernethy if, after all applicable taxes, the final payments would be larger than if the change of control payments were not reduced and therefor subject to an excise tax. In the event of termination due to
disability, Mr.&nbsp;Abernethy is entitled to 12&nbsp;months of base salary paid semi-monthly over 12&nbsp;months, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of
employment by Mr.&nbsp;Abernethy in the fiscal year and the denominator of which is 12, an acceleration of unvested&nbsp;shares that would have vested over the 12 continuous months after the date of termination, and payment of COBRA benefits to
continue then-current coverage for a period of 12&nbsp;months following termination. In the event of a termination due to Mr.&nbsp;Abernethy&#146;s death, his beneficiaries or estate, would be entitled to an acceleration of unvested&nbsp;shares that
would have vested over the 12 continuous months after the date of termination, a lump sum amount equal to his target annual bonus multiplied by a fraction the numerator of which is the number of full months of employment by Mr.&nbsp;Abernethy in the
fiscal year and the denominator of which is 12 and any accrued and unpaid compensation on the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr.</I></B><B><I></I></B><B><I>&nbsp;Gros</I></B>, in connection with the end of his employment with the Company on December&nbsp;31,
2017, received 1.25 times the amount of his annual base salary and target annual bonus, to be paid equally over 15 months, an acceleration of unvested shares that would have vested over the 15 continuous months after the date of the end of his
employment, and payment of COBRA benefits to continue then-current coverage for a period of 15 months following the date of the end of his employment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CEO PAY RATIO </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order
to reflect our employee compensation practices, we have calculated the annual base salary of our median employee while taking only annual base salary into account, as well as the ratio of the base salary of our CEO as compared to the annual base
salary of such median employee. In calculating the annual base salary of our median employee we used the applicable methodology listed above. For fiscal 2017, the median of the annual base salary of our employees (other than our CEO) was $127,000,
and the annual base salary of our CEO, Kevin C. Gorman, Ph.D., as reported in the Summary Compensation Table included in this Proxy Statement, was $640,000. Based on this information, the ratio of the annual base salary of our CEO to the median of
the annual base salary of all employees (other than the CEO) was approximately 5 to 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the information above, under SEC
rules, we are required to calculate and disclose the annual total compensation of our median employee, as well as the ratio of the annual total compensation of our median employee as compared to the annual total compensation of our CEO (&#147;CEO
Pay Ratio&#148;). To identify our median employee, we used the following methodology: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To determine our total population of employees, we included all full-time and part-time as of December&nbsp;31, 2017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To identify our median employee from our employee population, we calculated the aggregate amount of each employee&#146;s fiscal 2017 base salary (using a reasonable estimate of the hours worked and overtime actually
paid during fiscal 2017 for hourly employees and actual salary paid for our remaining employees) and bonuses attributable to fiscal 2017 performance and the grant date fair value of equity awards granted in fiscal 2017 using the same methodology we
use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In making this determination, we annualized the base salary and target bonus compensation of employees who were employed by us for less than the entire fiscal year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal 2017, the median of the annual total compensation of our employees (other than our CEO) was $252,000 and the annual total
compensation of our CEO, Kevin C. Gorman, Ph.D., as reported in the Summary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Compensation Table included in this Proxy Statement, was $7,556,374. Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total
compensation of all employees was approximately 30 to 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CEO Pay Ratio above represents our reasonable estimate calculated in a
manner consistent with SEC rules and applicable guidance. SEC rules and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions
particular to that company. As a result, and as explained by the SEC when it adopted these rules, in considering the pay ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among
different companies, even companies within the same industry, but rather to allow stockholders to better understand and assess each particular company&#146;s compensation practices and pay ratio disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS COMPENSATION SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Philosophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation philosophy is based on the following guiding principles: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aligning the long-term interests of stockholders and directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Compensating directors appropriately and adequately for their time, effort and experience. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The elements of director compensation consist of annual cash retainers and equity awards, as well as customary and usual expense reimbursement
in attending Company meetings. In an effort to align the long-term interests of our stockholders and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, the mix of cash and equity compensation has historically been, and is currently,
weighted more heavily to equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, the Board and the Company&#146;s stockholders approved certain annual limits on compensation to
be paid to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director will not exceed $1,250,000 in total value during any year. In addition, the aggregate value of the initial option grant or other similar stock awards granted under the 2011 Plan or
otherwise to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon or in connection with his or her initial election or appointment to the Board will not exceed $2,000,000 in total value. The Board has
the authority to make exceptions to these limits in extraordinary circumstances, in its discretion, provided that any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is granted or paid such additional compensation may not
participate in the decision to grant or pay such additional compensation. No exceptions were made in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each year, our Compensation
Committee reviews <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation levels with its compensation consultant and recommends to our Board, as it deems appropriate, changes to such compensation levels. Our director compensation
for fiscal 2017 is described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation for Fiscal 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are reimbursed for expenses incurred in connection with performing their duties
as directors of the Company. For 2017, directors who are not employees of the Company received a $50,000 annual retainer. The Company provided the Chairman of the Board, William H. Rastetter, an additional $30,000, making his total annual cash
retainer $80,000. In addition to the cash compensation set forth above, the Chairman of the Audit Committee received an additional $20,000 annual cash retainer. The Chairman of the Compensation Committee received an additional $20,000 annual cash
retainer. The Chairman of the Nominating/Corporate Governance Committee received an additional $9,000 annual cash retainer. The Chairman of the Science and Medical Technology Committee received an additional $9,000 annual cash retainer. Each other
director who was a member of the Audit Committee, the Compensation Committee, the Nominating/Corporate Governance Committee or the Science and Medical Technology Committee received an additional annual cash retainer of $12,000, $12,000, $5,000 and
$5,000, respectively, for each Committee on which he or she served. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, for 2017, each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director received a grant of a nonstatutory stock option to purchase 15,000&nbsp;shares of the Company&#146;s common stock (except that the Chairman of the Board received an option to purchase
18,000&nbsp;shares) at the 2017 Annual Meeting of Stockholders. The options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors have exercise prices equal to the fair market value of the Company&#146;s common stock on the date
of the grant, are subject to a <FONT STYLE="white-space:nowrap">ten-year</FONT> term and vest monthly over the <FONT STYLE="white-space:nowrap">one-year</FONT> period following the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation paid by the Company for the fiscal year
ended December&nbsp;31, 2017 to the directors of the Company named below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Director Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin C. Gorman, Ph.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William H. Rastetter, Ph.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">531,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">616,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary A. Lyons (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">497,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph A. Mollica,&nbsp;Ph.D. (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">509,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George J. Morrow (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">504,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corinne H. Nevinny (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">512,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard F. Pops (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">524,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alfred W. Sandrock, Jr., M.D. Ph.D. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">506,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen A. Sherwin,&nbsp;M.D. (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">513,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amounts in this column reflect compensation earned in 2017, all of which was paid during 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown represent the full grant date fair value of option awards granted in 2017 as determined pursuant to ASC 718. The assumptions used to calculate the value of such awards are set forth under Note 9 of the
Notes to the Consolidated Financial Statements included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. The grant date fair values of all option awards are based on
a per share Black-Scholes value of $29.53. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">During 2017, Dr.&nbsp;Gorman was an employee of the Company, and as such, did not receive any compensation for service on the Board of Directors. As of December&nbsp;31, 2017, Dr.&nbsp;Gorman had outstanding options to
purchase 1,306,500 shares of common stock, and 106,000 outstanding restricted stock units. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Dr.&nbsp;Rastetter had outstanding options to purchase 146,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Mr.&nbsp;Lyons had outstanding options to purchase 115,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Mollica resigned from the Board of Directors in October 2017. As of December&nbsp;31, 2017, Dr.&nbsp;Mollica had outstanding options to purchase 115,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Mr.&nbsp;Morrow had outstanding options to purchase 70,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Ms.&nbsp;Nevinny had outstanding options to purchase 115,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Mr.&nbsp;Pops had outstanding options to purchase 115,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Dr.&nbsp;Sandrock had outstanding options to acquire 70,000 shares of common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, Dr.&nbsp;Sherwin had outstanding options to purchase 115,000 shares of common stock. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive
officers of the Company serve at the discretion of the Board of Directors. There are no family relationships among any of the directors, executive officers or key employees of the Company. None of our directors or executive officers has been
involved in any of the legal proceedings specified in Item&nbsp;401(f) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in the past 10 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or Ratification of Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s Audit Committee Charter, the Company&#146;s Audit Committee is responsible for reviewing and approving
the terms and conditions of all related person transactions. In connection with its review, approval or ratification of related person transactions, the Company&#146;s Audit Committee takes into account all relevant available facts and circumstances
in determining whether such transaction is in the best interests of the Company and its stockholders. Any transaction that would disqualify a director from meeting the &#147;independent director&#148; standard as defined under the Nasdaq Stock
Market rules requires review by the Company&#146;s Audit Committee prior to entering into such transaction. For all other related person transactions the Company reviews all agreements and payments for related person transactions and based on this
review, a report is made to the Company&#146;s Audit Committee quarterly disclosing all related person transactions during that quarter, if any. All related person transactions shall be disclosed in the Company&#146;s applicable filings with the SEC
as required under SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transactions During Fiscal 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no related person transactions during fiscal 2017. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER MATTERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the
date of this proxy statement, the Company knows of no other matters to be submitted to the stockholders at the Annual Meeting. If any other matters properly come before the Annual Meeting, it is the intention of the persons named in the proxy to
vote the&nbsp;shares they represent as the Board of Directors may recommend. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Householding&#148; of Proxy Materials.</I></B> The SEC has adopted rules that permit companies and intermediaries such as brokers
to satisfy delivery requirements for proxy statements with respect to two or more stockholders sharing the same address by delivering a single Notice addressed to those stockholders. This process, which is commonly referred to as
&#147;householding,&#148; potentially provides extra convenience for stockholders and cost savings for companies. The Company, as well as certain brokers, household proxy materials, unless contrary instructions have been received from the affected
stockholders. Once you have received notice from your broker or us that they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no
longer wish to participate in householding and would prefer to receive a separate Notice, please notify your broker if your&nbsp;shares are held in a brokerage account or us if you hold registered&nbsp;shares. If you hold registered&nbsp;shares, you
may direct your written request to the Company&#146;s Corporate Secretary at 12780 El Camino Real, San&nbsp;Diego, California 92130 or contact the Company&#146;s Corporate Secretary at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-617-7600.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Procedures.</I></B> To
be considered for inclusion in next year&#146;s proxy materials, a stockholder must submit his, her or its proposal in writing by December&nbsp;4, 2018, which is the date that is 120&nbsp;days prior to the first anniversary of the mailing date of
this proxy statement, to the Company&#146;s Corporate Secretary at 12780 El Camino Real, San&nbsp;Diego, California 92130. Any proposal must comply with the requirements as to form and substance established by the SEC for such proposal to be
included in our proxy statement. Stockholders are also advised to review our bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2011 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY&nbsp;21, 2011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPROVED BY THE STOCKHOLDERS: MAY&nbsp;25, 2011 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;23, 2013 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;22, 2014 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;28, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;20, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: MAY&nbsp;22, 2017 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED BY THE STOCKHOLDERS: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION DATE: FEBRUARY&nbsp;20, 2021 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. G<SMALL>ENERAL</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Successor to and Continuation of Prior Plans</B>. The Plan is intended as the successor to and continuation of the Neurocrine Biosciences, Inc. 2003 Incentive Stock Plan, 2001 Stock Option Plan, 1997 Incentive Stock Plan, 1996 Director Stock Option
Plan and 1992 Incentive Stock Plan (together the &#147;<B><I>Prior Plans</I></B>&#148;). On the Effective Date, awards will automatically be granted to the Company&#146;s Directors pursuant to the terms of Section&nbsp;10 of the Neurocrine
Biosciences, Inc. 2003 Incentive Stock Plan (the &#147;<B><I>2011 Automatic Director Awards</I></B>&#148;). From and following the Effective Date, no additional stock awards shall be granted under the Prior Plans except for the 2011 Automatic
Director Awards. From and after the Effective Date, all outstanding stock awards granted under the Prior Plans shall remain subject to the terms of the Prior Plans; provided, however, any shares subject to outstanding stock awards granted under the
Prior Plans that expire or terminate for any reason prior to exercise or settlement or are otherwise forfeited prior to issuance of the shares because of the failure to meet a contingency or condition required to vest such shares shall not again
become available for issuance under either the Prior Plans or this Plan. Except with respect to the 2011 Automatic Director Awards, all Awards granted on or after the Effective Date of this Plan shall be subject to the terms of this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Eligible Award Recipients</B>. The persons eligible to receive discretionary Awards are Employees, Directors and Consultants. The
persons eligible to receive Stock Awards under the Director Grant Program are Eligible Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Available Awards</B>. The Plan
provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii)&nbsp;Nonstatutory Stock Options, (iii)&nbsp;Stock Appreciation Rights (iv)&nbsp;Restricted Stock Awards, (v)&nbsp;Restricted Stock Unit Awards,
(vi)&nbsp;Performance Stock Awards, and (vii)&nbsp;Other Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Purpose</B>. The Company, by means of the Plan, seeks to
secure and retain the services of the group of persons eligible to receive Awards as set forth in Section&nbsp;1(b), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a
means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Section</B><B></B><B>&nbsp;162(m) Transition Relief.</B> Notwithstanding anything in the Plan to the contrary: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any provision in the Plan that refers to &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code will only
apply to any Award that is intended to qualify, and is eligible to qualify, as &#147;performance-based compensation&#148; under Section&nbsp;162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act (the
&#147;<B><I>TCJA</I></B>&#148;) for remuneration provided pursuant to a written binding contract which was in effect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on November&nbsp;2, 2017 and which was not modified in any material respect on or after such date (the &#147;<B><I>Transition Relief</I></B>&#148;), as determined by the Board, in its sole
discretion, in accordance with the TCJA and any applicable guidance, rulings or regulations issued by the U.S. Department of the Treasury, the Internal Revenue Service or any other governmental authority (collectively, the &#147;<B><I>TCJA
Guidance</I></B>&#148;) (each such Award, a &#147;<B><I>162(m) Award</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>any Award (including any 162(m) Award)
that was granted prior to May&nbsp;24, 2018 will be subject to and governed by the terms of the Plan, as in effect on the date of grant of such Award (or as in effect on the date of any subsequent amendment of the Plan, to the extent applicable, but
no later than November&nbsp;2, 2017 with respect to any 162(m) Award and no later than May&nbsp;23, 2018 with respect to any Award that is not a 162(m) Award); <I>provided, however</I>, that any such terms which refer to a subsection of
Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder) as in effect on December&nbsp;31, 2017 (or with respect to any Award that is not a 162(m) Award, as amended by the TCJA or any
TCJA Guidance and as in effect on January&nbsp;1, 2018 (or as subsequently amended thereafter), to the extent applicable); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)
</B>any Award (including any 162(m) Award) that is granted on or after May&nbsp;24, 2018 will be subject to and governed by the terms of the Plan, as in effect on May&nbsp;24, 2018 (or as in effect on the date of any subsequent amendment of the
Plan, to the extent applicable, provided that with respect to any 162(m) Award, no such subsequent amendment will be effective if it would result in such 162(m) Award not being able to qualify for the Transition Relief); <I>provided, however</I>,
that (a)&nbsp;with respect to any 162(m) Award, any such terms which refer to a subsection of Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder) as in effect on December&nbsp;31,
2017, and (b)&nbsp;with respect to any Award that is not a 162(m) Award, any such terms which refer to a subsection of Section&nbsp;162(m) of the Code (or any regulations thereunder) will mean such subsection (or any regulations thereunder), as
amended by the TCJA or any TCJA Guidance and as in effect on January&nbsp;1, 2018 (or as subsequently amended thereafter), to the extent applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. A<SMALL>DMINISTRATION</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Administration by Board</B>. The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(d). However, the Board may not delegate administration of
the Director Grant Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Powers of Board</B>. Except with respect to the Director Grant Program, the Board shall have the
power, subject to, and within the limitations of, the express provisions of the Plan: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine from time to
time (A)&nbsp;which of the persons eligible under the Plan shall be granted Awards; (B)&nbsp;when and how each Award shall be granted; (C)&nbsp;what type or combination of types of Award shall be granted; (D)&nbsp;the provisions of each Award
granted (which need not be identical), including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to an Award; (E)&nbsp;the number of shares of Common Stock with respect to which a Stock Award shall be
granted to each such person; and (F)&nbsp;the Fair Market Value applicable to a Stock Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> To construe and
interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock
Award Agreement in a manner and to the extent it shall deem necessary or expedient to make the Plan or Award fully effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To settle all controversies regarding the Plan and Awards granted under it. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>To accelerate the time at which an Award may first be exercised or the time during which an Award or any part
thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> To suspend or terminate the Plan at any time. Suspension or termination of the Plan shall not impair rights and
obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary or
advisable. However, except as provided in Section&nbsp;10(a) relating to Capitalization Adjustments, to the extent required by applicable law or listing requirements, stockholder approval shall be required for any amendment of the Plan that either
(A)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits
accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, (D)&nbsp;materially extends the term of the Plan, or (E)&nbsp;expands the types of Awards available
for issuance under the Plan. Except as provided above, rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (1)&nbsp;the Company requests the consent of the affected Participant, and
(2)&nbsp;such Participant consents in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vii) </B>To submit any amendment to the Plan for stockholder approval,
including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of
compensation paid to Covered Employees, (B)&nbsp;Section&nbsp;422 of the Code regarding incentive stock options or <FONT STYLE="white-space:nowrap">(C)&nbsp;Rule&nbsp;16b-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B> To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards,
including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided however,
that except with respect to amendments that disqualify or impair the status of an Incentive Stock Option, a Participant&#146;s rights under any Award shall not be impaired by any such amendment unless (A)&nbsp;the Company requests the consent of the
affected Participant, and (B)&nbsp;such Participant consents in writing. Notwithstanding the foregoing, subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected
Participant&#146;s consent if necessary to maintain the qualified status of the Award as an Incentive Stock Option or to bring the Award into compliance with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ix) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote
the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> To
adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Administration of Director Grant Program</B>. The Board shall have the power, subject to and within the limitations of, the
express provisions of the Director Grant Program: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> To determine the provisions of each Stock Award to the extent
not specified in the Director Grant Program. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>To construe and interpret the Director Grant Program and the
Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Director Grant Program or in any Stock
Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Director Grant Program fully effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> To amend the terms of the Director Grant Program or a Stock Award granted thereunder, except that rights under any
such Stock Award granted before amendment of the Director Grant Program shall not be impaired by any amendment of the Director Grant Program unless (1)&nbsp;the Company requests the consent of the affected Participant, and (2)&nbsp;such Participant
consents in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Generally, to exercise such powers and to perform such acts as the Board deems necessary
or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Director Grant Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Delegation to Committee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) General</B>. The Board may delegate some or all of the administration of the Plan (except the Director Grant Program) to a Committee or
Committees. If administration of the Plan is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including
the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to
such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.
The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Section</B><B></B><B>&nbsp;162(m) and Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance</B>. The Committee may consist
solely of two or more Outside Directors, in accordance with Section&nbsp;162(m) of the Code, or solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors, in accordance with Rule
<FONT STYLE="white-space:nowrap">16b-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Delegation to an Officer</B>. The Board may delegate to one (1)&nbsp;or more
Officers the authority to do one or both of the following (i)&nbsp;designate Employees who are providing Continuous Service to the Company or any of its Subsidiaries who are not Officers to be recipients of Options and SARs (and, to the extent
permitted by applicable law, other Stock Awards) and the terms thereof, and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; provided, however, that the Board resolutions
regarding such delegation shall specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding the
foregoing, the Board may not delegate authority to an Officer to determine the Fair Market Value pursuant to Section&nbsp;14(z)(iii) below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Effect of Board&#146;s Decision</B>. All determinations, interpretations and constructions made by the Board in good faith shall not be
subject to review by any person and shall be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Cancellation and <FONT
STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</B>. Except in connection with a Corporate Transaction, as provided in Section&nbsp;10(a) relating to Capitalization Adjustments, or unless the stockholders of the Company have approved such
an action within twelve (12)&nbsp;months prior to such an event, neither the Board nor any Committee shall have the authority to: (i)&nbsp;reduce the exercise price of any outstanding Options or SARs under the Plan, or (ii)&nbsp;cancel any
outstanding Options or SARs that have an exercise price or strike price greater than the current Fair Market Value of the Common Stock in exchange for cash, Full Value Awards, or Options or SARs with an exercise price less than the original exercise
price of the Options or SARs that are cancelled. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL>
P<SMALL>LAN</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Share Reserve</B>. Subject to Section&nbsp;10(a) relating to Capitalization Adjustments, the aggregate
number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date shall not exceed nineteen million (19,000,000)&nbsp;shares. For clarity, the Share Reserve in this Section&nbsp;3(a) is a limitation on
the number of shares of the Common Stock that may be issued pursuant to the Plan and does not limit the granting of Stock Awards except as provided in Section&nbsp;8(a). Shares may be issued in connection with a merger or acquisition as permitted
by, as applicable, NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance shall not reduce the number of shares available for
issuance under the Plan. Furthermore, if a Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued, such expiration or termination shall not reduce (or otherwise
offset) the number of shares of Common Stock that may be available for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Reversion of Shares to the Share Reserve</B>. If any shares of common stock issued
pursuant to a Stock Award are forfeited back to the Company because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited shall revert to and again become available for
issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Limitation on Full Value Awards</B>. The aggregate number of shares of Common Stock that may be issued
pursuant to grants of Full Value Awards shall not exceed fifty percent (50%)&nbsp;of the aggregate number of shares of Common Stock available for issuance under this Plan as set forth in Section&nbsp;3(a), subject to adjustment as provided in
Sections 3(b) and 10(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Shares Not Available For Subsequent Issuance</B>. If any shares subject to a Stock Award are not
delivered to a Participant because the Stock Award is exercised through a reduction of shares subject to the Stock Award (i.e., &#147;<B><I>net exercised</I></B>&#148;), the number of shares that are not delivered to the Participant shall no longer
be available for issuance under the Plan. Also, any shares used to pay the exercise price of a Stock Award or that are withheld in satisfaction of applicable tax withholding obligations shall no longer be available for issuance under the Plan. Any
shares repurchased on the open market with the proceeds of the exercise price of a Stock Award shall not again be available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Incentive Stock Option Limit</B>. Notwithstanding anything to the contrary in this Section&nbsp;3 and, subject to the provisions of
Section&nbsp;10(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options shall be nineteen million (19,000,000)&nbsp;shares of Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Section</B><B></B><B>&nbsp;162(m) Limitation on Annual Grants</B>. Subject to the provisions of Section&nbsp;10(a) relating
to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section&nbsp;162(m) of the Code, a maximum of five hundred thousand (500,000)&nbsp;shares of Common Stock subject to Options, SARs and Other
Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred percent (100%)&nbsp;of the Fair Market Value on the date any such Stock Award is granted may be granted to any Participant
during any calendar year; provided, however that in connection with his or her initial employment, an Employee may be granted such forms of Stock Awards for up to an additional five hundred thousand (500,000)&nbsp;shares of Common Stock which shall
not count against such annual limit. Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred percent
(100%)&nbsp;of the Fair Market Value on the date the Stock Award are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards shall not satisfy the requirements to be considered
&#147;qualified performance-based compensation&#148; under Section&nbsp;162(m) of the Code unless such additional Stock Awards are approved by the Company&#146;s stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit.</B> The aggregate value of all compensation granted
or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any period commencing on the date of the Company&#146;s regular Annual Meeting for a particular year and ending
on the date of the Company&#146;s regular Annual Meeting for the next subsequent year (the &#147;<B><I>Annual Period</I></B>&#148;), including Awards granted and cash fees paid by the Company to such
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, will not exceed one million two hundred fifty thousand dollars ($1,250,000) in total value. In addition, the aggregate value of the Initial Award(s) (or other similar stock award(s)
granted under the Plan or otherwise to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director upon or in connection with his or her initial election or appointment to the Board) will not exceed two million
dollars ($2,000,000) in total value; for the avoidance of doubt, the aggregate compensation granted or paid, as applicable, to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to an Annual
Period in which such individual is first appointed or elected to the Board shall not exceed the sum of the two preceding limitations in this Section&nbsp;3(g). The value of any stock awards, for purposes of the limitations described in this
Section&nbsp;3(g), shall be calculated based on the grant date fair value of such stock awards for financial reporting purposes.&nbsp;The limitations in this Section&nbsp;3(g) shall apply beginning with the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Annual period in which the Company&#146;s 2016 Annual Meeting occurs. The Board may make an exception to the applicable limit in this Section&nbsp;3(g) for any
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director in extraordinary circumstances, as the Board may determine in its discretion, provided that any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director who is granted or paid such
additional compensation may not participate in the decision to grant or pay such additional compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Source of Shares</B>.
The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise; provided, however that the Company may not repurchase shares to be
used under this Plan to the extent such repurchased shares would exceed the limitation in Section&nbsp;3(a). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. E<SMALL>LIGIBILITY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Eligibility for Specific Stock Awards</B>. Incentive Stock Options may be granted only to employees of the Company or a &#147;parent
corporation&#148; or &#147;subsidiary corporation&#148; thereof (as such terms are defined in Sections 424(e) and (f)&nbsp;of the Code). Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants;
provided, however, Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405 promulgated
under the Securities Act, unless the stock underlying such Stock Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code because the Stock Awards are granted pursuant to a corporate transaction (such as a spin
off transaction) or unless such Stock Awards comply with the distribution requirements of Section&nbsp;409A of the Code. Stock Awards granted under the Director Grant Program in Section&nbsp;7 may be granted only to Eligible Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Ten Percent Stockholders</B>. A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of
such Option is at least one hundred ten percent (110%)&nbsp;of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5)&nbsp;years from the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> T<SMALL>O</SMALL> O<SMALL>PTIONS</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL>
A<SMALL>PPRECIATION</SMALL> R<SMALL>IGHTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Option or SAR shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be
issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, then the Option shall be a Nonstatutory Stock Option. The provisions of separate Options or
SARs need not be identical; provided, however, that each Option Agreement or SAR Agreement shall conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the
following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Term</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, no Option or
SAR shall be exercisable after the expiration of ten (10)&nbsp;years from the date of its grant or such shorter period specified in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Exercise Price</B>. Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise price (or strike
price) of each Option or SAR shall be not less than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Option or SAR is granted. Notwithstanding the foregoing, an Option or SAR
may be granted with an exercise price (or strike price) lower than one hundred percent (100%)&nbsp;of the Fair Market Value of the Common Stock subject to the Option or SAR if such Option or SAR is granted pursuant to an assumption of or
substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. Each SAR will be denominated in shares of Common
Stock equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Purchase Price for Options</B>. The purchase price of Common Stock acquired pursuant
to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant
Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The permitted
methods of payment are as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> by cash, check, bank draft or money order payable to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>if the option is a Nonstatutory Stock Option, by a &#147;<B><I>net exercise</I></B>&#148; arrangement pursuant to
which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, that the Company shall
accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; provided, further, that shares of Common Stock
will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are reduced to pay the exercise price pursuant to the &#147;<B><I>net exercise,</I></B>&#148; (B)&nbsp;shares are
delivered to the Participant as a result of such exercise, and (C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> in any other form of legal consideration that may be acceptable to the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Exercise and Payment of a SAR</B>. To exercise any outstanding SAR, the Participant must provide written notice of exercise to the
Company in compliance with the provisions of the SAR Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on
the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such
date, over (B)&nbsp;the strike price that will be determined by the Board at the time of grant of the SAR. The appreciation distribution in respect to a SAR may be paid in Common Stock, in cash, in any combination of the two or in any other form of
consideration, as determined by the Board and contained in the SAR Agreement evidencing such SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Transferability of Options and
SARs</B>. The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the
transferability of Options and SARs shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Restrictions on Transfer</B>. An Option or SAR shall not be
transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Participant only by the Participant. Except as explicitly provided herein, neither an Option nor a SAR may be transferred.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Domestic Relations Orders</B>. Notwithstanding the foregoing, an Option or SAR may be transferred pursuant to a
domestic relations order; provided, however, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Beneficiary Designation</B>. Notwithstanding the foregoing, the Participant may, by delivering written notice to the
Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect Option exercises, designate a third party who, in the event of the death of the Participant, shall thereafter be entitled to
exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, the executor or administrator of the Participant&#146;s estate shall be entitled to exercise the
Option or SAR and receive the Common Stock or other consideration resulting from such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Vesting Generally</B>. The total number of shares of Common Stock subject to an
Option or SAR may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be
based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to any Option or SAR provisions
governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Termination of Continuous
Service</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates (other than for Cause or upon the Participant&#146;s death
or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Award as of the date of termination of Continuous Service) but only within such period of time ending on the
earlier of (i)&nbsp;the date three (3)&nbsp;months following the termination of the Participant&#146;s Continuous Service (or such longer or shorter period specified in the applicable Award Agreement), or (ii)&nbsp;the expiration of the term of the
Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR
shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) Extension of Termination Date</B>. If the exercise of an Option or SAR following the termination of the
Participant&#146;s Continuous Service (other than for Cause or upon the Participant&#146;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under
the Securities Act, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a total period of three (3)&nbsp;months (that need not be consecutive) after the termination of the Participant&#146;s Continuous Service during
which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided
in a Participant&#146;s Award Agreement, if the immediate sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#146;s Continuous Service (other than for Cause) would violate the
Company&#146;s insider trading policy, then the Option or SAR shall terminate on the earlier of (i)&nbsp;the expiration of a period equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous
Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#146;s insider trading policy, or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the
applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Disability of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other
agreement between the Participant and the Company, if a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was
entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date twelve (12)&nbsp;months following such termination of Continuous Service (or
such longer or shorter period specified in the Award Agreement), or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his or
her Option or SAR within the time specified herein or in the Award Agreement (as applicable), the Option or SAR (as applicable) shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) Death of Participant</B>. Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and
the Company, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or (ii)&nbsp;the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the
termination of the Participant&#146;s Continuous Service (for a reason other than death), then the Option or SAR may be exercised (to the extent the Participant was entitled to exercise such Option or SAR as of the date of death) by the
Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant&#146;s death, but only within the period ending on the earlier of (i)&nbsp;the date eighteen (18)&nbsp;months following the date of death (or such longer or shorter period specified
in the Award Agreement), or (ii)&nbsp;the expiration of the term of such Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR is not exercised within the time specified herein or in the Award
Agreement (as applicable), the Option or SAR shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Termination for Cause</B>. Except as explicitly provided otherwise
in a Participant&#146;s Award Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant&#146;s Continuous Service is terminated for Cause, the Option or SAR shall terminate immediately
upon such Participant&#146;s termination of Continuous Service, and the Participant shall be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</B>. No Option or SAR, whether or not vested, granted to an Employee who
is a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, shall be first exercisable for any shares of Common Stock until at least six months following the date of grant of the
Option or SAR. Notwithstanding the foregoing, consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;in the event of the Participant&#146;s death or Disability, (ii)&nbsp;upon a Corporate Transaction in which such Option or
SAR is not assumed, continued, or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the Participant&#146;s Award Agreement or in another applicable agreement or in
accordance with the Company&#146;s then current employment policies and guidelines), any such vested Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any
income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. P<SMALL>ROVISIONS</SMALL> O<SMALL>F</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>WARDS</SMALL> O<SMALL>THER</SMALL> T<SMALL>HAN</SMALL> O<SMALL>PTIONS</SMALL>
A<SMALL>ND</SMALL> S<SMALL>ARS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Restricted Stock Awards</B>. Each Restricted Stock Award Agreement shall be in such
form and shall contain such terms and conditions as the Board shall deem appropriate. To the extent consistent with the Company&#146;s Bylaws, at the Board&#146;s election, shares of Common Stock may be (i)&nbsp;held in book entry form subject to
the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii)&nbsp;evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms and
conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical; provided, however, that each Restricted Stock Award Agreement shall
conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Consideration</B>. A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash, check, bank draft or
money order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate, or (C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible
under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Vesting</B>. Shares of Common Stock awarded under the Restricted Stock Award Agreement may
be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)
Termination of Participant&#146;s Continuous Service</B>. If a Participant&#146;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the
Participant that have not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) Transferability</B>. Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement shall be
transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award
Agreement remains subject to the terms of the Restricted Stock Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Dividends</B>. A Restricted Stock Award Agreement may provide that
any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Restricted Stock Unit Awards</B>. Each Restricted Stock Unit Award Agreement shall be in such form and shall contain such terms and
conditions as the Board shall deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical;
provided, however, that each Restricted Stock Unit Award Agreement shall conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Consideration</B>. At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if
any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit
Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Vesting.</B> At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or
conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)
Payment</B>. A Restricted Stock Unit Award will be settled by the delivery of shares of Common Stock as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) Additional Restrictions</B>. At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems
appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Dividend Equivalents</B>. Dividend equivalents may be credited in respect of shares of Common Stock covered by a
Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the
Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the
underlying Restricted Stock Unit Award Agreement to which they relate, including any vesting restrictions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vi)
Termination of Participant&#146;s Continuous Service</B>. Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the
Participant&#146;s termination of Continuous Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Performance Awards. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Performance Stock Awards</B>. A Performance Stock Award is a Stock Award that may vest or may be exercised contingent
upon the attainment during a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the completion of a specified period of Continuous Service. The length of any Performance Period, the Performance
Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Committee, in its sole discretion. The maximum number of shares
covered by an Award that may be granted to any Participant in a calendar year attributable to Stock Awards described in this Section&nbsp;6(c)(i) (whether the grant, vesting or exercise is contingent upon the attainment during a Performance Period
of the Performance Goals) shall not exceed five hundred thousand (500,000)&nbsp;shares of Common Stock; provided, however that in connection with his or her initial employment, an Employee may be granted Performance Stock Awards for up to an
additional five hundred thousand (500,000)&nbsp;shares of Common Stock which shall not count against such annual limit. The Board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
may provide for or, subject to such terms and conditions as the Board may specify, may permit a Participant to elect for, the payment of any Performance Stock Award to be deferred to a specified
date or event. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Performance Stock Award, as determined
by the Board and contained in the Performance Stock Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Performance Stock Award in such manner as
determined by the Board. Any additional shares covered by the Performance Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Performance Stock Award Agreement to which they
relate, including any vesting contingent upon the attainment during a Performance Period of certain Performance Goals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Board Discretion</B>. The Board retains the discretion to reduce or eliminate the compensation or economic benefit due
upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Section</B><B></B><B>&nbsp;162(m) Compliance</B>. Unless otherwise permitted in compliance with the requirements of
Section&nbsp;162(m) of the Code with respect to an Award intended to qualify as &#147;performance-based compensation&#148; thereunder, the Committee shall establish the Performance Goals applicable to, and the formula for calculating the amount
payable under, the Award no later than the earlier of (a)&nbsp;the date ninety (90)&nbsp;days after the commencement of the applicable Performance Period, or (b)&nbsp;the date on which twenty-five percent (25%)&nbsp;of the Performance Period has
elapsed, and in either event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior to the payment of any compensation under an Award intended to qualify as &#147;performance-based
compensation&#148; under Section&nbsp;162(m) of the Code, the Committee shall certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where such relate solely to the
increase in the value of the Common Stock). Notwithstanding satisfaction of any completion of any Performance Goals, to the extent specified at the time of grant of an Award to &#147;covered employees&#148; within the meaning of Section&nbsp;162(m)
of the Code, the number of shares of Common Stock, Options, or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of such further
considerations as the Committee, in its sole discretion, shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Other Stock Awards</B>. Other forms of Stock Awards
valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof may be granted either alone or in addition to Stock Awards provided for under Section&nbsp;5 and the preceding provisions of
this Section&nbsp;6. Subject to the provisions of the Plan, the Board shall have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common
Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. I<SMALL>NITIAL</SMALL> A<SMALL>ND</SMALL> A<SMALL>NNUAL</SMALL> G<SMALL>RANTS</SMALL> T<SMALL>O</SMALL> E<SMALL>LIGIBLE</SMALL>
D<SMALL>IRECTORS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) General</B>. The Director Grant Program in this Section&nbsp;7 provides that Eligible Directors shall
receive certain Stock Awards at designated intervals over their period of Continuous Service on the Board. For the avoidance of doubt, all Stock Awards granted the Plan, including any Stock Awards granted under this Section&nbsp;7, are subject to
all the terms and conditions of the Plan, including but not limited to the share reserve limitations of Section&nbsp;3 and the cancellation and regrant restrictions set forth in Section&nbsp;2(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Eligibility</B>. Stock Awards shall be granted under this Section&nbsp;7 to all Eligible Directors who meet the criteria specified
below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Director Grants. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Initial Award</B>. At the time a person is first elected or appointed to serve on the Board, provided such person is an
Eligible Director, he or she automatically shall, upon the date of his or her initial election or appointment as an Eligible Director, be granted an Option to purchase a number of shares of Common Stock as determined by the Board in its sole
discretion, on the terms and conditions set forth in Section&nbsp;7(d) (each such Option is an &#147;<B><I>Initial Award</I></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Annual Awards</B>. On the date of each Annual Meeting, commencing with the Annual Meeting in 2012, each person who is
then a Eligible Director and who has served as an Eligible Director on the Board for a period of at least six (6)&nbsp;months shall be granted an Option to purchase a number of shares of Common Stock as determined by the Board, in its sole
discretion on the terms and conditions set forth in Section&nbsp;7(d) (each such Option is an &#147;<B><I>Annual Award</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Director Option Grant Provisions. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Option Type</B>. Each Option automatically granted under this Section&nbsp;7 shall be a Nonstatutory Stock Option. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) Term</B>. No Option shall be exercisable after the expiration of ten (10)&nbsp;years from the date it was granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) Exercise Price</B>. The exercise price of each Option shall be one hundred percent (100%)&nbsp;of the Fair Market
Value of the Common Stock subject to the Option on the date the Option is granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> <B>Vesting</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(1)</B> Initial Awards granted pursuant to this Section&nbsp;7 shall vest monthly with respect to 1/36th of the shares over
the three (3)&nbsp;year period following the date of grant, subject to the Eligible Director&#146;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the third anniversary of the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(2)</B> Annual Awards granted pursuant to this Section&nbsp;7 shall vest monthly with respect to 1/12th of the shares over
the one (1)&nbsp;year period following the date of grant, subject to the Eligible Director&#146;s Continuous Service through the applicable vesting dates, so that the Option will be fully vested on the first anniversary of the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(3)</B> Each Option granted pursuant to this Section shall automatically fully accelerate vesting upon a Corporate
Transaction, subject to the Eligible Director&#146;s Continuous Service through the date of the Corporate Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) Remaining Terms</B>. The remaining terms and conditions of each Option shall be as set forth in an Option Agreement in
the form adopted from time to time by the Board; provided, however, that the terms of such Option Agreement shall be consistent with the terms of the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. C<SMALL>OVENANTS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> C<SMALL>OMPANY</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Availability of Shares</B>. During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of
Common Stock reasonably required to satisfy such Stock Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Securities Law Compliance</B>. The Company shall seek to obtain
from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this
undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any
such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained. A Participant shall not be eligible for the grant of a
Stock Award or the subsequent issuance of Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) No Obligation to Notify or Minimize Taxes</B>. The Company shall have no duty or obligation to any Participant to advise such holder as
to the time or manner of exercising such Stock Award. Furthermore, the Company shall have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock
Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. M<SMALL>ISCELLANEOUS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)
Use of Proceeds from Sales of Common Stock</B>. Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall constitute general funds of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Corporate Action Constituting Grant of Stock Awards</B>. Corporate action constituting a grant by the Company of a Stock Award to any
Participant shall be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or
accepted by, the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Stockholder Rights</B>. No Participant shall be deemed to be the holder of, or to have any of the
rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms, if applicable, and
(ii)&nbsp;the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)
No Employment or Other Service Rights</B>. Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto shall confer upon any Participant any right to continue to
serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or
without cause, (ii)&nbsp;the service of a Consultant pursuant to the terms of such Consultant&#146;s agreement with the Company or an Affiliate, or (iii)&nbsp;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any
applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)
Incentive Stock Option $100,000 Limitation</B>. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder
during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated
as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Investment
Assurances</B>. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and
experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone
or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award
for the Participant&#146;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (A)&nbsp;the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act,
or (B)&nbsp;as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the
Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) Withholding Obligations</B>. Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole
discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares
of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to
be withheld by law (or such lesser amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from
any amounts otherwise payable to the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)
Electronic Delivery</B>. Any reference herein to a &#147;written&#148; agreement or document shall include any agreement or document delivered electronically or posted on the Company&#146;s intranet (or other shared electronic medium controlled by
the Company to which the Participant has access). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) Deferrals</B>. To the extent permitted by applicable law, the Board, in its sole
discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made
by Participants. Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise
providing services to the Company. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#146;s termination
of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) Compliance with Section</B><B></B><B>&nbsp;409A</B>. To the extent that the Board determines that any Award granted hereunder is
subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award shall incorporate the terms and conditions necessary to avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code. To the extent applicable, the Plan
and Award Agreements shall be interpreted in accordance with Section&nbsp;409A of the Code. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are
publicly traded and a Participant holding an Award that constitutes &#147;<B><I>deferred compensation</I></B>&#148; under Section&nbsp;409A of the Code is a &#147;<B><I>specified employee</I></B>&#148; for purposes of Section&nbsp;409A of the Code,
no distribution or payment of any amount shall be made upon a &#147;<B><I>separation from service</I></B>&#148; before a date that is six (6)&nbsp;months following the date of such Participant&#146;s &#147;<B><I>separation from service</I></B>&#148;
(as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) Minimum Vesting</B>. After the Effective Date of the Plan, generally (i)&nbsp;no Full Value Award that vests on the basis of the
Participant&#146;s Continuous Service with the Company shall vest at a rate that is any more rapid than ratably over a three (3)-year period and (ii)&nbsp;no Full Value Award that vests based on the satisfaction of Performance Goals shall provide
for a Performance Period of less than twelve (12)&nbsp;months. Notwithstanding the foregoing, Full Value Awards may be granted by the Committee after the Effective Date that do not meet the foregoing minimum vesting guidelines, provided that such
Awards shall be limited to no more than 5% of the total number of shares reserved for issuance under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. A<SMALL>DJUSTMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGES</SMALL> I<SMALL>N</SMALL>
C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL> C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Capitalization
Adjustments</B>. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a), (ii)&nbsp;the
class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(e), (iii)&nbsp;the class(es) and maximum number of securities that may be awarded to any person pursuant to
Sections 3(f) and 6(c)(i) , and (iv)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) Dissolution or Liquidation</B>. Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or
liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) shall terminate
immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#146;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company
notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject
to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) Corporate Transaction</B>. The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless
otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Stock Awards May Be Assumed. In the event of a Corporate Transaction, any surviving corporation or acquiring
corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but
not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to
Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#146;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose
to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants. The terms of any assumption,
continuation or substitution shall be set by the Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Stock Awards Held by Current Employee and Director
Participants. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such
outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants that are Employees or Directors and whose Continuous Service has not terminated prior to the effective
time of the Corporate Transaction (referred to as the &#147;<B><I>Current Employee and Director Participants</I></B>&#148;), the vesting of such Stock Awards (and, with respect to Options and SARs, the time when such Stock Awards may be exercised)
shall be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board shall determine (or, if the Board shall not determine such a date, to the
date that is fifteen (15)&nbsp;days prior to the effective time of the Corporate Transaction), and such Stock Awards shall terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any
reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Corporate Transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) Stock Awards Held by Persons other than Current Employee and Director
Participants</B>. In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such
outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Employee and Director Participants, such Stock Awards shall terminate if not exercised
(if applicable) prior to the effective time of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised
notwithstanding the Corporate Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) Payment for Stock Awards in Lieu of Exercise</B>. Notwithstanding the foregoing, in the
event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but will receive a
payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of the Stock Award (including, at the
discretion of the Board, any unvested portion of such Stock Award), over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) Change in Control</B>. A Stock Award may be subject to acceleration of vesting and exercisability upon or after a Change in Control as
may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration shall occur.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) Plan Term</B>. The Board may suspend or terminate the Plan at any time. Unless terminated sooner by the Board, the Plan shall
automatically terminate on the day before the tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)&nbsp;anniversary of the earlier of (i)&nbsp;the date the Plan is adopted by the Board, or (ii)&nbsp;the date the Plan is approved by the
stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) No
Impairment of Rights</B>. Suspension or termination of the Plan shall not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>.&nbsp;</B>T<SMALL>HIS</SMALL> P<SMALL>LAN</SMALL>
<SMALL>SHALL</SMALL> <SMALL>BECOME</SMALL> <SMALL>EFFECTIVE</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE<B></B></SMALL><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13. C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B>T<SMALL>HE</SMALL> <SMALL>LAWS</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> S<SMALL>TATE</SMALL> <SMALL>OF</SMALL> C<SMALL>ALIFORNIA</SMALL> <SMALL>SHALL</SMALL> <SMALL>GOVERN</SMALL> <SMALL>ALL</SMALL> <SMALL>QUESTIONS</SMALL> <SMALL>CONCERNING</SMALL> <SMALL>THE</SMALL> <SMALL>CONSTRUCTION</SMALL>,
<SMALL>VALIDITY</SMALL> <SMALL>AND</SMALL> <SMALL>INTERPRETATION</SMALL> <SMALL>OF</SMALL> <SMALL>THIS</SMALL> P<SMALL>LAN</SMALL>, <SMALL>WITHOUT</SMALL> <SMALL>REGARD</SMALL> <SMALL>TO</SMALL> <SMALL>THAT</SMALL>
<SMALL>STATE</SMALL>&#146;<SMALL>S</SMALL> <SMALL>CONFLICT</SMALL> <SMALL>OF</SMALL> <SMALL>LAWS</SMALL> <SMALL>RULES<B></B></SMALL><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14. D<SMALL>EFINITIONS</SMALL>. </B>A<SMALL>S</SMALL> <SMALL>USED</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>,
<SMALL>THE</SMALL> <SMALL>FOLLOWING</SMALL> <SMALL>DEFINITIONS</SMALL> <SMALL>SHALL</SMALL> <SMALL>APPLY</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> <SMALL>CAPITALIZED</SMALL> <SMALL>TERMS</SMALL> <SMALL>INDICATED</SMALL>
<SMALL>BELOW</SMALL>:<B></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148;
or &#147;subsidiary&#148; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board shall have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is
determined within the foregoing definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> &#147;<B><I>Annual Meeting</I></B>&#148; means the first meeting of the
Company&#146;s stockholders held each calendar year at which Directors of the Company are selected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>
&#147;<B><I>Award</I></B>&#148; means a Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>&#147;<B><I>Award Agreement</I></B>&#148; means a written agreement
between the Company and a Participant evidencing the terms and conditions of an Award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to,
the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend,
dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used
in Statement of Financial Accounting Standards No.&nbsp;123 (revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a Capitalization Adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> &#147;<B><I>Cause</I></B>&#148; shall mean, with respect to a Participant, the occurrence of any of the following events:
(i)&nbsp;such Participant&#146;s commission of any crime involving fraud, dishonesty or moral turpitude; (ii)&nbsp;such Participant&#146;s attempted commission of or participation in a fraud or act of dishonesty against the Company that results in
(or might have reasonably resulted in) material harm to the business of the Company; (iii)&nbsp;such Participant&#146;s intentional, material violation of any contract or agreement between Participant and the Company or any statutory duty
Participant owes to the Company; or (iv)&nbsp;such Participant&#146;s conduct that constitutes gross insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business
of the Company; provided, however, that the action or conduct described in clauses (iii)&nbsp;and (iv)&nbsp;above will constitute &#147;<B><I>Cause</I></B>&#148; only if such action or conduct continues after the Company has provided such
Participant with written notice thereof and not less than five business days to cure the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> &#147;<B><I>Change in
Control</I></B>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more
than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be
deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person
that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of
Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the
Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the
Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the
designated percentage threshold, then a Change in Control shall be deemed to occur; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>there is consummated a
merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do
not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or
(B)&nbsp;more than fifty percent (50%)&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of
the outstanding voting securities of the Company immediately prior to such transaction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>the stockholders of the Company approve or the Board approves a
plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent
(50%)&nbsp;of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such
sale, lease, license or other disposition; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> individuals who, on the date the Plan is adopted by the Board,
are members of the Board (the &#147;<B><I>Incumbent Board</I></B>&#148;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any
new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing or any other provision of this Plan, the term Change in Control shall not include a sale of assets, merger or
other transaction effected exclusively for the purpose of changing the domicile of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> &#147;<B><I>Code</I></B>&#148;
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>
&#147;<B><I>Committee</I></B>&#148; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section&nbsp;2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> &#147;<B><I>Company</I></B>&#148; means Neurocrine Biosciences, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> &#147;<B><I>Consultant</I></B>&#148; means any person, including an advisor, who is (i)&nbsp;engaged by the Company or an Affiliate
to render consulting or advisory services and is compensated for such services, or (ii)&nbsp;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a
fee for such service, shall not cause a Director to be considered a &#147;<B><I>Consultant</I></B>&#148; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form <FONT
STYLE="white-space:nowrap">S-8</FONT> Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#146;s securities to such person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an Affiliate, whether as
an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, shall not terminate a Participant&#146;s Continuous Service; provided, however, if the Entity
for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service shall be considered to have terminated on the date such Entity ceases to
qualify as an Affiliate. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of
(i)&nbsp;any leave of absence approved by the Board or Chief Executive Officer, including sick leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate, or their successors. Notwithstanding the
foregoing, a leave of absence shall be treated as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#146;s leave of absence policy, in the written terms of any leave of absence
agreement or policy applicable to the Participant, or as otherwise required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> &#147;<B><I>Corporate
Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> a sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the
consolidated assets of the Company and its Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>a sale or other disposition of at least ninety
percent (90%)&nbsp;of the outstanding securities of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>a merger, consolidation or similar
transaction following which the Company is not the surviving corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>a merger, consolidation or
similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>
&#147;<B><I>Covered Employee</I></B>&#148; shall have the meaning provided in Section&nbsp;162(m)(3) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>
&#147;<B><I>Director</I></B>&#148; means a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> &#147;<B><I>Director Grant Program</I></B>&#148; means the
grant program in effect under Section&nbsp;7 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a
Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to
last for a continuous period of not less than twelve (12)&nbsp;months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under
the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan document, which is the date
of the annual meeting of stockholders of the Company held in 2011 provided this Plan is approved by the Company&#146;s stockholders at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> &#147;<B><I>Eligible Director</I></B>&#148; means a Director who is not an Employee and is eligible to participate in the Director
Grant Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service
solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an &#147;<B><I>Employee</I></B>&#148; for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> &#147;<B><I>Entity</I></B>&#148; means a corporation, partnership, limited liability company or other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> &#147;<B><I>Exchange Act Person</I></B>&#148; means any natural person, Entity or &#147;group&#148;
(within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;<B><I>Exchange Act Person</I></B>&#148; shall not include (i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the
Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a
registered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the
Company; or (v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company
representing more than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market
Value of a share of Common Stock shall be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a
source the Board deems reliable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>Unless otherwise provided by the Board, if there is no closing sales price
for the Common Stock on the date of determination, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B> In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in
good faith and in a manner that complies with Sections 409A and 422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B> &#147;<B><I>Full Value Award</I></B>&#148;
generally means any Award granted under the Plan, but does not include any Option or a SAR granted pursuant to Section&nbsp;5 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B> &#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 of the Plan that is intended
to be, and qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc)</B>
&#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or
indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item&nbsp;404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation <FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be
required under Item&nbsp;404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation
<FONT STYLE="white-space:nowrap">S-K;</FONT> or (ii)&nbsp;is otherwise considered a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means any option granted pursuant to Section&nbsp;5 of the Plan that does not
qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company
within the meaning of Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option
or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg)</B> &#147;<B><I>Option
Agreement</I></B>&#148; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh)</B> &#147;<B><I>Optionholder</I></B>&#148; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such
other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in
part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(d). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj)</B> &#147;<B><I>Other Stock Award Agreement</I></B>&#148; means a written agreement
between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk)</B> &#147;<B><I>Outside Director</I></B>&#148; means a Director who either (i)&nbsp;is not a current employee of the Company or an
&#147;affiliated corporation&#148; (within the meaning of Treasury Regulations promulgated under Section&nbsp;162(m) of the Code), is not a former employee of the Company or an &#147;affiliated corporation&#148; who receives compensation for prior
services (other than benefits under a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan) during the taxable year, has not been an officer of the Company or an &#147;affiliated corporation,&#148; and does not receive remuneration
from the Company or an &#147;affiliated corporation,&#148; either directly or indirectly, in any capacity other than as a Director, or (ii)&nbsp;is otherwise considered an &#147;outside director&#148; for purposes of Section&nbsp;162(m) of the Code.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll)</B> &#147;<B><I>Own,</I></B>&#148; &#147;<B><I>Owned,</I></B>&#148; &#147;<B><I>Owner,</I></B>&#148;
&#147;<B><I>Ownership</I></B>&#148; A person or Entity shall be deemed to &#147;<B><I>Own,</I></B>&#148; to have &#147;<B><I>Owned,</I></B>&#148; to be the &#147;<B><I>Owner</I></B>&#148; of, or to have acquired &#147;<B><I>Ownership</I></B>&#148;
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm)</B> &#147;<B><I>Participant</I></B>&#148; means a person to whom an Award is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Stock Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn)</B> &#147;<B><I>Performance Criteria</I></B>&#148; means the
one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination
of, the following as determined by the Board: (i)&nbsp;earnings (including earnings per share and net earnings, in either case before or after any or all of: interest, taxes, depreciation and amortization, legal settlements or other income
(expense), or stock-based compensation, other <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses and changes in deferred revenue); (ii)&nbsp;total stockholder return; (iii)&nbsp;return on equity or average stockholder&#146;s equity;
(iv)&nbsp;return on assets, investment, or capital employed; (v)&nbsp;stock price; (vi)&nbsp;margin (including gross margin); (vii)&nbsp;income (before or after taxes); (viii)&nbsp;operating income; (ix)&nbsp;operating income after taxes; <FONT
STYLE="white-space:nowrap">(x)&nbsp;pre-tax</FONT> profit; (xi)&nbsp;operating cash flow; (xii)&nbsp;sales or revenue targets; (xiii)&nbsp;increases in revenue or product revenue; (xiv)&nbsp;expenses and cost reduction goals; (xv)&nbsp;improvement
in or attainment of working capital levels; (xvi)&nbsp;economic value added (or an equivalent metric); (xvii)&nbsp;market share; (xviii)&nbsp;cash flow; (xix)&nbsp;cash flow per share; (xx)&nbsp;cash burn; (xxi)&nbsp;share price performance;
(xxii)&nbsp;debt reduction; (xxiii)&nbsp;implementation or completion of projects or processes (including, without limitation, discovery of a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> drug candidate, recommendation of a drug candidate to
enter a clinical trial, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals,
presentation of studies and launch of commercial plans, compliance programs or education campaigns); (xxiv)&nbsp;customer satisfaction; (xxv)&nbsp;stockholders&#146; equity; (xxvi)&nbsp;capital expenditures; (xxvii)&nbsp;debt levels;
(xxviii)&nbsp;financings; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income; (xxxii)&nbsp;billings; (xxxiii)&nbsp;employee hiring; (xxxiv)&nbsp;funds from
operations; (xxxv)&nbsp;budget management; (xxxvi)&nbsp;strategic partnerships or transactions (including acquisitions, joint ventures or licensing transactions); (xxxvii)&nbsp;engagement of thought leaders and patient advocacy groups;
(xxxviii)&nbsp;enhancement of intellectual property portfolio, filing of patent applications and granting of patents; (xxxix)&nbsp;litigation preparation and management; and (xl)&nbsp;to the extent that an Award is not intended to comply with
Section&nbsp;162(m) of the Code, other measures of performance selected by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)</B> &#147;<B><I>Performance
Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more
business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board
(i)&nbsp;in the Award Agreement at the time the Award is granted or (ii)&nbsp;in such other document setting forth the Performance Goals at the time the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Performance Goals are established, the Board shall appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&nbsp;to
exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated Performance Goals; (3)&nbsp;to exclude the effects of changes
to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as
determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels
during the balance of a Performance Period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(9)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under the Company&#146;s bonus plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed
under generally accepted accounting principles; (11)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles; and (12)&nbsp;to exclude the effects of the
timing of acceptance for review and/or approval of submissions to the U.S. Food and Drug Administration or any other regulatory body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp)</B> &#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or
more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq)</B> &#147;<B><I>Performance Stock Award</I></B>&#148; means a Stock Award granted under the terms and conditions of
Section&nbsp;6(c)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr)</B> &#147;<B><I>Plan</I></B>&#148; means this Neurocrine Biosciences, Inc. 2011 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock which is granted pursuant to the terms
and conditions of Section&nbsp;6(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt)</B> &#147;<B><I>Restricted Stock Award Agreement</I></B>&#148; means a written agreement
between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148; means a right to receive shares of Common Stock which is granted pursuant to
the terms and conditions of Section&nbsp;6(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(vv)</B> &#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148; means a
written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement shall be subject to the terms and conditions
of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ww)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(xx)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(yy)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148; means a right to receive the appreciation on
Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(zz)</B> &#147;<B><I>Stock Appreciation Right
Agreement</I></B>&#148; or &#147;<B><I>SAR Agreement</I></B>&#148;) means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aaa)</B> &#147;<B><I>Stock Award</I></B>&#148; means any right to receive Common Stock granted under the Plan, including an Incentive
Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a SAR, a Performance Stock Award or any Other Stock Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bbb)</B> &#147;<B><I>Stock Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the
terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ccc)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than fifty
percent (50%)&nbsp;of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall
have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct
or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ddd)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or is deemed to Own pursuant to Section&nbsp;424(d) of
the Code) stock possessing more than ten percent (10%)&nbsp;of the total combined voting power of all classes of stock of the Company or any Affiliate. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Appendix B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>EUROCRINE</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
F<SMALL>EBRUARY</SMALL>&nbsp;6, 2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The
Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to
Eligible Employees under an Employee Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company, by means of the Plan, seeks to
retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>DMINISTRATION</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board will
administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board will have the power, subject to, and within the limitations of, the express provisions of the
Plan: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;To determine when and how Purchase Rights will be granted and the provisions of each Offering
(which need not be identical). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To designate from time to time which Related Corporations will be
eligible to participate in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To construe and interpret the Plan and Purchase Rights, and to
establish, amend and revoke rules and regulations for the administration of the Plan. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or
expedient to make the Plan fully effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;To settle all controversies regarding the Plan and
Purchase Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;To amend the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vi)</B>&nbsp;&nbsp;&nbsp;&nbsp;To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(vii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote
the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(viii)</B>&nbsp;&nbsp;&nbsp;&nbsp;To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or
appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If
administration is delegated to a Committee, the Committee will have, in connection with the administration of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee
is authorized to exercise (and references to the Board in this Plan and in any applicable Offering Document will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the
Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or
not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;All determinations, interpretations and constructions made by the Board in good faith will not be subject to
review by any person and will be final, binding and conclusive on all persons. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;11(a) relating to Capitalization Adjustments, the aggregate number of shares of
Common Stock that may be issued under the Plan will not exceed three hundred thousand (300,000) shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If any Purchase Right terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The stock
issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under
an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate and will comply
with the requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering will be incorporated by reference into the Plan and treated as
part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during
which the Offering will be effective, which period will not exceed twenty-seven (27)&nbsp;months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise
indicates in forms delivered to the Company: (i)&nbsp;each form will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase
Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be
exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board will have the discretion to structure an Offering so that if the Fair Market Value
of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that Offering will
terminate immediately as of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>LIGIBILITY</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Purchase Rights may be
granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b), to Employees of a Related Corporation. Except as provided in Section&nbsp;5(b), an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for
such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two (2)&nbsp;years. In addition, the Board may provide that no Employee will
be eligible to be granted Purchase Rights unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the Related Corporation is more than twenty (20)&nbsp;hours per week and more than five (5)&nbsp;months per
calendar year or such other criteria as the Board may determine consistent with Section&nbsp;423 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board may provide that each person who, during the course of an Offering, first becomes an Eligible
Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under that Offering, which Purchase Right will thereafter
be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;the date on which such Purchase Right is granted will be the &#147;Offering Date&#148; of such Purchase
Right for all purposes, including determination of the exercise price of such Purchase Right; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;the Board may provide that if such person first becomes an Eligible Employee within a specified period of
time before the end of the Offering, he or she will not receive any Purchase Right under that Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase
Rights are granted, such Employee owns stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section&nbsp;5(c), the rules of
Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;As specified by Section&nbsp;423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only
if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s rights to purchase stock of the Company or any Related
Corporation to accrue at a rate which exceeds twenty-five thousand dollars ($25,000) of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective
Offering Dates) for each calendar year in which such rights are outstanding at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;Officers of
the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees who are
highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a
Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding fifteen percent (15%) of such Employee&#146;s
earnings (as defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later
than the end of the Offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board will establish one (1)&nbsp;or more Purchase
Dates during an Offering on which Purchase Rights granted pursuant to that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;In connection with each Offering made under the Plan, the Board may specify (i)&nbsp;a maximum number of
shares of Common Stock that may be purchased by any Participant pursuant to such Offering, (ii)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant on any Purchase Date pursuant to such Offering, (iii)&nbsp;a
maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering, and/or (iv)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase
Date pursuant to such Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under such Offering would exceed any such maximum aggregate number, then, in the absence of any Board action
otherwise, a pro rata (based on each Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock available will be made in as nearly a uniform manner as will be practicable and equitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the
lesser of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;an amount equal to eighty-five percent (85%) of the Fair Market Value of the shares of
Common Stock on the Offering Date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;an amount equal to eighty-five percent (85%) of the Fair Market
Value of the shares of Common Stock on the applicable Purchase Date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by
completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board.
Each Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with
a third party. To the extent provided in the Offering, a Participant may begin such Contributions on or after the Offering Date. To the extent provided in the Offering, a Participant may thereafter decrease (including to zero) or increase his or her
Contributions. To the extent specifically provided in the Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through payment by cash or check prior to a Purchase Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;During an Offering, a Participant may cease making Contributions and withdraw from the Offering by
delivering to the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate
and the Company will distribute to such Participant all of his or her accumulated but unused Contributions without interest. A Participant&#146;s withdrawal from an Offering will have no effect upon his or her eligibility to participate in any other
Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the
Participant either (i)&nbsp;is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by law) or (ii)&nbsp;is otherwise no longer eligible to participate. The Company will distribute to
such individual all of his or her accumulated but unused Contributions without interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;Purchase
Rights will not be transferable by a Participant except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. During a Participant&#146;s lifetime, Purchase
Rights will be exercisable only by such Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise specified in an Offering, the Company
will have no obligation to pay interest on Contributions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase of
shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued upon the exercise of Purchase Rights
unless specifically provided for in the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the Offering, if any
amount of accumulated Contributions remains in a Participant&#146;s account after the purchase of shares of Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of
an Offering, then such remaining amount will be held in such Participant&#146;s account for the purchase of shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in
such next Offering, in which case such amount will be distributed to such Participant after the final Purchase Date without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase of shares of Common
Stock is at least equal to the amount required to purchase one (1)&nbsp;whole share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be distributed in full to such Participant after the final Purchase Date
of such Offering without interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;No Purchase Rights may be exercised to any extent unless the shares
of Common Stock to be issued upon such exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities
and other laws applicable to the Plan. If, on a Purchase Date, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed
until the shares of Common Stock are subject to such an effective registration statement and the Plan is in such compliance, except that the Purchase Date will not be delayed more than twelve (12)&nbsp;months and the Purchase Date will in no event
be more than twenty-seven (27)&nbsp;months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights
will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan
such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary
for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell
Common Stock upon exercise of such Purchase Rights. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who
will receive any shares of Common Stock and/or Contributions from the Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated
to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any
shares of Common Stock and/or Contributions to the executor or administrator of the estate of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or
Contributions to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL> T<SMALL>RANSACTIONS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust:
(i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a); (ii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights; and
(iii)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Corporate Transaction, (i)&nbsp;any surviving or acquiring corporation (or its parent
company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii)&nbsp;if
any surviving or acquiring corporation (or its parent company)<B> </B>does not assume or continue outstanding Purchase Rights or does not substitute similar rights for outstanding Purchase Rights, then the Participants&#146; accumulated
Contributions will be used to purchase shares of Common Stock within ten (10)&nbsp;business days prior to the Corporate Transaction under such Purchase Rights, and such Purchase Rights will terminate immediately after such purchase. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>A<SMALL>MENDMENT</SMALL>, S<SMALL>USPENSION</SMALL> <SMALL>OR</SMALL> T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board may amend the Plan at any time in any respect the Board deems necessary or advisable. However,
except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan
while the Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;Any benefits, privileges, entitlements and
obligations under any outstanding Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to
whom such Purchase Rights were granted, (ii)&nbsp;as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other
interpretive guidance issued thereunder relating to Employee Stock Purchase Plans) including, without limitation, any such regulations or other guidance that may be issued or amended after the Adoption Date, or (iii)&nbsp;as necessary to obtain or
maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the Plan or any Offering Document to the contrary, the
Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant in order to adjust for mistakes
in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common
Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities regarding the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of any Offering to enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code; and (v)&nbsp;establish other limitations or procedures as the Board
determines in its sole discretion advisable that are consistent with the Plan. The actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the
initial terms of each Offering and the Purchase Rights granted under each Offering. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Plan will become effective on the Effective Date. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is
adopted (or if required under Section&nbsp;12(a), materially amended) by the Board. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;A Participant will not be deemed to be the holder of, or to have any of the rights of a
holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering will
in any way alter the at will nature of a Participant&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part of
the Company or a Related Corporation to continue the employment of a Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;The provisions of the
Plan will be governed by the laws of the State of Delaware without resort to that state&#146;s conflicts of laws rules. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EFINITIONS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in the Plan, the following definitions will apply
to the capitalized terms indicated below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Adoption Date</I></B>&#148; means
February&nbsp;6, 2018, which is the date the Plan was adopted by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that
occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization,
reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other
similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any
convertible securities of the Company will not be treated as a Capitalization Adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable
regulations and guidance thereunder<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Committee</I></B>&#148; means a committee of
one (1)&nbsp;or more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Company</I></B>&#148; means Neurocrine Biosciences, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Contributions</I></B>&#148; means the payroll deductions and other additional payments
specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically provided for in the Offering, and then only if the
Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a
series of related transactions, of any one or more of the following events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;a sale<B> </B>or other
disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;a merger, consolidation or similar transaction following which the Company is not the surviving
corporation; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iv)</B>&nbsp;&nbsp;&nbsp;&nbsp;a merger, consolidation or similar transaction following which the Company is the
surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Director</I></B>&#148; means a member
of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan document,
which is the date of the annual meeting of stockholders of the Company held in 2018, provided that this Plan is approved by the Company&#146;s stockholders at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Eligible Employee</I></B>&#148; means an Employee who meets the requirements set forth in the
document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Employee</I></B>&#148; means any person, including an Officer or Director, who is
&#147;employed&#148; for purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an
&#147;Employee&#148; for purposes of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;
means a plan that grants Purchase Rights intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Fair Market Value</I></B>&#148; means, as of
any date, the value of the Common Stock determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is listed on any
established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the
exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date
of determination, then the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(iii)</B>&nbsp;&nbsp;&nbsp;&nbsp;In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board
in good faith in compliance with applicable laws and in a manner that complies with Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Offering</I></B>&#148; means the grant to Eligible Employees of Purchase Rights, with the
exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for
that Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an
Offering to commence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Officer</I></B>&#148; means<B> </B>a person who is an officer of the
Company or a Related Corporation within the meaning of Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Participant</I></B>&#148; means an Eligible Employee who holds an outstanding Purchase Right.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Plan</I></B>&#148; means this Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase Date</I></B>&#148; means one or more dates during an Offering selected by
the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally
beginning on the Offering Date or on the first Trading Day following a Purchase Date and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Purchase Right</I></B>&#148; means an option to purchase shares of Common Stock granted pursuant
to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Related Corporation</I></B>&#148; means any &#147;parent corporation&#148; or
&#147;subsidiary corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which
more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such
corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the
Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%). For purposes of the foregoing clause (i), the Company will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be deemed to &#147;Own&#148; or have &#147;Owned&#148; such securities if the Company, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or
shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb)</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Trading Day</I></B>&#148; means any day on which the exchange(s) or market(s) on which shares
of Common Stock are listed (including, but not limited to, the NYSE, the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto) is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:80pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Important Notice
Regarding the Availability of Proxy Materials for the Annual Meeting:</B> The Combined Document is/are available at www.proxyvote.com. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp; </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.50pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>This Proxy is solicited on behalf of the Board of
Directors</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 ANNUAL MEETING OF STOCKHOLDERS</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD May&nbsp;24, 2018</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned stockholder of NEUROCRINE BIOSCIENCES, INC., a Delaware corporation, hereby acknowledges receipt of the Notice of Annual Meeting of
Stockholders and Proxy Statement, each dated April&nbsp;3, 2018, and hereby appoints Kevin C. Gorman and Matthew C. Abernethy, and each of them, proxies and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> with full power to each of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the 2018 Annual Meeting of
Stockholders of NEUROCRINE BIOSCIENCES, INC. to be held on May&nbsp;24, 2018 at 10:30 a.m. local time, at the Company&#146;s corporate headquarters located at 12780 El Camino Real, San Diego, California 92130, and at any adjournment or adjournments
thereof, and to vote all&nbsp;shares of Common Stock which the undersigned would be entitled to vote, if then and there personally present, on the matters set forth on the reverse side.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION IS INDICATED, WILL BE
VOTED FOR THE ELECTION OF THE TWO NOMINEES FOR DIRECTOR NAMED IN THE PROXY STATEMENT, FOR THE ADVISORY VOTE ON THE COMPENSATION PAID TO THE COMPANY&#146;S NAMED EXECUTIVE OFFICERS, FOR THE APPROVAL OF THE AMENDMENT TO THE COMPANY&#146;S 2011 EQUITY
INCENTIVE PLAN, FOR THE APPROVAL OF THE COMPANY&#146;S 2018 EMPLOYEE STOCK PURCHASE PLAN, FOR RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG LLP AS THE COMPANY&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AND TO TRANSACT SUCH
OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE ANNUAL MEETING OR ANY CONTINUATION, ADJOURNMENT OR POSTPONEMENT THEREOF.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(This Proxy should be marked, dated and signed by the stockholder(s) exactly as his or her name appears hereon, and returned promptly in the enclosed envelope.
Persons signing in a fiduciary capacity should so indicate. If&nbsp;shares are held by joint tenants or as community property, both should sign.)</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Continued and to be signed on reverse side</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> </div>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g474270g50g78.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neurocrine Biosciences, Inc.</I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>12780 EL CAMINO REAL</I></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>SAN DIEGO, CA
92130</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY INTERNET - www.proxyvote.com</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the meeting
date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Delivery of Future PROXY MATERIALS</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you would like to reduce the costs incurred by Neurocrine Biosciences, Inc. in mailing stockholder communications, you can consent to receiving all future
proxy statements, proxy cards and annual reports electronically via <FONT STYLE="white-space:nowrap">e-mail</FONT> or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when
prompted, indicate that you agree to receive or access stockholder communications electronically in future years.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY PHONE -
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-690-6903</FONT></FONT></FONT></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the meeting date. Have your proxy card in
hand when you call and then follow the instructions.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTE BY MAIL</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark, sign and date your proxy card and return it in the postage-paid envelope we have
provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">KEEP&nbsp;THIS&nbsp;PORTION&nbsp;FOR&nbsp;YOUR&nbsp;RECORDS</TD></TR>
</TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;-&nbsp;
-&nbsp;- </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right">DETACH&nbsp;AND&nbsp;RETURN&nbsp;THIS&nbsp;PORTION&nbsp;ONLY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1.00pt;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="5" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Withhold</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For&nbsp;All</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Except</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">To withhold authority to vote for any<BR>individual nominee(s), mark &#147;For All<BR>Except&#148; and write the number(s)&nbsp;of&nbsp;the<BR>nominee(s) on the line below.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman"><B>The Board of Directors recommends that you vote FOR ALL of the following Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>1.&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Election of Directors</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Nominees</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13">(01) William J. Rastetter, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;(02) George J. Morrow</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; font-size:8pt; font-family:Times New Roman"><B>&nbsp;The Board of Directors recommends you vote FOR proposals 2, 3, 4 and 5:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>For</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Against</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:8pt"><B>Abstain</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>2.</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13"><FONT STYLE="font-size:8pt">Advisory vote to approve the compensation paid to the Company&#146;s named executive officers.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:8pt"><B>3.</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="13"><FONT STYLE="font-size:8pt">To approve an amendment to the Company&#146;s 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to
19,000,000.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:8pt"><B>4.&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"><FONT STYLE="font-size:8pt">To approve the Company&#146;s 2018 Employee Stock Purchase Plan.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="14"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:8pt"><B>5.&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="13"><FONT STYLE="font-size:8pt">To ratify the appointment of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman"><B>NOTE: </B>Company to transact such other business as may properly come before the Annual Meeting or
any continuation, adjournment or postponement thereof.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="15"></TD>
<TD HEIGHT="8" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.70em; font-size:8pt; font-family:Times New Roman">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator,
or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership,&nbsp;please sign in full corporate or partnership name, by authorized officer.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="7" VALIGN="bottom"></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD></TR>

<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:8pt"><B>&nbsp;&nbsp;&nbsp;Signature [PLEASE SIGN&nbsp;WITHIN&nbsp;BOX]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;Signature (Joint
Owners)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g474270g08k92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474270g08k92.jpg
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M 0$              04' @8)" 3_Q !!$0 ! @4"! (%!PD)       ! @,
M! 41(08Q!Q)!40AA$R)Q@:$4%R,R4I'P&2158I26L='A%30U4U>RTM/5_]H
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MT#UJ,ZBK"8SR(EK%?IR$,35 "8G/H@U,#TB&BI D%)C%-622"'/DFVY)(O\
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-\0@\0@\0@\0@\0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g474270g31f09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474270g31f09.jpg
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M3:]ALI.Y=3IDJNDB/P'9""K(5#$DO$ULRNJ*MD:2%R<.&TCF+F'Y>!B4D)S
M0F)N7]GYK,?#,_-)/X9M+(_S"0]'Q9OL-(0TS\2\[[3:$H1Z4IQC&]#BQ@D(
M848 C&1C2E&$;"%:-J-&A"-:CGHQJ(UB.54:U$1O")G"CVMI*A1*V393Y%=
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MK<;>B@96P14M:9&,*CA(KV^C$C_BVM?\PUG[1GC]*(__  C9?^7K3R\N..?
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M^Z)78KS]*E-**2TXX<?[:DK1&1S11GDMMU]L<92B46NQ[;3ZP%'V!U=((U7
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MMB;)+Z3_ $0'/J;>RM;+;6:C:H:FAV,5\P9A%UW73PH5?X09I25D:0B%CPH
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M=:=0IMQ"LI6G*<YQSY<UKVN8]K7L<BM<UR(YKFJG"M<U>45%3R5%3A4\ESU
M<T8PI$8Q8\@!&& <!'B,$HW(\91%&K7C(-Z(YCV.1S7(CFJBHBYQB^+7UY#Z
M_=M9,BKTW%4UKM^';O5/="(P]!DV%*L,[!BXP9(0C<$J/FGF9'Z>:=/'! F
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M6G[;C]F]T[_IM:?[X[^_RAQ]++[\;!^K:O\ 8L?1.A_%#_K*T_;<?LWNG?\
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MR0*( 8X_U]W"_!>>$]R_HRF6KO;'P6CM1=BZWUK[%;-U3N/5^J]G04U1R>N
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M61@35(-/,2^*T:-[DY>GFBKQF!^5OU!UC<M>^3S159Y1MEZ?]-K?6MK8>(4
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MI)(U\"MV^755K6B8QPTBU]>28CB-:CC<G.G#GJY6JU6(O"<)KWRQM#U;17=
MUJ(AX^R;IT2J-]VXI9LF0R42_P!BV$5&048Q'B@M2JKV\BCM&PK7,.YJJ_O=
MHISN^0OQQC)YO 1$HQ.Z][$2+0;FQH[6U:>JJW 3'#F*F78S!KFZ+(H'4 ,P
MJ2^C62A""FC#%.#NACOL!'.#1XZORM?)L5)!1 .VF-3RIKU\ WM :*3,9'#_
M  GP_9_"-.CR> (53(X2D<-HW,<Z871.KZH1>D6PWJ/L0]&[;J#"I.U+&"E7
M.ZC5&OOL2HZH25\YNF0==LHSDL70DK_#EI&9*=):0+.I+G+LV[-*)GO3K"N;
M4M>K)RMW,61JMHJU/(?!^E)N>(E+A?\ 6NMH*4SJ^'M!FVPZ5+6+:4)F%O15
M%169<")L!(QZ5*JS-I97C]_=]W/ISE9G^]76R$JLE:AKC,6!L&O2UI%AX2B7
MIR8EH"-BJ]+!6$1@ZN C"4RS-V^I"5'8\T7%ZWLIUFAAXFVDY*\T,*BIZY>L
MYV2J*:YKJ<UU$36W2]M6R6I^O(NG.PH+$^;7X2T6*P32;%;)6O5U-0B(FGS3
MV;.))'Q\R[\M&K/SQZ8C4D,I^_[_ *<QD/W\Z]J@<29Q5\C9T:[":OGJ3G7=
MJF;#7-J*MX%)F]8F259 G*1,7JJRQ99\Y7ZC;[(6Y58*PW*"Q-5>'*E4LKPO
M]_YOC]GY\NH#NIUW,BXB1<N,DR_-05-F@8L*EWBR&'/WH;7I$)7(!ZJ5R=CK
MC;$YVMKQF1K5,-L$S&*ML(Z<&P,<P^ICC[OT_P".9(U=V U'NDF2&UA;?JU,
M3&0$N4>) V8.$<"LT+&6&)S'6"5A0(.8*^3S427)QT1('2,#\R"'GA8THAMA
M3*<<9F3C&.,8XQCC&.,8XQCC&.,8XQFMO<*H.7GJ]O.NLM9?)<UW/2X;"<>I
M;Y]88Q9P&&\>6?-UXR'8;:Q]OWBD_=/YXVO1IR5VWZ[*<O:Q+2, CN>$:.6[
MV0CE7_=:P[E=]B+FM[A$6=J][&:G<Y:Z05C?]Y\9OM+&I]JO"U$^U4SCQY.7
M(=XXQCC&=D/5C93.W>O.I+ZDA))DK3(H.;<PKU9Q9(%O,!9$JQ_J3_SR,/4A
M*_Q9:4VK.585A68*;C4NI-GNZWM[!AGF?'3_ /*25]IB?8O\&,)%X_E(J>7'
M&3)U:S;;Z]43T=W/+"$PZ\\_PD">!)1??_WXB<<^?'"^_G,VB0T. =(R8,5&
MA24PIA<M(" BCG2BQF\M#+D2V6D/FJ':SEMA1+CN6F\Y0WE*<^7-:S/YY"1,
M5'LMC 1D>$.RZ2^R.(&,,RT\8MU9;S;3+:$(=*6\\LEQ*<+?6ZZIW*LN*SEC
M+(NFI=?[!D]=RUMKHDL3JVV&76G-NY6V$).G:WV'J9]9\>TI <R!]#;3NT4U
M%2K)<<R]*HD6AD'A!D,,<\<_;Y+^E%_M1,OAV*BWBP#WHT!TZ*0^W&&NACN%
MQS93:624 $J;R\&@AE"6GTCK;P\VE*',*3C&,,9^$1,46*Z"7&1Y03PK@#P9
M 8SPKH+WE[H;H[C:FG!7?+'N#J1EE?ECU(SY8XQGSN5VONY&R[!0[N0P%10>
M7(P)>1(M>6<KC1LJ8S[ "\C#Y4&UZ1U989\V\^TCTL9[W(>(=:-'=BXYQB20
M0W(LN C+:/;+RK)2#6U-904@G*U9(2^EQ+V5*RYA7GGS8SW( !0UAE 0B&4C
ML"):0,REI(@WJ^&%PWA&$X'']2O89QCVVO4KVTI\\\8SS>%%(\_B!AW_ %,N
M#J]YEMWU#NY0IUC/K2KS9=4VVIQK/X%Y;1E2<Y2GR8SP6 "XO#JPA%NX=P_A
MQ8S*EX>PL9S#V%Y1E7NX<#$<PYY^O"Q1E>?J8:REC+6OMRK>K:'>-C61;<?6
MJ16;%=[(2TAM"DQM>BBIB4(\O-M+I*A G,(]:O6\[Z$>K.<XY;S)0H,23,.[
MM!$CFDF=\!@&XCU3XKVM7A/>OEF;UK7[+;-BH=7IQ>/;;'<5M'6B\^"3K68&
M#%:Y4151BF.SO=PO:SER^29P4=D=T?K$[WVENQ$<5$";%MTA/1,4<IA1\; ?
MNPJX">L5;@RSQ($..8-6PXMI1+;N6U*1G&>2NZ>O"?2M9EAAF@MGT\*P6/)8
M)DA'S0LDN(9 O(SN+XB$;R]7H-S&D1CT<QL2NN-',U7JYU!U&=>P-C/J&U7.
MK.M*HTP]65:.<> 0->^<&.=(\8X3!5$"P*G89\=Q0O88FJ%RNYM5E*S'"U2:
ML*)XQX9U^+2RK OMLJ7AIOW5MM++5Y>_E!3P0R0V"7LE?NE^WN[!][7KW-;V
MIZ*OK]_P3W<_'.4*O'N5?NSW_6<I_3N\_P#HJ?\ ^KY3P_\ [Q_SO],<K\%_
MJ_QR?CP8I'8&J0-I;\'ZF]I-J,7]L+7<"_KN*Z^(A8R/JY2)::=>E+UV,I4L
M4:?*&"CN!#5O$>$W$H>1,R!!KX<5&OJ#J<8V_P W8#[33QRR:&KK1UTT5DPL
M(,4TL[E:>'#GB.R20WC)RD=XU[FJQZ=I'38T7J_*?\GS5.D</1+=8VO]0-NW
M2?L<&RK9 ;^?>P*BMBL6MF$K25Y*B% =$<])5@R6TC2-6,YKQ+.M^N)L_P#[
MO+O#_P"QU(__ *TYK?S!#_*K6_YU[_D667T@G?DGLG_0?\\S6Z?DX.TV==LL
M'AM^(;*2#=D1<H@$C8ND/IVK6_%KKMW?LU/K+?=Y$#5)@ZU52%F328*/!2^2
MF6QEM+5GM#<T^8(?Y5:W_.O?\BROTAG?DGLGZ*'_ #S[?WX3+/Q4];8"3'H\
M,7Q#F1OIYREO?#[6U*,290/@ZN %KDXX?O8V<7KV&&I=:3!TQ\A<!$*"/<"!
M:79;4J<?,$/\JM;_ )U[_D6/I#._)+8_T4/^>?UYD4FU1BZC!4F,\-3OQ5H2
MI7>;V+2U4VV=>JE+4BW63ZC3.GTZ:@.Z0$I6P)0>X6H RN110]8=BK#+1"H;
MY66X'E\P0_RJUO\ G7O^193Z0SOR3V3_ *%_GF8K@Z?3X>0L1#WAO^(7)1<G
M;X6\5^!(OFC&XVI6N&J%7J_UJ%A'>%3LKLZ3)@)&=F=L3*C-BS1EJL(\Q8I
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M3X 8(6?'"EY'*=ON*1UI)@R63'Q5B-()_9XW<\)I4"21&*.0%B/=[ @50XY
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M.,8XQCC&8;W_ *=@-]ZBNFKK#Z66+'%KQ&27LY?>A+ "I)L#-,-H_>K5'2;
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M6.)-BD79<69&3>(3YF 5&K&'4 0*4TZ&IAE0ZV\M(RG&U]C80.F]Y7P9TR'
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g474270g32t06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474270g32t06.jpg
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M4@G",%[J<5@@1C:4:QR3"*YQ4(AFM&HB3M(ZV5UKJ@:6^Z:T$_;&W,:?-ZE
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M;K^88^S?ZD?V0V?_ !-]H?ZR\?*Z]_MX7V-2_P OQ\D:+^PF_;-U_,,?9O\
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MD@4#SQI2(ES$,D++!9@\C"E1<N*4G#<C,9_'YJ9'DQ\J9596%?&M(CH4M"N
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ML *K@XJYQNR&!@$/";_RY90Q-8'CXJ/^\_+D--)_O7CFQR9 8<:1+D/0<>*
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MUC41C$24X2HC41&^IJ)PF=@/.*LZFQQC,&]C]J6+2VH#^P:C3X]^M$$YKZO
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MX,?)#6?H:'^R_P#CQ]FCT._9@UE^X$/YEQ\K]F^F9G[3/X,?)#6?H:'^R_\
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MD/M=EWB+< <T,^4'KC9?M#=9XH<.,L'@Z!09X?:V;(J?:)3Y,E^FM:^W(?\
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MI^KVN)!BC3(UOY4-,R/+8$EH<IYQI(^5":;)R.3QS9T:TD:_?U$V@OXK2%?
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MPL7YCWF9&7N\FL<B.5L8]9O@\KTVLZL>D=0M;ZS4%Q#+-C6^HP+FML:]!R%
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M  *U<TTG_6N%_P#VO_Q)&=.PO^SOM/\ WZ#_ /8J?.=#QQO]/%[_ -KZ-_\
MF/<A_JK_ -:V_P#RV)^XN?IY_P"CO_[.AO\ ZWVC_P"W6YT@[!_T1.N'_DM(
M_P#P?/)EF?\ 0%-^:L__ !<_+;5__;/U0_\ $;__ /L.;R5+_LQ7_P#TB!_^
MLWS9X_\ S ?_ (;/W)D W/\ TM9?^.E?_>?EP\^V8W'&,<8QQC'&,<8QQC'&
1,<8QQC'&,<8QQC'&,<8S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g474270g50g78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474270g50g78.jpg
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M P,# P,# P,# P/_P  1"  F 1D# 1$  A$! Q$!_\0 @P   04  @,!
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M:_"'B]XUXYR!DEN6]9RRE3X66HF)8AP1J\F7;R):NGLO(*@!OVR :N5MA.(
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M$$R[CT'0:Z<9&L(>.81,6T08QD8T;,(]DV3*DW:,VB1$&S=!,H 4B2*28%*
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M?(<Y2^)[%TYQQ>8KB<DX_;S3^5A*O=DWT#+U*6<F[)!%%8$4G7XRJI=S)&Z
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M524((+W))1)=(Z9NLP8#%$BI2F[1*/Z=0T%-WY(GA)SAQMY,Y&Y;X9I4Y?\
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M5)=-WTRQGWK)\_0D@,UBA&NP%D>-%'I_M*L=J9$@]3B == :V*]PQU3 V:@
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GBAMXZ=?R,E6&,-!3C=IL#I!I(."G'U( ]=!,5H%H%H%H%H%H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g474270g59p42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474270g59p42.jpg
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M 0$! 0$! 0'_P  1"  [ (4# 1$  A$! Q$!_\0 '0 !  (" P$!
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M*7,$U8'#>.+)=31ZBP-S3TO'LCIUFK-UQ_%-];+*O$5J/,;P0'TJW]9BE\F
M92JTEFZ%1CZ7O=A-93L4D<[V59>QY"R[B[-;Z:6_-6;N.3R9:/=WADE52_:
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M=,% ]?!WLY_2^5?0C3[M]@J)OE.Z/=6&K^8J3DISN)GFMV?.$]B*YUZ^(5+
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M,@ 4H!P2//=^I!N:N.NU&VKI*"A^Y]=<#OC"!O3]S].=9&C0,/Q\^G[8E_\
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M4/R1>P_\SRT7BVPM7/\ 3O6S600$%FZZ9%A=5CH<;R=MU?TFR]< >/@/@ ^
M /\ 7! < < < Z2V)Q#@G-^(+C1-DJ#4<D8>4CE)ZV5VZQ!9F'3;5LAY@LRF
MB5,[UG(P_M3O6,C%'0E6:J8G8KD5-\CJ;3JG1\C$=/-K<5;LZ\T393"3:U-L
M87]2T-JL%SKY:S-K)4VVSE(DESQ*;V0229GF*Y(%CU$G:I5FA$CF*BJ*B"0-
M.+H\5U53K#8#LWZ_=70D4<X[=8/ITS$_="0I[6Z,+AD%L9#U H0V.:.-DO0G
M Y3)E*6O&$RI12+Y4 2@.J,GA%O?2W/ A S'VD[:]LC.Q:O].>%,A5O'-L]W
M3LL[_P"8(MYCRC4:LORF93R6-A]+Q\VGWD>N9-&0_J<F,&ZKL]?QW%R";2WP
MXVH*%YM5^A7;XY4]?(FYZX] \4];NL%4USQ@X6GG+=XZM>2,@2#-)A+Y)R1,
MMF3>>M;YDBJNG&LP;1\="5V%(Y=_HM:B(F/</Y1^B]EGXQ*3DVV;X<&1P!P!
MP!P!P#7W:Y+/CC6O.+75I."4V)>XTM3##IK)(H140UO3Z+79PL@L_=IJ,4'4
M8NL,C%A)@2)6E&K)"56;QRKI=,=5*JN%;\"!?Z?3IRS)U_N,S[';;?HR>R&8
M6"5(AZY&61E='E+H(3*-FM+JQVV-7>Q4K9\@6IA!OWJ$5)2K:/CZQ'.%Y=U(
MS4@PB132:12HE\*\W^BS5P2' ' ' /P<MFSULX9O$$731V@JV=-7"9%F[ELN
MF9)=!=%0#)JHK)',FJF<IB*$,8I@$HB' /*$GBR^/=OME]5Z)=\HTW76%SOD
M6M,<.UG+63H2CC"LK0_CF[-]$1UM;IRPE8HI-E'4J9Z\<)D#W#A4WSSF;X+J
M>I7@I-)O5BZM)NM6MFY%SWK(Z:>L=WB>M9?GM1:!=+V=P03O<C3-]R7 G%%%
M!=,3T>_VZR48Y@54,83&K8F-\%.)BE*!>D9:2;MK.E%A19;J<BQ? P$%5H:-
MKM8A8FN5^&:),(>"@8YG$0T4P;E]"#*-C(]%NR8M$2_BDV:H)(IE^"$ ."9R
5W ' ' ' ' ' ' ' ' ' ' ' /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
